20 juin

Diabetes https://diabetes.diabetesjournals.org

• 02:00
  Lipodystrophy Prevalence, “Lipodystrophy-Like Phenotypes,” and Diagnostic Challenges Diabetes
  Familial partial lipodystrophy (FPLD) is a rare heterogeneous disease (1). By using a DEXA-derived fat mass ratio (FMR) (percent trunk fat divided by percent leg fat) with a cutoff (>1.2 in females and >1.7 in males), Agrawal et al. (2) identified “lipodystrophy-like phenotypes” in approximately (…)
• 02:00
  AKR1A1 and Kidney Disease: Promise and Perils of the Multiverse Diabetes
  Janssen R&D LLCJohnson and Johnson Pharmaceutical Research and Development10.13039/100014489
• 02:00
  Response to Comment on Hu et al. Single-Cell Transcriptomics Reveals Novel Role of Microglia in Fibrovascular Membrane of Proliferative Diabetic Retinopathy. Diabetes 2022;71:762–773 Diabetes
  National Natural Science Foundation of China10.13039/501100001809819708218220123982271100National Key Research and Development Program of China10.13039/5011000121662017YFA01041002017YFA0104103
• 02:00
  Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al. Diabetes
  The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein–coupled receptor involved in the regulation of blood glucose levels and food intake. Stabilized agonists targeting GLP-1R are used in the treatment of type 2 diabetes and have recently become a breakthrough obesity therapy. (…)
• 02:00
  The Whole Human Pancreas: An Understudied Organ in Diabetes Diabetes
  Type 1 and type 2 diabetes both cause life-changing morbidity and earlier mortality, with effects on the individual, their family, and wider society. Working lives are affected, with knock-on effects for the wider economy. Many questions remain about the etiology of both types of diabetes and (…)
• 02:00
  Issues and Events Diabetes
• 02:00
  Comment on Hu et al. Single-Cell Transcriptomics Reveals Novel Role of Microglia in Fibrovascular Membrane of Proliferative Diabetic Retinopathy. Diabetes 2022;71:762–773 Diabetes
  We are writing this letter to discuss the article by Hu et al. (1), which reported that retinal microglia are involved in fibrosis in fibrovascular membranes of proliferative diabetic retinopathy. Unfortunately, when we reanalyzed the online reposited data (GSE165784), we were unable to (…)

15 juin

Diabetes https://diabetes.diabetesjournals.org

• 10:16
  Sans titre Diabetes

14 juin

Diabetes https://diabetes.diabetesjournals.org

• 02:00
  2011-LB: Patterns of Genetic Risk for Type 2 Diabetes Are Specific to Ancestry Diabetes
  Introduction & Objective. The heterogeneity of type 2 diabetes (T2D) risk has a genetic basis that can be reflected in genetic risk scores (GRS). It is currently unknown if the nature of genetic risk for T2D varies with ancestral backgrounds. The aim of this study was to determine if (…)
• 02:00
  2012-LB: Type 2 Diabetes GWAS Signal C2CD4A/B Insulin Resistance Mechanisms in Skeletal Muscle Diabetes
  Mechanisms of insulin action differ between fasting and postprandial states across tissues, with postprandial disturbance in insulin action being crucial in the development of type 2 diabetes (T2D). We generated single nucleus (sn-) chromatin accessibility and transcriptome profiles of 287 (…)
• 02:00
  2013-LB: Population-Scale Skeletal Muscle Single-Nucleus Multiomic Profiling Reveals Extensive Context-Specific Genetic Regulation Diabetes
  Skeletal muscle, the largest human organ by weight, is relevant to several polygenic metabolic traits and diseases including type 2 diabetes (T2D). Identifying genetic mechanisms underlying these traits requires pinpointing the relevant cell types, regulatory elements, target genes, and causal (…)
• 02:00
  2014-LB: Association between Variants in Genes Involved in the Metabolism of Uric Acid and the Risk of Type 2 Diabetes Diabetes
  Introduction & Objective: Epidemiological and experimental evidence suggests that hyperuricemia is involved in the pathophysiology of type 2 diabetes (T2D), inducing insulin resistance or beta cell failure. Therefore, our objective was to investigate a possible association between variants (…)
• 02:00
  2015-LB: Actionable Pharmacogenomic Variants in the Kuwaiti Population Diabetes
  Pharmacogenomics plays a pivotal role in advancing precision medicine by addressing critical public health concerns like Adverse Drug Reactions (ADRs) and dosage regulations. The emergence of Next Generation Sequencing (NGS) techniques, coupled with the rapid expansion of pharmacogenomic data, (…)
• 02:00
  2016-LB: Uptake Kinetics and Presentation of Donor Alloantigen by Lymph Node Stromal Cells for Attenuating the Alloimmune Response in Pancreatic Islet Transplantation Diabetes
  Objective & Background: Pancreatic islet transplantation requires lifelong immunosuppression, reducing its applicability. We aim to eliminate the need for immunosuppression by co-transplanting fibroblastic reticular cells (FRCs), a lymph node stromal cell subtype. FRCs are unconventional (…)
• 02:00
  2017-LB: Comparison of Nuclear Preparation for Single-Nucleus RNA-seq of Adipose Tissue Diabetes
  Introduction & Objective: To appreciate the pathophysiological changes in the transcriptome and cell type landscape during obesity, single-nucleus (sn)RNA-seq overcomes the difficulty of maintaining intact transcripts. Sedimentation of dissociated live cells is used to concentrate adipocytes (…)
• 02:00
  2018-LB: ABHD17B Modulates Diet-Induced Abdominal Obesity and Chronic Inflammation Diabetes
  Overnutrition induces abdominal obesity and chronic inflammation in humans. Despite the central role of hyperactive pro-inflammatory macrophages, the mechanisms underlying macrophage dysregulation due to overnutrition remains poorly understood. Here, we present the first evidence of the (…)
• 02:00
  2019-LB: The Characteristic Activity of Regulatory B Cells during the Occurrence and Development of Insulin Resistance Diabetes
  Introduction & Objective: To investigate the aberrant distribution and clinical relevance of regulatory B cells (Bregs) subsets in the peripheral blood of individuals with different levels of insulin resistance (IR).Methods: A cohort of 124 subjects were divided into five groups according to (…)
• 02:00
  201-OR: Fasting and Postprandial Triglycerides in Early Pregnancy Correlate with Mean Glucose and Time-in-Range by CGM at 28 Weeks of Gestation Diabetes
  Recent studies of obesity in pregnancy have demonstrated a link between higher maternal fasting and postprandial triglycerides (FTG, PPTG) and neonatal subcutaneous and liver fat. Maternal TG can be hydrolyzed by placental lipases to free fatty acids (FFA) for fetal fat accretion, which may be (…)
• 02:00
  2020-LB: Immunometabolomics Reveals Little Autoimmunity in Type 1 Diabetes (T1D)—Cross-Sectional Pathway Analysis across Multiple Autoimmune Diseases Diabetes
  Introduction & Objective: Metabolic reprogramming has a critical role in the differentiation and function of PBMCs in autoimmune diseases. Here, comparative cellular immune-metabolomics was applied to multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and (…)
• 02:00
  2021-LB: FABULINUS—A Randomized, Controlled Trial with FrexalimAB, to Assess Endogenous Insulin Secretion in New-Onset Stage 3 Type 1 Diabetes Adults and Adolescents Diabetes
  Introduction: Type 1 diabetes (T1D) is caused by autoimmune destruction of pancreatic ?-cells. The CD40/CD40L immune checkpoint leads to activation of both innate and adaptive immune cells. Frexalimab is the first second-generation antibody against CD40L to be studied in T1D.Objective: To (…)
• 02:00
  2022-LB: Diabetes Primes Neutrophils for Neutrophil Extracellular Trap by Metabolic Reprogramming Diabetes
  Neutrophils are primed for neutrophil extracellular trap (NET) formation during diabetes and excessive NET formation from primed neutrophils compromises wound healing in patients with diabetes. Here, we demonstrate that trained immunity mediates diabetes-induced NET priming in neutrophils. Under (…)
• 02:00
  2023-LB: Type 2 or Type 3c Diabetes Not an Exclusion Criteria for Total Pancreatectomy with Islet Auto Transplantation (TPIAT) Diabetes
  Purpose: Total pancreatectomy with islet auto-transplantation (TPIAT) is now a standard of care for patients with severe chronic pancreatitis. However, evaluation and patient selection is necessary to benefit from this difficult procedure. Several patients with CP also have underlying diabetes, (…)
• 02:00
  2024-LB: Reversal of Diabetes by Human Stem Cell–Derived Islets Implanted with an Immunomodulatory Microgel in a Retrievable Site Diabetes
  Introduction & Objective: Islet transplantation for T1D is limited by donor availability and need for immunosuppression. Stem cell-derived islets could represent a solution as an unlimited source, but chronic immunosuppression remains a critical barrier. Immunomodulatory SA-FasL engineered (…)
• 02:00
  2025-LB: Anti-apoptotic BCL2 Delivery to Protect Stem Cell–Derived Beta Cells from Transplantation-Induced Cell Death Diabetes
  Cadaveric islet transplantation in most type 1 diabetic (T1D) patients restores euglycemia. However, cadaveric islets are limited, transplantation often requires multiple organ donors, and significant apoptotic cell death shortly after transplantation prevents widespread implementation of this (…)
• 02:00
  2026-LB: Investigating the Role of NKX6.1 in Pancreatic Endocrine Cell Differentiation Diabetes
  Protocols to generate stem cell-derived beta cells have allowed novel investigations into the differentiation, specification and function of human beta cells. The transcription factor Nkx6.1 is critical to the specification of insulin-producing pancreatic ? cells in mice. Knockout of Nkx6.1 in (…)
• 02:00
  1499-P: Possible Association of GAD65 Antibody with Pancreatic Adenocarcinoma Diabetes
  Objective: To demonstrate a role of serum anti-glutamic acid decarboxylase 65 antibodies titer (GAD65) as a possible paraneoplastic marker of pancreatic adenocarcinoma.Case Presentation: A 29-year-old male with polysubstance abuse presented to the emergency room with polyuria, polydipsia, and (…)
• 02:00
  149-OR: Liver Health in Adolescents with Youth-Onset Type 2 Diabetes Diabetes
  Introduction: Youth-onset type 2 diabetes (Y-T2D) and metabolic liver disease (MASLD) commonly coexist. MASLD can advance to fibrosis/cirrhosis with no treatments beyond lifestyle intervention. Limited liver data in Y-T2D led us to investigate MASLD in the ST2OMP study, which will compare (…)
• 02:00
  14-OR: Autonomous Artificial Intelligence Diabetic Eye Exams Mitigates Disparities in Screening Completion for Youth Diabetes
  Diabetic retinal disease (DRD) is a complication of diabetes mellitus that can lead to vision loss; early detection through screening and treatment can prevent this. Few individuals with diabetes meet recommended DRD screening guidelines, and racial/ethnic minority youth are even less likely to (…)
• 02:00
  14-PUB: The Effect of Structured Intensive Lifestyle Intervention on Muscle Mass in Patients with Type 2 Diabetes Receiving GLP-1 Receptor Agonists Diabetes
  Glucagon-like-peptide-1 receptor agonists (GLP-1RAs) emerged as an important treatment option for type 2 diabetes (T2D) for their dual efficacy in improving glycemia and reducing body weight. However, they significantly reduce fat free mass (FFM), a surrogate for muscle mass, putting patients at (…)
• 02:00
  1500-P: Oral Exposure to Cigarette Smoke Condensate Leads to Glucose Intolerance and Immune-Cell Alterations in the Gut Diabetes
  Introduction & Objective: Smoking is associated with an increased risk for diabetes, yet the underlying mechanism remains elusive. Since smoking correlates with many gastrointestinal tract diseases, we aimed to investigate whether cigarette smoke influences metabolic health through gut (…)
• 02:00
  1501-P: Four Loci, Four Fates—Differential Regulation of IRF5 Promoter in Prodiabetogenic Stress Diabetes
  Introduction: Interferon regulatory factor (IRF)-5 is a transcription factor sitting at the crossroads of diverse cell processes. Emerging evidence supports its upregulation in response to different stimuli, however, the associated molecular mechanisms remain elusive.Methods: Four distinct IRF5 (…)
• 02:00
  1502-P: Metabolic Dysfunction Associated Steatohepatitis–Derived HCC Model Mouse for Cancer Immunology Diabetes
  Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) is a is linked to type II-diabetes and marked by steatosis, steatohepatitis, fibrosis and eventually HCC. The number of patients with MASH-derived HCC is increasing worldwide. Currently, the first line of cancer treatment (…)
• 02:00
  1503-P: Nano-thin Conformal Coating onto Human Islets to Preserve Cell Function and Induce Immunoprotection for Islet Transplantation Diabetes
  Allogenic islet transplantation is a promising treatment option for patients with Type 1 Diabetes (T1D). Systemic immunosuppression is required to mitigate donor islet rejection, but this can present with adverse side-effects and reduce patient quality of life. To address this, it has been (…)
• 02:00
  1636-P: Targeting a Long Noncoding RNA lncMGC Ameliorates Obesity-Associated Adipose Tissue Dysfunction in Mice Diabetes
  The long noncoding RNA (lncRNA) lncMGC, plays a pathological role in the diabetic kidney. However, its role in obesity, insulin resistance (IR), and type 2 diabetes is not known. Here we examined whether targeting lncMGC with a locked nucleic acid-modified LNA-GapmeR antisense oligonucleotide (…)
• 02:00
  1637-P: TLC-6740, a Liver-Targeted Mitochondrial Protonophore, Increases Energy Expenditure and Lipid Utilization in Obese Mice Diabetes
  Background: TLC-6740, a liver-targeted mitochondrial protonophore, causes dose-dependent weight loss and metabolic benefit in diet-induced obese mice. Here, we evaluated mechanisms of TLC-6740-induced weight loss.Methods: Male C57 BL/6 mice housed at thermoneutrality (28°C) were fed a high-fat (…)
• 02:00
  1638-P: Metformin Enhances Upper Small Intestinal Lipid Sensing to Regulate Food Intake Independent of GDF15 Release Diabetes
  Metformin, a first-line therapy for obesity-associated diabetes, lowers feeding and weight by increasing plasma growth differentiation factor 15 (GDF15) levels, but whether GDF15-independent mechanisms are involved is unknown. The upper small intestine (USI) detects lipids and triggers a (…)
• 02:00
  1639-P: Tirzepatide and Efruxifermin Demonstrate Therapeutic Benefits for NASH in a Preclinical Metabolic Syndrome Animal Model, B6-Alms1-del Mice Diabetes
  The escalating prevalence of metabolic syndrome has led to NAFLD and its severe form, nonalcoholic steatohepatitis (NASH), becoming a major public health concern. While numerous anti-NAFLD/NASH agents have entered development pipelines, only Resmetirom has advanced to the NDA stage. There (…)
• 02:00
  163-OR: RNAseq Analysis Reveals Temporal Dynamics of Colonic Immune Response to High-Fat Diet in Mice Diabetes
  Introduction & Objective: We previously showed that 1 week of high-fat diet (HFD) increases pro-inflammatory colonic macrophages (M?) and that their depletion was associated with improved glycemic control. The current study aimed to elucidate the temporal changes of gene expression of (…)
• 02:00
  1641-P: Effect of Specific Weight-Reducing Interventions on Metabolic and Immunological Outcomes in Mice Diabetes
  Introduction & Objective: Obesity leads to glucose intolerance and immune cell alterations in different organs. Nevertheless, it remains unknown whether these metabolic and immunological changes are reversible following weight loss and if they differ with specific weight-reducing (…)
• 02:00
  1642-P: Metabolic Effects of Semaglutide and Resmetirom at Thermoneutrality in the Diet-Induced Obese Mouse Diabetes
  Introduction & Objective: Semaglutide (GLP-1 receptor agonist) is currently approved for the treatment of type 2 diabetes and obesity and in late-stage clinical development for MASH. Resmetirom, a selective THR-? agonist, is waiting for approval for MASH. The present study aimed to compare (…)
• 02:00
  1643-P: P2Y 14 Receptor Regulates Whole-Body Glucose Homeostasis in High Fat Diet-Induced Obese and Diabetic Mice Diabetes
  Diverse G protein-coupled receptors (GPCRs) are expressed in different metabolic tissues and are involved in the regulation of whole-body glucose and energy homeostasis. Dysregulation of glucose homeostasis contributes to hyperglycemia in obesity and type 2 diabetes (T2D). Thus, GPCRs have (…)
• 02:00
  1644-P: The Dose Makes the Poison—High-Fat Diet Based on Extra Virgin Olive Oil Leads to Increased Liver Lipogenesis and Glucose Intolerance in Mice Diabetes
  Background & Objectives: Extra virgin olive oil (EVOO) has garnered attention for its potential anti-inflammatory and oxidative properties. However, the effect on metabolic health remains inconclusive. We previously showed that high-fat diets (HFD) based on coconut oil or lard led to glucose (…)
• 02:00
  1645-P: Metabolic and Adipogenic Effects of Di(isononyl) Cyclohexane-1,2-dicarboxylate (DINCH) In Vivo Diabetes
  As a substitute for phthalate plasticizers, DINCH holds significance. Human studies indicate that lipophilic xenobiotics, including DINCH, accumulate in adipose tissue, potentially disrupting adipocyte biology and contributing to metabolic disturbances like insulin resistance and obesity. In (…)
• 02:00
  1646-P: Apolipoprotein A4 Improves Glucose Homeostasis through Activation of BAT Thermogenesis in Obese Mice Diabetes
  Obesity is associated with impaired insulin sensitivity and the development of type 2 diabetes. Activation of brown adipose tissue (BAT) thermogenesis enhances triglyceride clearance and insulin sensitivity. Apolipoprotein A4 (ApoA4) induced by dietary lipids elevates BAT thermogenesis in lean (…)
• 02:00
  1647-P: Nonhuman Primate Obesity Model for the Translation of Target-Based Precision Medicine Diabetes
  The prevalence of obesity has increased worldwide in the past few decades. Because of the similarity of their absorption, distribution, metabolism, and excretion profile compared to that of humans, non-human primates (NHP) models are highly valuable in predicting the clinical response to new (…)
• 02:00
  1648-P: Opposing Roles of Sphingosine 1 Phosphate Receptors 1 and 2 in Fat Deposition and Glucose Tolerance in Obese Male Mice Diabetes
  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that regulates fundamental cellular processes such as proliferation, migration, apoptosis, and differentiation through five cognate G protein-coupled receptors (S1P1-S1P5). However, little is known about the role of S1P in obesity (…)
• 02:00
  1649-P: S-309309, a Novel MGAT2 Inhibitor, Enhances Intestinal Fatty Acid Beta Oxidation and Provides Metabolic Benefits in DIO Mice Diabetes
  Introduction & Objective: Pharmacological inhibition of Monoacylglycerol acyltransferase 2 (MGAT2) suppresses the food intake and the gain of body weight in high fat diet (HFD)-induced obesity (DIO) mice. However, the effects on metabolic abnormalities associated with obesity and detailed (…)
• 02:00
  164-OR: Macrophage Ucp1 Deficiency Inhibits Cold Exposure–Induced Insulin Sensitivity in High-Fat Diet Mice Diabetes
  Cold exposure (CE) could increase insulin sensitivity in high-fat-diet (HFD) mice, relying on adipose tissue Ucp1-induced heat release and macrophage M2 polarization. The function of thermogenic macrophages, a new subtype of macrophages that we have recently identified, has not been clearly (…)
• 02:00
  1650-P: Chronic Air Pollution Induces Brown Adipose Dysfunction and Insulin Resistance through Epigenetic Modification of Key Metabolic Circadian and Redox Targets Diabetes
  Background: Prior studies have demonstrated a strong link between air pollution and type 2 diabetes including brown adipose tissue (BAT) dysfunction, common proximate regulators are poorly characterized. We hypothesized that exposure to ambient fine particulate matter (2.5) modulates insulin (…)
• 02:00
  1790-LB: The Value of Duke Treadmill Score in Predicting Severity of Coronary Artery Disease In Diabetic Patients by SYNTAX Score Diabetes
  Aim & Object: One of the non invasive test is exercise tolerance test which carried out to identify prediction of severity of coronary artery disease and to assess the risk of major cardiac events. To establish prediction of coronary artery disease in patient having diabetic patient who (…)
• 02:00
  1791-LB: Metabolic Syndrome (MS) as a Risk Factor for Myocardial Infarction (MI), Coronary Heart Disease (CHD), Stroke, and Peripheral Artery Disease (PAD) in 41,215 People with Type 1 Diabetes (PwT1D) Diabetes
  Objective: To address the association between components of the MS and the occurrence of CV end-points in PwT1D.Methods: 14,328 PwT1D with MS (?2 of 4 criteria: BMI>30kg/m2, RR?140/90mmHg, microalbuminuria, Trig?150mg/dl or HDL2 [24.0; 32.1] vs 23.8 [21.7;26.2]), RRsys (135mmHg [125; 145] vs 124 (…)
• 02:00
  1792-LB: Long-Term Impact of Glucose Status on Risk of Restenosis after Percutaneous Transluminal Coronary Angioplasty—A Six-Year Follow-up Study Diabetes
  Patients with diabetes (DM) are at high risk for restenosis after coronary stenting. Information relating the long-term outcome of percutaneous transluminal coronary angioplasty (PTCA) to prediabetes is, however, limited. We retrospectively analyzed data of 951 patients (mean age 59.5±4.2 yrs, (…)
• 02:00
  1793-LB: Subclinical Atherosclerosis in Latent Autoimmune Diabetes—Insights from a Multicenter Prospective Interventional Study Diabetes
  Objective: To compare subclinical atherosclerosis (AS) between latent autoimmune diabetes in adults (LADA) and type 2 diabetes mellitus (T2D) and to evaluate the impact of early insulin intervention on AS progression in LADA.Methods: Sixty-four LADA patients and forty T2D patients, matched for (…)
• 02:00
  1794-LB: Comparison of Metabolic Visceral Fat Score with Other Abdominal Obesity Indicators in Predicting Left Ventricular Hypertrophy in Individuals with Type 2 Diabetes Diabetes
  Introduction & Objective: Left ventricular hypertrophy (LVH) is a common complication associated with higher cardiovascular risk in Type 2 diabetes mellitus (T2DM) patients. Although many abdominal obesity indices (AOIs) have been established, studies investigating their associations with (…)
• 02:00
  1795-LB: Elevation of Endogenous Glucose Production in Persons with Dysglycemia and Impaired Cardiac Function upon Myocardial Infarction Diabetes
  Introduction & Objective: Prediabetes (PRE) and type 2 diabetes (T2D) associate with excess risk and worse outcome of myocardial infarction (MI). Increased endogenous glucose production (EGP) contributes to hyperglycemia in critical illness, however, if elevated EGP associates with worsening (…)
• 02:00
  1796-LB: Adipocyte-Derived Extracellular Vesicles (AdEVs) Contribute to Insulin Resistance and Atherosclerosis in Obesity Diabetes
  Introduction: Cardiovascular disease is the leading cause of death worldwide. Obesity is a well-known major risk factor for atherosclerosis with 60% of all atherosclerotic burden due to metabolic syndrome, while other factors remain unknown. Adipose tissue (AT) inflammation is likely a (…)
• 02:00
  1797-LB: Detection of Potential Therapeutic Target Associated with Coronary Artery Disease in Type 2 Diabetes Patients—System Biology Approach Diabetes
  Introduction & Objective: Type 2 diabetes (T2D) and coronary artery disease (CAD), co-morbidity of which presents mortality risk, are both systemic diseases linked with altered immune response. Treatments for the co-morbid condition of T2D and CAD are not yet developed to a satisfactory (…)
• 02:00
  1798-LB: STK25 Promotes Diabetic Atherosclerotic Plaque Formation via Septin2 Regulating Mitophagy Diabetes
  Introduction & Objective: Serine/Threonine protein kinase 25 (STK25) was reported to regulate lipid accumulation and activation of inflammatory and fibrotic pathways as well as oxidative and endoplasmic reticulum stress in human aortic endothelial cell. However, the direct substrate of STK25 (…)
• 02:00
  1799-LB: Identification of Proteomics Signature for Vascular Complications in Type 2 Diabetes Diabetes
  Introduction: Robust predictive measures for Type 2 diabetes (T2D) vascular complications to facilitate early intervention strategies are needed.Methods: Fasting plasma from 363 Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial participants (mean±SD) age: 61.3±6.4 yrs, (…)
• 02:00
  179-OR: Assessing the Impact of Hypoglycemia among People with Diabetes in the U.S. and EU Diabetes
  Hypoglycemia, where blood glucose falls below 70 mg/dL, can be an unfortunately common and serious burden for people with diabetes (PWDs) on insulin. Despite this, its prevalence in the daily lives of PWDs is understudied among specific therapy types. This research aimed to comparatively assess (…)
• 02:00
  17-PUB: Glucagon-Like Peptide 1 Receptor Agonists' Heterogeneous Treatment Effects on Asthma Exacerbations—A Causal Machine-Learning Analysis Diabetes
  While recent studies suggest GLP1RA may reduce the risk of asthma exacerbation, it is unclear which subpopulations may derive greatest benefit. To address this question, we identified GLP1RA vs sulfonylureas (SU) new user cohorts in commercially insured patients ages 18-65 from MarketScan data (…)
• 02:00
  1800-LB: Reprogramming of Macrophage Metabolism by Pyruvate Dehydrogenase Attenuates Atherosclerosis through Mitigation of iNOS-Induced Foam Cell Formation Diabetes
  Background: Prior transcriptomic analyses have illuminated a correlation between the upregulation of glycolysis, induced by oxidized low-density lipoprotein (ox-LDL), and the extent of foam cell formation. This study aimed to elucidate the impact of metabolic redirection via pyruvate (…)
• 02:00
  1801-LB: Discovering Novel Cathepsin L Inhibitors Using Artificial Intelligence for Diabetic Nephropathy Diabetes
  Introduction & Objective: Cathepsin L (CTSL) has been demonstrated to play a significant role in the pathogenesis and progression of Diabetic Nephropathy (DN). However, there are currently no CTSL inhibitors available for clinical use. This study utilizes artificial intelligence models to (…)
• 02:00
  1802-LB: Magnetic Peripheral Nerve Stimulation (mPNS) for Treatment of Painful Diabetic Neuropathy (PDN)—Sensory, QoL Results Diabetes
  Objective: To determine if mPNS improved sensation, QoL in subjects with PDN over 90 days.Methods: Seventy-one subjects with PDN were treated in 6 site RCT comparing safety, effectiveness of mPNS and Conventional Medical Management (CMM). Subjects were randomized 3:1 to mPNS+CMM or Sham+CMM and (…)
• 02:00
  2009-LB: Deep Learning Enhances Chromatin Accessibility Signals and Discovers Links with Genetic Variations in Skeletal Muscle Rare Cells Diabetes
  Chromatin accessibility quantitative trait loci (caQTL) discovery is vital for linking epigenomic features with genetic variations in Type 2 diabetes (T2D). However, caQTL scans require clear epigenomic signals, posing challenges in rare cell types from single nucleus (sn) studies. To address (…)
• 02:00
  200-OR: Postpartum Islet-Cell Function in Individuals With and Without Gestational Diabetes Diabetes
  Gestational diabetes mellitus (GDM) affects approximately 10% of pregnancies. Although >60% individuals with GDM develop a disorder of glucose metabolism by 10 years postpartum, preventive care is lacking as the mechanisms leading to overt diabetes following pregnancy remain elusive. As part of (…)
• 02:00
  2010-LB: Glycemic Responses to Metformin Montherapy by SNP Clusters in Patients with Type 2 Diabetes Diabetes
  Introduction and Objective: Glycemic responses to metformin based on 8 SNP clusters in diabetes individuals, published by Suzuki (Nature, 2024), are unknown. Employing dataset from part of Taiwan Precision Medicine Initiative (TPMI), we explored the glycemic responses to metformin by quintile (…)
• 02:00
  1490-P: Diabetes Induces Impaired Fibrotic Response to Mesh Involving Macrophage Dysfunction Diabetes
  Introduction: Women with diabetes have ~5-fold increased risk of mesh exposure into vaginal cavity following synthetic mesh augmentation in the surgical repair of pelvic floor disorders. To define the mechanism relevant to host fibrotic response, we studied the impact of diabetes on (…)
• 02:00
  148-OR: Increased Insulin Secretion and Decreased Insulin Sensitivity in South Asian Youth without Diabetes Diabetes
  Introduction & Objective: The mechanisms underlying increased T2DM risk at lower BMI in South Asians (SA) compared to other ancestries are not known, but greater visceral fat (VFAT) for given BMI has been implicated. We examined the relationships of VFAT with insulin sensitivity (Si) and (…)
• 02:00
  1386-P: Cause-Specific Mortality Is Diversifying in Those with Diabetes—A Multicountry Analysis Diabetes
  Objective: This multi-country study explored trends in causes of death in people with diabetes.Methods: We used cause-specific mortality data in people with diabetes from 9 high-income countries (2000-2020). Data were from registries, health insurance, or other administrative sources. (…)
• 02:00
  1385-P: Association of Glycemic Variability with Brain Imaging Abnormalities in Persons with Type 2 Diabetes Diabetes
  Introduction & Objective: Persons with diabetes are prone to have atherosclerosis, stenosis, poor blood fluid properties, and other adverse blood vessel health conditions, leading to occurrence of stroke. Thus, this study aims to examine the effects of glycemic variability on brain imaging (…)
• 02:00
  1384-P: COVID-19 Vaccination Uptake among 3,779,733 Adults With and Without Diabetes Diabetes
  Introduction & Objective: Public health measures, especially vaccination, are important for COVID-19 risk reduction. Population level vaccine uptake in people with diabetes is understudied. We assessed COVID-19 vaccine uptake among adults with and without diabetes and the factors associated (…)
• 02:00
  1383-P: In the 21st Century, African Immigrants to the United States Do Not Value Obesity—The Africans in America Study Diabetes
  With acculturation superimposed on nutritional transitions, urbanization and globalization, 21st century attitudes of African immigrants towards optimal body size are unknown. To gain perspective on body image, we assessed in 412 Africans living in America: 1) ideal body size 2) body size (…)
• 02:00
  842-P: Improvement in Time in Range after Smart Insulin Pen Initiation in Austria Diabetes
  Introduction & Objectives: A prior multinational study showed improved time in range (TIR; 70-180 mg/dL) in people living with type 1 or type 2 diabetes (PLWD) after smart pen initiation for their bolus insulin. To understand country-specific experiences with smart pen use, this study (…)
• 02:00
  841-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes by Ethnicity and Race—ONWARDS 1–5 Diabetes
  Introduction & Objective: To assess, post hoc, the impact of ethnicity and race on the efficacy and hypoglycemia rates with once-weekly (OW) insulin icodec (icodec) vs once-daily (OD) basal insulin in adults with T2D.Methods: Efficacy and safety outcomes were assessed within each trial (…)
• 02:00
  840-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use—ONWARDS 1–5 Diabetes
  Introduction & Objective: To assess the treatment effects of once-weekly (OW) insulin icodec (icodec) vs once-daily (OD) basal insulin comparators ± concomitant glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in ONWARDS 1-5.Methods: A post hoc analysis by trial of insulin-naïve (…)
• 02:00
  83-OR: Metabolic Dysfunction–Associated Steatotic Liver Disease and Nonalcoholic Fatty Liver Disease Have Similar Clinical Profiles and Mortality Diabetes
  Introduction & Objective: Metabolic dysfunction associated steatotic liver disease (MASLD) has recently replaced the term nonalcoholic fatty liver disease (NAFLD). Concern remains whether evidence generated under NAFLD definition is fully applicable to MASLD. We compared the clinical profile (…)
• 02:00
  534-P: Structured CGM Education Delivered via Mobile Phone Is Associated with Increased Time in Range—Proof-of-Concept Study Results Diabetes
  Introduction & Objective: SmartStart CGM is a structured educational program for current users of continuous glucose monitoring (CGM) designed for use on a mobile phone. It presents basic and advanced information about using CGM and interpreting CGM data. We assessed the effects of (…)
• 02:00
  533-P: Geospatial Analysis of a Diabetes Management Program—Program Participation and Social Determinants of Health Diabetes
  Introduction & Objective: The American Diabetes Association has recognized Health Extension for Diabetes (HED) as a practice-tested diabetes support program. HED is a community-based program that offers a standardized education and individualized support to those with diabetes. HED improves (…)
• 02:00
  532-P: Comprehensive Analysis of Cardiovascular and Metabolic Health in Type 2 Diabetes Mellitus—Insights from the UDF Study on ABI, BMI, and Neuropathy Across Diverse Population Diabetes
  Studies link T2DM with obesity, poor glucose control, CV risk, peripheral arterial disease, and prevalent neuropathy in diverse populations. We analyzed 537 T2DM patients, across 18 centres (UDF Study), aged 12-89 for BMI, HbA1C, LDL, ABI, and neuropathy to assess obesity, cardiovascular, and (…)
• 02:00
  531-P: Role of Social and Family Status in Long-Term Follow-up of Patients with Diabetic Foot Diabetes
  Patients and Methods: 396 patients were identified from 3 diabetic foot (DF) clinics with follow-up for 1 year (2019-2022). Patients constituted study groups according to their social status: living in family (Group 1, n=154), periodical care (Group 2, n=132), living alone (Group 3, n=110). We (…)
• 02:00
  530-P: Self- and Family-Management Experiences of Barriers and Facilitators in the People Living with Diabetic Foot Ulcers and Comorbidity—A Qualitative Study Diabetes
  Objective: Diabetic foot ulcers are the leading cause of lower extremity amputations and require foot care for healing and prevention of recurrence, especially in family care settings. Patients’ high prevalence of co-morbidity is directly to risks of adverse outcomes including poor functional (…)
• 02:00
  52-OR: Emotional Distress and Insulin Initiation in the GRADE Trial Diabetes
  Introduction & Objective: We evaluated if higher emotional distress (depressive symptoms [DS] or diabetes distress [DD]) were associated with lower initiation of basal or rapid-acting insulin among participants enrolled in the GRADE Emotional Distress Study (EDS).Methods: Individuals with (…)
• 02:00
  529-P: Diagnosis Approach of Suspected Osteitis in Diabetic Foot Ulcer—The Multicentric French 2023 Survey Diabetes
  Bedside Blind Bone Biopsy (B4) through healthy skin is a valid alternative to bone biopsy usually performed in the operating (OR) or radiology (RR) room for the diagnosis of diabetic foot ulcer osteitis (DFU) (IWGDF/IFDSA 2023 guidelines). From 12.17.2015 to 12.31.2023, in our Diabetology unit, (…)
• 02:00
  527-P: How Stressed Are Feet? Novel Methods for Quantifying the Daily Cumulative Stress Imparted on Diabetic Foot Ulcers Diabetes
  Introduction: Physical stress is a key factor in diabetic foot ulcer (DFU) formation and healing. However, knowledge on the association of stress with DFU is still limited due to the complexities in quantifying the magnitude of stress imparted on feet over 24hr periods. This project utilized (…)
• 02:00
  1407-P: Gaps in the Initiation of Diabetes Drugs with Cardiovascular and Kidney Benefits by Medical Specialists Diabetes
  Introduction: Endocrinologists, cardiologists, and nephrologists commonly care for people with diabetes and coexisting cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD). Guidelines recommend that GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) be (…)
• 02:00
  1406-P: Accessibility of Diabetes Prevention Programs in Historically Redlined Areas of the U.S. Diabetes
  Introduction & Objective: Prior research demonstrated an association between historical redlining practices and diabetes-related mortality. The National DPP is an evidence-based, cost-effective, structured lifestyle change intervention to prevent type 2 diabetes (T2D). Whether historical (…)
• 02:00
  1404-P: U.S. Rural–Urban Disparities in Obesity Mortality, 2000–2019 Diabetes
  Introduction: Obesity prevalence is higher in US rural vs nonrural counties. The objective was to evaluate trends in obesity-related mortality by rurality.Method: We used CDC WONDER data, 2000?2019, on obesity as a multiple cause of death (ie, top 20 contributor) among US residents aged ?25 (…)
• 02:00
  1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A U.S. Population-Based Cohort Study Diabetes
  Introduction: Type 2 diabetes (T2D) is a common comorbidity among kidney transplant recipients (KTR) in the U.S. To date, there are no recent studies describing the use of glucose-lowering medications (GLM) in KTR. Thus, we investigated the prescribing trends of GLM among adult KTR with T2D in (…)
• 02:00
  1402-P: Novel Lipodystrophy Genotype Correlations Identified through the Rare and Atypical Diabetes Network (RADIANT) Diabetes
  Introduction: Lipodystrophy (LD) encompasses a group of heterogeneous disorders characterized by either generalized or partial lack of adipose tissue. Discovery of the genetic etiologies of LD has advanced understanding of the molecular mechanisms that govern fat-cell differentiation, (…)
• 02:00
  1401-P: Long-Term Impact of Diabetes Prevention Program (DPP) Interventions on Walking Endurance Diabetes
  Introduction & Objective: Type 2 diabetes (T2D) and prediabetes are associated with poor walking endurance, a marker of physical function. Our main aim was to examine the long-term effects of metformin or intensive lifestyle intervention (ILS) in adults at high risk of T2D on their 6-minute (…)
• 02:00
  1400-P: Hepatic Effectiveness of SGLT2 Inhibitors in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Diabetes
  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated promising effects on liver outcomes. However, comprehensive evidence regarding liver outcomes in direct comparison with thiazolidinediones (TZD) and glucagon-like peptide-1 receptor agonists (GLP1RA), which are recommended in (…)
• 02:00
  13-PUB: Safety and Efficacy of Tirzepatide in Patients with Solid-Organ Transplant Diabetes
  Objective: Preexisting diabetes mellitus (DM) and post-transplant diabetes mellitus (PTDM) impact outcomes post solid organ transplantation (SOT). Benefits of tirzepatide are well studied in DM but not in patients after SOT. This study describes safety and efficacy of tirzepatide in SOT.Methods: (…)
• 02:00
  650-P: Attitudes and Barriers to Implantable AID Solutions—Development of a New Assessment Tool Diabetes
  Major limitations of current automated insulin delivery (AID) systems are the subcutaneous insulin route and the need to wear devices on the body. The EU project “FORGETDIABETES” (supported by H2020-FETPROACT, n.951933) will develop a fully implantable AID systems to overcome these barriers. To (…)
• 02:00
  64-PUB: Risk of Complications in Type 2 Diabetes Mellitus with Increase in Disease Duration—A Report of Real-World Data of Indian Population Diabetes
  Introduction: T2DM is a progressive disease characterized by worsening of not only ? cell function but also an increased risk of complications with time.Methods: In this real world single center study we did a cross sectional analysis of patients to evaluate common markers of diabetes (…)
• 02:00
  64-OR: Continuous Glucose Monitoring among Pregnant Individuals with Glucose Intolerance Diabetes
  Introduction & Objective: Glucose intolerance is common in pregnancy but incompletely characterized. We used continuous glucose monitor (CGM)-derived metrics to assess dysglycemia amongst pregnant individuals with a varying levels of glucose intolerance.Methods: In this prospective (…)
• 02:00
  649-P: Medical Students’ Recognition of Psychosocial Issues in a Behavioral Diabetes Case Diabetes
  Introduction & Objective: Psychosocial care should be provided to all people with diabetes. Psychosocial problems can impair a person’s ability to carry out diabetes self-care. Thus, addressing these problems is critical to improve outcomes. To better understand medical students’ awareness (…)
• 02:00
  647-P: Outcomes Associated with the Medicare Diabetes Prevention Program Diabetes
  Introduction & Objective: The National Diabetes Prevention Program lifestyle change program (LCP) is an evidence-based behavior change intervention to prevent or delay type 2 diabetes among adults at high risk for type 2 diabetes. In 2018, the Centers for Medicare & Medicaid Services (…)
• 02:00
  646-P: Improved Outcomes with Intensive Follow-up in Pediatric Diabetes Patients with Care Concerns Diabetes
  Introduction: Standards of pediatric diabetes care recommend routine clinic visits quarterly, but in some cases more frequent visits may aid in improving hyperglycemia. This study aimed to determine if intensive follow-up affected DM outcomes.Methods: EHR data was reviewed (2020-23) to identify (…)
• 02:00
  645-P: Feasibility of Kanasina Gulabi, a Peer Support Intervention for Young Adults with Type 2 Diabetes in Mysore, India Diabetes
  Introduction & Objective: To address the knowledge gap and emotional burden in young adults with type 2 diabetes (T2D), we designed a four-week education and goal-based peer support intervention, Kanasina Gulabi (Kannada: My Dream Rose), implemented in Mysore, India between June and July (…)
• 02:00
  644-P: Racial Ethnic Disparities in Prescription of GLP-1 Receptor Agonists for People at High Risk for Diabetes on Atypical Antipsychotics Diabetes
  Introduction: Atypical antipsychotics (AAP) significantly increase the risk of obesity and type 2 diabetes (T2D). GLP-1 receptor agonists (GLP-1 RA) are weight-loss medications which may be beneficial in treating AAP-induced weight gain. We evaluated trends in prescriptions of GLP-1 RA among (…)
• 02:00
  47-OR: OPA1 Reprograms Macrophage Metabolism to Enforce Tolerance of Inflammation in Obesity Diabetes
  Introduction & Objective: Adipose tissue macrophages (ATMs) are key players orchestrating metabolic homeostasis through regulating metabolic inflammation. Mitochondrial dynamics and metabolic remodeling are pivotal for the function of macrophages. The aim of our study is to explore the role (…)
• 02:00
  479-P: Imeglimin Improves Hyperglycemia-Induced Mitochondrial Dysfunction and Increases SIRT1 and NAD + Biosynthesis in Schwann Cells Diabetes
  Hyperglycemia-induced oxidative stress is a major cause of the pathogenesis of diabetic neuropathy, and hyperglycemia-induced mitochondrial ROS production is considered as a significant mechanism of increased oxidative stress. On the other hand, imeglimin is the first in a new glimin class of (…)
• 02:00
  478-P: Preventing Peripheral Neuropathy in Adults with Type 2 Diabetes—A Meta-analysis of Randomized Clinical Trials Diabetes
  Background: Diabetic Peripheral Neuropathy (DPN) is a debilitating complication of diabetes. Current diabetes management guidelines recommend targeting modifiable risk factors like glycemia, blood pressure (BP), lipids, obesity, and smoking to prevent DPN, but their individual effectiveness is (…)
• 02:00
  1491-P: Examination of the Humanized Antibody to SerpinB13 in Autoimmune Diabetes Diabetes
  Studies in our laboratory suggest that a combinatorial approach with a monoclonal antibody (mAb) to serpinB13, a cathepsin L (catL) inhibitor, and a suboptimal dose of antibody to CD3, is therapeutically superior to single antibody use, when these reagents are delivered into NOD mice during the (…)
• 02:00
  1492-P: Quiescent Adipose-Derived Mesenchymal Stromal Cells (ADSCs) Rejuvenate Themselves and Provide Factors That Remotely Restore Cellular Functions of Aged ADSCs Diabetes
  Although a number of studies have shown therapeutic effects of mesenchymal stem cells (MSCs) on type 1 diabetes or diabetic complications, clinical applications of MSCs for these diseases are still limited. One of the reasons is aging of MSCs due to older donor age and ex vivo culture of MSCs (…)
• 02:00
  1493-P: Transglutaminase-Expressing Adipose Tissue Macrophages Positively Regulate Adipose Tissue Profibrotic Profile in Diet-Induced Obese Mice Diabetes
  Introduction: Adipose tissue fibrosis (ATF) in obesity-driven diabetes is characterized by increased extracellular matrix (ECM) deposition. Cell populations that induce ATF in diabetes have yet to be fully elucidated. Transglutaminase 2 (TGM2) is known to contribute to ECM stabilization. The (…)
• 02:00
  1494-P: Gr1 + Myeloid Cell Governs Adipose Tissue Remodeling via Controlling Macrophage Infiltration Diabetes
  Introduction & Objective: Pathological adipose tissue remodeling contributed to the development of insulin resistance and type 2 diabetes. The aberrant myeloid phenotype has recently been implicated in driving the diabetic environment. However, the role of myeloid cells in adipose remodeling (…)
• 02:00
  1496-P: The Highly Immunodeficient SRG Rat for Modeling Diabetes Diabetes
  Immunocompromised rodents are essential for pre-clinical testing of cell-based therapies. The SRG rat (Sprague Dawley Rag2-/-, Il2rg-/-) lacks mature B, T, and NK cells, and is normoglycemic under standard conditions. Compared to mice, the SRG rat offers more human-like metabolism, easier (…)
• 02:00
  1498-P: Intermittent Hypoxia Increased the Expression ofIL-1ß, IL-6, and IL-8 in Human Monocytes through the Downregulation of MicroRNA-146a Diabetes
  Sleep apnea syndrome (SAS) is characterized by recurrent episodes of oxygen desaturation and reoxygenation (intermittent hypoxia [IH]) and is a risk factor for systemic inflammation. Serum inflammation markers such as tumor necrosis factor (TNF)-?, interleukin (IL)-1?, IL-6, IL-8, IL-10, and (…)
• 02:00
  477-P: Peripheral Neuropathy—Evaluation of DPNCheck vs. mTCNS in Type 1 Diabetes Diabetes
  Introduction: The handheld DPNCheck (DPNC) nerve conduction study (NCS) device has shown high sensitivity (SENS) and specificity (SPEC) against classical NCS for detecting peripheral neuropathy (PN), but studies comparing DPNC to clinical assessments are lacking. We aimed to evaluate DPNC (…)
• 02:00
  476-P: Investigating C-Fiber Activation and Pain Sensitivity in Diabetic Sensorimotor Neuropathy with Transcutaneous Electrical Nerve Stimulation Diabetes
  Introduction & Objective: We aimed to assess C-fiber excitability via transcutaneous-electrical nerve stimulation (TENS) in diabetic sensorimotor neuropathy (DSPN) and its association with epidermal innervation and quantitative sensory testing. Pain perception was evaluated in (…)
• 02:00
  475-P: Peroxisome Proliferator-Activated Receptor Delta (PPAR?)—A Key Modulator in the Pathogenesis of Diabetes Mellitus and Mycobacterium Tuberculosis Comorbidity Diabetes
  The interplay between lipid metabolism and immune response in macrophages plays a pivotal role in various infectious diseases, notably tuberculosis (TB). Herein, we illuminate the modulatory effect of heat-killed Mycobacteria tuberculosis (HKMT) on macrophage lipid metabolism and its (…)
• 02:00
  474-P: Novel Changes in Chromatin 3D Architecture under Diabetic Conditions in Human Macrophages Diabetes
  Aberrant activation of monocytes and macrophages in diabetes increases chemokines and cytokines associated with chronic inflammation and diabetic vascular complications like atherosclerosis and nephropathy. Epigenetic mechanisms are implicated; however, the chromatin 3D reorganization during (…)
• 02:00
  473-P: Hyperglycemia Increases the Biomechanical Response in Endothelial Cells Diabetes
  Introduction and Objective: Cardiovascular disease (CVD) is a common complication associated with diabetes. Hyperglycemia can lead to vascular changes resulting in endothelial dysfunction. While many studies have shown the molecular mechanisms by which hyperglycemia affects the vasculature, few (…)
• 02:00
  472-P: Molecular Pathogenesis of Sex-Specific Vascular Contributions to Cognitive Impairment and Dementia and in Type 1 Diabetes Diabetes
  Introduction & Objective: Type 1 diabetes (T1D) is a serious disease that affects millions of people worldwide and is a major factor for vascular contributions to cognitive impairment and dementia (VCID). However, whether and how sex affects VCID in diabetics is rarely reported. In this (…)
• 02:00
  471-P: Anti-NFKB Inhibitor Beta Antibody Correlates with Cardiovascular Disease in Type 1 Diabetic Patients with Autoimmune Disease Diabetes
  Cardiovascular disease (CVD) is a major cause of mortality in Type 1 diabetes (T1D). Studies suggest that autoimmunity may influence CVD development in T1D. We created a novel T1D-CVD mouse model by deleting ApoE via CRISPR/Cas9 editing in nonobese diabetic (ApoE-/-/NOD) mice, an autoimmune T1D (…)
• 02:00
  470-P: Severe Liver Fibrosis (F4) Assessed via Liver Fibroscan Is Associated with Elevated NT-ProBNP in Asymptomatic Type 2 Diabetes Mellitus Patients Receiving SGLT2i Therapy Diabetes
  Aim: Identify relationship between different stages of liver fibrosis (LF) & N-terminal pro-B type natriuretic peptide (NT-ProBNP).Methods: Between Oct’ 22 & Mar’ 23, 66 T2DM patients receiving dapagliflozin & waist cmf > 80 cms (F) & > 90 cms (M) irrespective of their A1c & (…)
• 02:00
  46-PUB: A Quantitative Framework for Evaluating the Performance of Whole-Population Remote Patient Monitoring for Type 1 Diabetes Care Diabetes
  Introduction: Care providers continue to adopt platforms that enable remote patient monitoring (RPM) for type 1 diabetes (T1D) care through the algorithmic analysis of continuous glucose monitor (CGM) data. No provider-facing quantitative framework is available to track how the use of such (…)
• 02:00
  46-OR: Palmitic Acid Coordinates Impaired Adipose Tissue ICOS high Treg Immunosuppression and Systemic Metabolic Disturbance during Obesity Diabetes
  Treg cells serve essential roles in immunological tolerance and tissue homeostasis remodeling. However, the precise mechanism by which Treg cells specifically regulate the immune response in adipose tissue during obesity remains largely unexplored. Here we show that Foxp3, the master (…)
• 02:00
  469-P: Both LDL Cholesterol and LDL Particles Associated with MACE in Tibetan Patients with Type 2 Diabetes Diabetes
  Background: LDL-C remains the primary treatment target for reducing major cardiovascular events (MACE) in patients with T2D. Our previous study revealed T2D patients residing in the Tibet Plateau exhibited elevated levels of LDL-C, LDL-particle number (LDL-P), but not small density LDL particles (…)
• 02:00
  468-P: Association between Sudomotor Function and Coronary Atherosclerosis in Patients with Type 2 Diabetes Diabetes
  Object: This study aims to investigate the relationship between sudomotor function and coronary atherosclerosis in patients with type 2 diabetes.Methods: A total of 147 patients with type 2 diabetes were enrolled (64.60% male, 59.58±10.20 years). Using sudoscan detector to assess the mean (…)
• 02:00
  467-P: Type 2 Diabetes and Chronic Kidney Disease as Predictors of Cardiovascular Events in Patients with Coronary Artery Disease Diabetes
  This study aims to investigate the single and joint effects of T2DM and CKD on cardiovascular events in patients with coronary artery disease (CAD). We prospectively investigated 1044 patients with CAD over 8.5±5.0 years. Cardiovascular events occurred more frequently in T2DM patients (n=347) (…)
• 02:00
  466-P: Therapeutic Efficacy of Monthly Semaglutide-Loaded Microsphere Injections in Zucker Diabetic Fatty Rats Diabetes
  Introduction: This study aimed to develop semaglutide-loaded microsphere monthly injectables using a novel biodegradable microsphere manufacturing technology, and to compare its therapeutic efficacy with both semaglutide solution, administered weekly injectables, and semaglutide microsphere, (…)
• 02:00
  465-P: Distribution of Remnant Cholesterol in Patients with Type 2 Diabetes and in Nondiabetic Patients with Established Cardiovascular Disease Diabetes
  High remnant cholesterol is associated with the metabolic syndrome and with type 2 diabetes (T2DM) and has attracted much interest as a cardiovascular risk factor. However, its distribution in T2DM patients with established cardiovascular disease is not clear. This issue is addressed in the (…)
• 02:00
  464-P: The Visceral Adiposity Index Predicts Cardiovascular Events Both in Coronary Artery Disease Patients With and in Those Without Diabetes Diabetes
  The Visceral Adiposity Index (VAI) is calculated based on waist circumference, BMI, triglyceride and HDL-cholesterol levels and is a validated measure of visceral adiposity. In the general population, the VAI has been shown to be an independent risk factor for premature mortality. Its power to (…)
• 02:00
  463-P: Remnant Cholesterol as a Predictor of Major Cardiovascular Events in Cardiovascular Disease Patients with Differing Glycemic State Diabetes
  Remnant cholesterol has attracted interest as a marker of cardiovascular event risk. The power of remnant cholesterol to predict major cardiovascular events (MACE) in patients with differing fasting glucose state is unclear and is addressed in the present study. We prospectively recorded MACE (…)
• 02:00
  462-P: Medication Documentation in Patients with Type 2 Diabetes Undergoing Coronary Angiography Diabetes
  The utilization of multiple medications and the increasing complexity of medication regimens associated with chronic diseases such as type 2 diabetes (T2DM) necessitate the implementation of a medication documentation (MD). A complete medication plan serves to enhance medication safety and (…)
• 02:00
  461-P: Metabolic Profile Alterations in Patients with Obstructive Sleep Apnea and Type 2 Diabetes Diabetes
  The co-occurrence of Obstructive Sleep Apnea (OSA) in individuals with Type 2 Diabetes (T2D) is well-established. Several studies have shown that T2D patients with moderate to severe OSA exhibit a more unfavorable glycemic profile. In this retrospective analysis, we conducted a chart review of (…)
• 02:00
  460-P: Dual Role of Factor XI in Mortality and Diabetes—Insights from the Ludwigshafen Risk and Cardiovascular Health Study Diabetes
  Introduction & Objective: We investigated the effect of FXI on mortality in a cohort at increased risk for cardiac death, with a specific focus on risk-modification in case of type 2 diabetes (T2D) or current heart failure.Methods: The prospective LURIC study recruited 3063 persons (…)
• 02:00
  45-PUB: Persistent Performance Improvement Using Interdisciplinary Resources and Continuous Glucose Monitoring in Patients with Poorly Controlled Type 2 Diabetes Diabetes
  Aims: The purpose of this study was to examine the effects of a pharmacist managed monitoring and interaction program using continuous glucose monitoring in a population of poorly controlled (A1C >10 %) patients with type 2 diabetes.Methods: This study was conducted in the outpatient clinical (…)
• 02:00
  459-P: Association of Intraoperative Mean Glucose with Clinical Outcomes in Patients with Acute Ischemic Stroke Treated by Mechanical Thrombectomy Diabetes
  Introduction & Objective: Poststroke hyperglycemia is common and associated with adverse outcomes for patients with acute ischemic stroke (AIS). However, the evidence of glucose level during mechanical thrombectomy (MT) are limited. This study aimed to investigate the association between (…)
• 02:00
  458-P: Whole Left Ventricular Cardiac MRI in High-Risk People with Type 1 Diabetes Reveals Pathological Extracellular Volume Fraction and T1 Relaxation Times Diabetes
  Introduction: Diffuse myocardial fibrosis is a negative CV prognostic marker. We employed advanced cardiac MRI (CMR) techniques for detailed left ventricular myocardial tissue characterization people with type 1 diabetes (PwT1D) and high CV risk.Methods: Quantitative native T1 mapping (T1) and (…)
• 02:00
  457-P: Association of System Inflammation Index with Risk of Cardiovascular Mortality among Individuals with Type 2 Diabetes Diabetes
  Introduction & Objective: This study aimed to examine the associations of system inflammation index, including system inflammation response index (SIRI) and system immune-inflammation index (SII), with cardiovascular mortality in adults with type 2 diabetes (T2D).Methods: This analysis (…)
• 02:00
  456-P: The ApoB/LDL-C Ratio Predicts Cardiovascular Events in Coronary Artery Disease Patients Independent of Type 2 Diabetes Status Diabetes
  A high ApoB/LDL-C ratio reflects small LDL particle size which like type 2 diabetes (T2DM) is associated with insulin resistance. Whether the ApoB/LDL-C ratio and the presence of T2DM are mutually independent predictors of cardiovascular events is unclear and is addressed in the present study. (…)
• 02:00
  455-P: The Triglyceride–Glucose Index and Type 2 Diabetes are Mutually Independent Predictors of Major Cardiovascular Events in Patients with Established Cardiovascular Disease Diabetes
  The triglyceride-glucose index (TyG) is a validated biomarker of insulin resistance. Its power to predict major cardiovascular events (MACE) in patients with established cardiovascular disease is unclear and is addressed in the present study. We enrolled 1790 consecutive patients, 1481 with (…)
• 02:00
  454-P: Screening for Cardiovascular Abnormalities in Chinese patients with Early-Onset Type 2 Diabetes Combined with Cluster Classification Diabetes
  Introduction: Patients with early-onset type 2 diabetes (EOD) have 1.6-fold increased risk of cardiovascular death. Our study intends to screen for early cardiovascular abnormalities in EOD patients, and distinguish the population with cardiovascular risk through cluster classification.Method: A (…)
• 02:00
  453-P: Remnant Cholesterol Predicts Major Cardiovascular Events in Coronary Artery Disease Patients with NAFLD Diabetes
  Remnant cholesterol has attracted interest as a marker of cardiovascular event risk. The power of remnant cholesterol to predict major cardiovascular events (MACE) in patients with non-alcoholic fatty liver disease (NAFLD) is unclear and is addressed in the present study. We enrolled a high-risk (…)
• 02:00
  452-P: Folic Acid on Homocysteine Levels in Type 2 Diabetes Patients—Systematic Review and Meta-analysis of Randomized Controlled Trials Diabetes
  Introduction and objectives: The beneficial effect of folate has been observed in various conditions; however, the available evidence on homocysteine and reduction of cardiovascular disease (CVD) in type 2 diabetes (T2D) is limited. This study aims to quantitatively assess the effects of folate (…)
• 02:00
  2099-LB: Increased Expression of PFKFB3 in Diabetic Pancreatic ß-Cells May Compensate for the Maintenance of Glucose Metabolism Diabetes
  Background: In diabetic pancreatic ?-cells, glycolysis is activated, and the up-regulation of the glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase3 (PFKFB3) has been suggested to be involved in these intracellular metabolic changes, but its physiological significance remains (…)
• 02:00
  2098-LB: Identification and Structural Elucidation of a Novel KATP Channel Modulator Demonstrating Dual Pharmacochaperone and Inhibitory Actions Diabetes
  Introduction & Objectives: Pancreatic KATP channel trafficking defects underlie congenital hyperinsulinism (CHI) cases unresponsive to the KATP opener diazoxide, the mainstay medical therapy for CHI. Current clinically used KATP channel inhibitors have been shown to act as pharmacochaperones (…)
• 02:00
  2097-LB: HNF4A and HNF1A Exhibit Tissue-Specific Target Gene Regulation in Pancreatic Beta Cells and Hepatocytes Diabetes
  HNF4A and HNF1A encode transcription factors that are important for the development and function of the pancreas and liver. Mutations in both genes have been directly linked to Maturity Onset Diabetes of the Young (MODY) and type 2 diabetes (T2D) risk. To better define the pleiotropic gene (…)
• 02:00
  2096-LB: Mitochondrial DNA Integrity Is Required for ß-Cell Health In Vivo Diabetes
  Type 2 diabetes (T2D) is a metainflammatory disease characterized by impairments in mitochondrial function and ultrastructure that contribute to the overall disruption of ?-cell function. Mitochondria rely on both the nuclear genome as well as their own 16.6 kilobase-pair circular genome to (…)
• 02:00
  2093-LB: Aging and Beta-Cell Function Diabetes
  Introduction and Objective: Alterations of glucose homeostasis and insulin secretory capacity increase with age and represent leading causes of morbidity and mortality. In order to prevent and/or improve diabetes-associated ailments of the pancreatic beta cell during aging we propose to leverage (…)
• 02:00
  2092-LB: Receptor-Mediated G12 Signaling Strongly Promotes Insulin Secretion from Pancreatic Beta Cells Diabetes
  Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. The inability of pancreatic ?-cells to release enough insulin is key pathological sign. Glucose-induced insulin secretion is regulated by G protein-coupled receptors (GPCRs) located on the cell (…)
• 02:00
  2091-LB: Viral Infection Drives Aberrant Pancreatic Beta-Cell Bioenergetics and Autophagy via a Candidate Type 1 Diabetes Gene PGM1 Diabetes
  Introduction & Objective: Viral infection is one of the major environmental factors in Type 1 Diabetes (T1D). PGM1 is a T1D GWAS gene encoding phosphoglucomutase 1, which bidirectionally converts G6P to G1P. PGM1 resides at the junction between many arms of metabolic pathways. Our previous (…)
• 02:00
  2090-LB: Characters of Intra-islet Ductal Cells Related to Alpha-Cell Regeneration in Zinc-Binding Site–Mutated CRY1-Expressing Diabetic Mice Diabetes
  Introduction & Objective: We previously suggested that the regions of intra-islet ductal cells (IIDCs) play roles as the source for endocrine cells, particularly for ?-cells, in C414A-CRY1 transgenic mice (TG) (ADA 2023), the characters of IIDCs relevant to the ?-cell neogenesis are yet (…)
• 02:00
  208-OR: Impact of Carbohydrate-Restricted Nutrition Therapy and Continuous Remote Care among People with Type 2 Diabetes in Rural vs. Urban Areas Diabetes
  Diabetes outcomes and complications are often worse in rural (R) versus urban (U) areas, commonly due to challenges accessing health services. Our telemedicine clinic aims to address these barriers, offering carbohydrate-restricted nutrition therapy via continuous remote care for people with (…)
• 02:00
  2089-LB: An Adult Clock Component Links Circadian Rhythms to Pancreatic ß-Cell Maturation Diabetes
  Pancreatic ? cell clocks attune insulin secretion to daily energy cycles, and desynchrony from genetic or behavioral disruptions triggers metabolic dysfunction, fueling type 2 diabetes risk. How ubiquitous circadian clocks orchestrate ? cell-specific outputs, however, is not well understood. In (…)
• 02:00
  2088-LB: The Downregulation of SCGN Induced by Lipotoxicity Promotes NLRP3-Mediated ß-Cell Pyroptosis Diabetes
  Background & Objective:Lipotoxicity exacerbates ?-cell injury to contribute type 2 diabetes development. In lipotoxic conditions, secretagogin (SCGN), a protein highly expressed in islets, is found to undergo downregulation. Thus, we aim to explore the role of SCGN in lipotoxicity-induced (…)
• 02:00
  2087-LB: Novel Human Islet Spheroid Models of Type 1 Diabetes Diabetes
  Recently, it has emerged that ?-cells co-orchestrate their own demise by increasing their visibility to the immune system, stressing the importance of studying both the immune and the ?-cell components of T1D simultaneously. To enable accurate, high-throughput and longer-term studies of these (…)
• 02:00
  2086-LB: Islet Surface Modification with Bissulfosuccinimidyl Suberate Prevents the Instant Blood-Mediated Inflammatory Reaction—A Novel Approach Diabetes
  Introduction and Objectives: In pancreatic islet cell transplantation, the early graft loss is due to the instant blood-mediated reaction (IBMIR). Control of early inflammatory events could improve the efficacy of islet cell transplantation and may enhance the long-term function of transplanted (…)
• 02:00
  2085-LB: Alleviation of Instant Blood-Mediated Inflammatory Reaction in Human Islets with Aptamers Diabetes
  Introduction and Objective: The instant blood-mediated inflammatory reaction (IBMIR) is a major factor that causes damage to transplanted islets. The blockade of pro-inflammatory mediators is a promising approach to improve islet engraftment. We hypothesized that blocking of key pro-inflammatory (…)
• 02:00
  2084-LB: Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D) Diabetes
  Introduction & Objective: Tirzepatide is a once weekly GIP and GLP-1 receptor agonist approved in the US for treatment of T2D (May 2022) and obesity (Nov 2023). We assessed real-world patient characteristics and effectiveness in people with obesity or overweight without T2D.Methods: This (…)
• 02:00
  2083-LB: Effect of 8-Hour Time-Restricted Eating vs. Daily Calorie Restriction on Sleep in Adults with Type 2 Diabetes Diabetes
  Objective: This study compared the effect of 8-h time-restricted eating (TRE) versus calorie restriction (CR) and a no-intervention control (CON) group on body weight and sleep in adults with obesity and type 2 diabetes (T2D).Methods: Adults with obesity and type 2 diabetes (n = 75) were (…)
• 02:00
  2082-LB: Heterogeneity in Adipose Progenitor (AP) Populations from Subcutaneous Abdominal and Thigh Adipose Tissues of Women Diabetes
  Introduction & Objective: Lower body fat distribution decreases risk for T2D, but the mechanisms involved are poorly understood. The objective of this study was to compare AP populations of paired samples of upper body abdominal (A) vs lower body thigh (T) adipose tissues that may contribute (…)
• 02:00
  2081-LB: Efficacy and Safety of Semaglutide and Tirzepatide—A Comparative Analysis of Clinical Trials Diabetes
  Introduction & Objective: In the past years, many obesity drugs were approved by the FDA and withdrawn. Semaglutide and tirzepatide are dominating the obesity market. We analyzed published phase 2/3 clinical trials to evaluate their efficacy and safety.Methods: We selected 17 randomized (…)
• 02:00
  2080-LB: Metabolite Profiles of Liver Fat and BMI in the MultiEthnic Study of Atherosclerosis (MESA) and Mediators of Atherosclerosis in South Asians Living in America (MASALA) studies Diabetes
  Introduction: Hepatic steatosis occurs across the body mass index (BMI) spectrum. We aimed to identify a metabolite signature for hepatic steatosis and BMI in a diverse population.Methods: We included participants from the MESA (n=1,226) and MASALA (N=668) cohorts with untargeted LC-MS (…)
• 02:00
  207-OR: Food Insecurity Patterns and Mental Health among Youth and Young Adults with Diabetes Diabetes
  Introduction & Objective: We explored the associations of food insecurity (FI) patterns with symptoms of depression, anxiety, stress, and changes therein in youth and young adults (YYA) with type 1 (T1D) and type 2 diabetes (T2D).Methods: Longitudinal data (2016-2022) from 747 YYA with T1D (…)
• 02:00
  2079-LB: Sociodemographic Profile and Obesity—An Indian Perspective Diabetes
  Introduction & Objective: Diverse sociodemographic profiles play a pivotal role in shaping health behaviours. This survey presents the lifestyle habits and health profiles among different socio-economic populations in India.Methods: A pan-Indian survey using social media and awareness camps, (…)
• 02:00
  2078-LB: Effects of Obesity on Bladder Cancer and the Intervention Effect of Semaglutide Diabetes
  Objective: Limited research has been conducted on the impact of semaglutide on bladder cancer in individuals with obesity. Hence, this study employed proteomics in conjunction with bioinformatics technology to demonstrate that semaglutide potentially operates through a mechanism that reduces the (…)
• 02:00
  1519-P: Endothelial Injury Predicts Carbohydrate Metabolism Trajectories after COVID-19 Diabetes
  Introduction & Objective: Diabetes and SARS-CoV-2 infection target the endothelium causing perfusion abnormalities. We hypothesized that COVID-19 impairs insulin action and/or insulin secretion, and that systemic endothelial injury (EI) slows post-hospitalization recovery of these (…)
• 02:00
  1429-P: Multimorbidity among Adults with Diabetes in India Diabetes
  Introduction: Limited information is available on the burden of multimorbidity among diabetics in India.Methods: We conducted a cross-sectional study among 12284 adults aged ? 30 years, using multistage cluster random sampling, from rural and urban areas of North and South India. Trained (…)
• 02:00
  1428-P: Impact of Socioeconomic Inequalities on COVID-19 Mortality of People Living with Diabetes during the 2020 Epidemic Waves in France Diabetes
  Introduction & Objective: The aim was to describe the impact of socioeconomic inequalities (SEI) on COVID-19 mortality in people living with pharmacologically treated diabetes (TD) during the two 2020 epidemic waves (W1: March-May; W2: September-December) in European France.Methods: TD were (…)
• 02:00
  1427-P: Factors Predicting Significant Improvement in Glycemic Control after Endocrinology Referral in Patients with Type 2 Diabetes Mellitus and Hemoglobin A1c ? 10% Diabetes
  Endocrinology referral has been shown in several studies to significantly improve glycemic control in patients with uncontrolled type 2 diabetes mellitus (DM2). However, studies identifying factors that predict glycemic improvement are lacking. This is a retrospective study of adults (N =138, (…)
• 02:00
  1487-P: Obesity Induces Metabolic Dysfunction in Adipose Tissue T-Cells Diabetes
  Individuals with obesity or diabetes often have impaired immune responses to infection despite elevated systemic inflammation. T cells are essential for controlling adaptive immune responses, and during chronic obesity, adipose tissue T (ATT) cells display features of exhaustion, which are (…)
• 02:00
  935-P: Cardiovascular and Mortality Outcomes with SGLT2 Inhibitors in Patients with Atrial Fibrillation and Type 2 Diabetes Diabetes
  Introduction & Objective: Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown clinical benefits in patients with heart failure (HF), chronic kindey disease and type 2 diabetes(T2DM). However, limited data exist on their effects on clinical outcomes in patients with AF and (…)
• 02:00
  934-P: Prescribing Patterns of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure With or Without Type 2 Diabetes—A Continuing Review Diabetes
  Introduction: The prevalence of heart failure (HF) continues to increase and guidelines strongly recommend initiation of quadruple pharmacologic therapy including a sodium glucose co-transport 2 inhibitor (SGLT2i) for patients with all classifications of HF irrespective of type 2 diabetes (T2D). (…)
• 02:00
  933-P: Effects of Dapagliflozin and Metformin on Vascular Function in Newly Diagnosed Type 2 Diabetes—A Randomized Controlled Trial (DMVascular Study) Diabetes
  Aims: We aim to evaluate impact of Metformin vs Dapagliflozin vs combination (Dapagliflozin/Metformin) on surrogate measures of cardiovascular risk - endothelial function, artery stiffness and carotid artery intima-media thickness (CIMT) in a 12 week, randomized controlled study.Methods: We (…)
• 02:00
  932-P: Clinical Efficacy, Safety, and Tolerability of Single-Pill Combination of Dapagliflozin and Linagliptin in Uncontrolled Indian Type 2 Diabetes Mellitus Patients—A Randomized Double-Blind Study Diabetes
  Introduction: While Dapagliflozin and Linagliptin are known for robust glycaemic efficacy T2DM patients when used individually, although it remained unknown whether their combined use is associated with further improved efficacy, safety and tolerability in Indian scenario.Objective: To determine (…)
• 02:00
  62-OR: Continuous Glucose Monitoring in Pregnancies with Type 1 Diabetes—A Retrospective Study Diabetes
  Introduction & Objective: Prior studies do not identify if continuous glucose monitor (CGM) metrics at a critical gestational age (GA) can distinguish risk of adverse pregnancy outcomes (APOs). We evaluated 3rd trimester CGM metrics by GA and APO status in gravidas with type 1 diabetes (…)
• 02:00
  629-P: Serum Creatinine–to–Cystatin C Ratio Is Related to Handgrip Strength as Well as Muscle and Fat Mass in People with Type 2 Diabetes Independently of Glycemic Control and Daily Protein Intake Diabetes
  Sarcopenia is one of the serious diabetic complications and it is related to poorer glycemic control and other diabetic chronic complications. Therefore, it is necessary to diagnose sarcopenia as early as possible in people living with diabetes. Serum creatinine to cystatin C ratio (Scr/Scys) (…)
• 02:00
  628-P: Receipt and Perceived Importance of Nutrition Counseling among Older Adults with Type 1 Diabetes (T1D) Diabetes
  Introduction & Objective: Dietetics guidelines recommend adults with T1D are referred to nutrition counseling for individualization of an eating plan. We characterized the extent to which older adults receive nutrition counseling and how important they perceive it to be.Methods: Adults (?65 (…)
• 02:00
  627-P: Prediabetes Reduction from Food Allergen Elimination—A Controlled Pilot Study Diabetes
  Currently Diabetes affects over 500 million people, worldwide, and the expense of treating this disease exceeded $870 Billion US dollars. Diabetes Mellitus Type 2 (DM2) is comorbid with numerous other pathologies including obesity and hypertension. The objective of this 6-month controlled pilot (…)
• 02:00
  626-P: Insulin Dosing Strategies Surrounding Food Intake among Older Adults with Type 1 Diabetes (T1D) Diabetes
  Introduction & Objective: T1D management evolves over the lifespan, as the risk for hypoglycemia increases. Data are limited to guide diabetes education and nutrition in older adults. Our objective was to assess strategies employed by older adults with T1D employ to accurately dose insulin (…)
• 02:00
  625-P: Association between Vitamin D Status and Thyroid Function in Individuals with Type 2 Diabetes Mellitus Diabetes
  Background: More studies have revealed role of vitamin D(VD) in chronic diseases. Our study aimed to investigate its association with thyroid function in Type 2 Diabetes Mellitus(T2DM).Methods: 730 patients with T2DM were enrolled. Thyroid and VD levels were measured. Patients were divided into (…)
• 02:00
  624-P: Cardiometabolic Improvements Increase with Weight Loss among People with Type 2 Diabetes in a Carbohydrate-Restricted Nutrition Therapy Diabetes
  Background: Recent therapeutic advancements yield cardiovascular benefit with weight loss (WL) significantly greater than the 5% target, but carbohydrate restriction has been associated with improved cardiometabolic markers independent of WL. We explored differences in cardiometabolic outcomes (…)
• 02:00
  623-P: Remission of Type 2 Diabetes by Low-Calorie Meal Replacement and Real Food–Based Diets—A Six-Month Pilot Intervention in China Diabetes
  Objective: To determine the feasibility of achieving type 2 diabetes (T2D) remission by low calorie meal replacement diet (LCMRD) and real food-based diet (LCRFD) in Chinese people with T2D.Methods: This 6-month intervention consisted of a 3-month isocaloric intensive weight loss phase (815-835 (…)
• 02:00
  622-P: Carbohydrate Counting and Bolus Calculator Mobile-Based Application in Adults with Type 1 Diabetes Mellitus—A Randomised Controlled Study Diabetes
  Introduction & Objective: Carbohydrates counting is crucial for proper glycaemic control of Type 1 diabetes mellitus (T1DM). We aimed to study the usefulness and safety of a mobile application (app) for Carbohydrates counting and bolus calculation (CHOC/BC) developed at King Fahad medical (…)
• 02:00
  621-P: A First Glimpse into the Usual Dietary Intake of Older Adults with Type 1 Diabetes (T1D) Diabetes
  Introduction & Objective: We characterized dietary intake of older adults with T1D as a first step towards developing interventions and informing guidelines in this growing and understudied population.Methods: Older adults (?65 years) with T1D recruited through a university-affiliated (…)
• 02:00
  620-P: Snack-Related Insulin Adjustments in Type 1 Diabetes—A Delphi Consensus Diabetes
  Introduction & Objective: Snacks are a part of normal eating patterns for many people, including those living with type 1 diabetes (T1D). However, the research on snacks and related insulin adjustments is limited. The aim of this Delphi study was to define a list of recommendations related (…)
• 02:00
  61-PUB: Factors Associated with Pancreatic Anti-islet Antibodies in Persons with Newly Diagnosed Diabetes Mellitus Diabetes
  Introduction: Individuals initially diagnosed with diabetes mellitus (DM) may be positive for diabetes-associated autoantibodies (DAA+). The aim was to identify characteristics associated with DAA+ in a group of individuals with newly diagnosed DM, by comparing DAA+ individuals with their (…)
• 02:00
  61-OR: Effectiveness of Telemedicine plus Conventional Care vs. Conventional Care Alone in Reducing Complications of Diabetes—A Pilot Study Diabetes
  Telehealth interventions are increasingly recognized as effective strategies for improving health and ensuring better patient outcomes. This study focuses on Diabetes Tele-Management System (DTMS®), a comprehensive telemedicine program established in Kerala, India in 1997. In this (…)
• 02:00
  619-P: Oral Hygiene Practices Linked to Dietary Fiber and Essential Nutrients Intake and Glycemic Management in Type 2 Diabetes Diabetes
  Introduction & Objective: In type 2 diabetes (T2D), dietary therapy focusing on high-fiber foods is recommended for better glycemic management. However, oral health issues like tooth loss disturb essential nutrient intake. This study investigates the relationship between oral hygiene, (…)
• 02:00
  618-P: Development of a New Index Based on 24-Hour Urinary Creatinine to Predict Improvement of Lumbar Spine BMD after One Year of Zoledronic Acid Treatment for Osteoporosis Diabetes
  Introduction & Objective: Muscle and bone can interact with each other, but the effect of muscle on osteoporosis treatment is not clear. This study aims to study the correlation between 24 h Ucr (24-hour urinary creatinine excretion, an indicator of muscle mass) and the change of lumbar (…)
• 02:00
  617-P: Impact of Culturally Sensitive, Mobile Health Based Nutrition Platform in Metabolic Health of African Americans in Southeast Virginia Diabetes
  Mobile health (mHealth) lifestyle interventions for obesity have gained popularity. However, acceptance and efficacy of these in minority populations is less known. The aim of this study was to assess efficacy of a 12-week culturally sensitive mHealth dietary intervention on weight in African (…)
• 02:00
  317-OR: Identification of Genetic Regulators of Circulating Biomarkers of Kidney Decline in Diabetes Diabetes
  Background: Over the past decade, major progress has been made in identifying predictors of kidney disease progression in patients with diabetes mellitus (DM). Despite this progress, however, a key feature that has yet to be considered in current prognostic models, and one that is critical (…)
• 02:00
  316-OR: Interoception Predicts Impaired Awareness of Hypoglycemia (IAH) in Adults with Type 1 Diabetes (T1D) Diabetes
  Introduction: Recurrent hypoglycemia attenuates hypoglycemia symptoms, making symptom detection more challenging and leading to IAH. However, some with T1D maintain hypoglycemia awareness despite symptom attenuation. Interoception, or the ability to sense, interpret, and integrate internal (…)
• 02:00
  315-OR: Task-Induced Alterations in the Salience Network amongst Patients with Type 1 Diabetes Diabetes
  Introduction & Objective: Patients with Type 1 Diabetes (T1D) have altered brain functional connectivity (FC) at resting state, particularly in attention and decision-making brain regions. Recent studies have shown that assessing FC during a cognitive task may be more predictive of (…)
• 02:00
  314-OR: A Randomized Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes Mellitus (T1DM) Diabetes
  Introduction: Activation of GPR119 receptors (expressed on enteroendocrine and pancreatic islet cells) augments glucagon counter-regulatory responses to hypoglycemia in pre-clinical models. This response is studied using MBX-2982, a GPR119 agonist, in participants with T1D.Methods: This phase 2a (…)
• 02:00
  313-OR: Metoclopramide Improves Hypoglycemic Counterregulation in Diabetic Rats Diabetes
  Introduction & Objective: To investigate the potential of metoclopramide, a dopamine antagonist, in mitigating impaired hypoglycemic counterregulation in a diabetic animal model.Methods: Diabetes was induced in 10-week-old Sprague-Dawley rats with streptozotocin (STZ, 65 mg/kg IP). Rats were (…)
• 02:00
  312-OR: OPAT Is Protective of Major Amputation following Hospitalization for Diabetic Foot Infection Diabetes
  Introduction & Objectives: Diabetic foot ulcers are a common complication of diabetes associated with high morbidity and mortality. It is estimated that the United States spends up to $13 billion USD each year on DFUs, with individual costs rising to $15,000 per year. Much of this (…)
• 02:00
  1708-P: Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ?25 kg/m2—A Six-Month Real-World Study Diabetes
  Overweight and obesity are increasingly recognized as potential targets for early intervention. Unlike injectable treatments, oral formulations are more easily accepted by people with diabetes. In Asian Indians, BMI ? 25 kg/m2 is considered obesity. Study participants were de-identified from the (…)
• 02:00
  170-OR: Case-Control Study on Whole-Methylome Analysis of Monocytes in Acute Diabetic Charcot Foot—Identifying Differentially Methylated Genes Diabetes
  Introduction: Diabetic Charcot Foot (DCF) is a serious diabetes complication that damages bones and joints. Monocyte epigenetic modifications, notably DNA methylation, during DCF are unresolved. This study aims to analyze the whole-methylome of monocytes in acute DCF to identify differentially (…)
• 02:00
  1579-P: Altered Serum Ceramides as Part of Dyslipidemia in Adolescents with Metabolic Dysfunction–Associated Steatotic Liver Disease Diabetes
  Introduction & Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) in adults is associated with altered plasma ceramides, and may serve as liver metabolic biomarkers. However, less is known about whether similar changes are present in adolescents. We performed a (…)
• 02:00
  1851-LB: “You feel isolated. You’re kind of in over your head”—Experiences of Caregivers of Aging People with Diabetes Diabetes
  Type 1 diabetes (T1D) is becoming more prevalent in the aging U.S. population due to treatment advancements resulting in people with T1D living longer and more people being diagnosed with T1D as adults. Unfortunately, resources to care for aging people with T1D are sparse. This dearth of (…)
• 02:00
  1850-LB: Role of Cardiovascular Risk Communication in Motivating Self-Management of Young-Onset Type 2 Diabetes (YOD)—A Mixed-Methods Study Diabetes
  Introduction & Objective: Optimal self-management may help mitigate the high cardiovascular risk of YOD (defined as age at type 2 diabetes diagnosis DisclosureM. Abraha: None. J. Senga: None. C.H. Yu: None. B.R. Shah: None. C. Ke: Advisory Panel; Sanofi. Speaker's Bureau; (…)
• 02:00
  184-OR: Association between Composite Dietary Antioxidant Index and Stroke among U.S. Adults with Diabetes—Insights from NHANES Diabetes
  Introduction & Objective: While previous research suggests a negative correlation between the Composite Dietary Antioxidant Index (CDAI) and stroke prevalence, particularly in pre-diabetes, data on this relationship in diabetic individuals remain limited. This study aims to assess the (…)
• 02:00
  1849-LB: Social Determinants of Health and Early-Onset Type 2 Diabetes—A Qualitative Study Diabetes
  Objective: To explore how social determinants of health (SoDH) affect disease perception and diabetes care in Koreans with early-onset type 2 diabetes (T2D).Methods: A qualitative research study included 35 Koreans (54.29% men) out of 83 contacts, diagnosed with T2D prior to 40 years of age. (…)
• 02:00
  1578-P: Recombinant Decorin Improves Features of Diabetes-Related Steatotic Liver Disease in Mice Diabetes
  Although type 2 diabetes closely associates with metabolic dysfunction-associated steatotic liver disease (MASLD) and accelerates its progression to steatohepatitis (MASH), fibrosis and hepatocellular carcinoma (HCC), still no treatment has been approved for MASLD. The extracellular matrix (…)
• 02:00
  1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience Diabetes
  Introduction: Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been recently approved for the treatment of overweight and obesity given its proven effectiveness and safety in phase 3 clinical trials. In this study, we aim to evaluate weight loss outcomes associated with tirzepatide in the (…)
• 02:00
  1706-P: Software-Aided Self Selection of Weight Loss Diet Plan for Facilitating Diabetes Management in Primary Care Diabetes
  Introduction and Objectives: The addition of a new anti-diabetes drugs have further strengthened pharmacological management of diabetes. However, attention to diet continues to be a cornerstone of diabetes management, particularly because of the preponderance of obesity in individuals with (…)
• 02:00
  1705-P: Obesity Phenotype Exhibit Differential Signatures of Circulating Biomarkers with Susceptible Obesity-Related Comorbidities Diabetes
  Background: Obesity is a heterogeneous disease with different phenotypes based on physiological and biological differences in energy intake and expenditure. A recent study determined that guided therapy based on the classification of obesity phenotypes achieved better outcomes with respect to (…)
• 02:00
  1704-P: Misperception of One’s Own Obesity Status—Causes and Consequences—Insights from a Large Nationwide Survey Diabetes
  Introduction & Objective: Correct self-perception of BMI (Body Mass index) status is essential to adopt a healthy lifestyle and experience improved quality of life. The current study evaluates the extent of misperception in the Indian population and its influence on an individual’s (…)
• 02:00
  1703-P: Integrated Transcriptome, Proteome, Metabolome, and Microbiome Analyses Identify Multiomics Signature of Glycolipid Metabolism Disorder—A Cross-Sectional Study Diabetes
  Introduction: The prevalence of glycolipid metabolism disorder continues to increase globally and has become a serious threat to human health. Multi-omics provide unprecedented insights into the underlying pathophysiological mechanisms of glycolipid metabolism disorder and identifying potential (…)
• 02:00
  1702-P: High Circulating MIF Levels Indicate the Association with Atypical Antipsychotic-Induced Metabolic Adverse Effects Diabetes
  Atypical antipsychotics (AAPs) are first-line medications for schizophrenia (SZ). However, their use is frequently associated with the development of metabolic adverse effects, and the mechanisms behind these negative effects remain inadequately elucidated. Macrophage migration inhibitory factor (…)
• 02:00
  1701-P: Benefits and Risks in 1,101 Duodenal–Jejunal Bypass Liner (DJBL) Treated Patients Diabetes
  DJBL (aka EndoBarrier®) is a novel endoscopic duodenal jejunal liner device for obesity, both with and without diabetes. In view of uncertainty re risk vs benefit, during 2017, an independent, secure, online registry was established under the auspices of the Association of British Clinical (…)
• 02:00
  1700-P: Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes—Results from Phase 3 SURMOUNT-2 Trial Diabetes
  Introduction & Objective: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved in the US for treatment of type 2 diabetes and obesity. In the phase 3, randomized, double-blind, placebo (PBO)-controlled SURMOUNT-2 (NCT04657003) (…)
• 02:00
  16-OR: Preadministration of SGLT2 Inhibitor Reduces Frequency of Anti-VEGF Agent Administration in Patients with Mild Diabetic Macular Edema—A Multicenter Randomized Controlled Open-Label Trial Diabetes
  Introduction & Objective: There are various unmet needs for anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). We previously reported that using sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduced the frequency of anti-VEGF agent administration (…)
• 02:00
  1847-LB: Fear of Hypoglycemia and Sleep among Parents of Young Children with Type 1 Diabetes Diabetes
  Background: Parents’ fear of hypoglycemia (FH) is common and associated with increased parental anxiety and stress. We examined the associations among FH and parental sleep in a sample of parents of young children with type 1 diabetes (T1D). We additionally explored whether FH and parental sleep (…)
• 02:00
  1848-LB: Peer Mentors in a Young Adult Transition Intervention Diabetes
  Introduction & Objective: Peer support interventions in diabetes have the potential to offer emotional support, improve health-related outcomes, and be delivered virtually. However, attention is focused largely on the individuals who receive rather than those who deliver support. We describe (…)
• 02:00
  1710-P: Weight Stigma and Discrimination among Hispanics and Non-Hispanic Whites and Blacks with Obesity and Diabetes in the U.S. Diabetes
  Introduction: People with obesity experience stigma and discrimination for their physical appearance and weight. Data is limited among stigmatization and prejudices among Hispanics (HISP) and non-Hispanic Whites (NHW) and Blacks (NHB) with obesity and diabetes in the U.S. We compare prejudices, (…)
• 02:00
  169-OR: LC3+ Extracellular Vesicles (EVs) Are Associated with Altered ß-Cell Autophagy, Islet Inflammation, and Diabetes Diabetes
  Introduction: EVs, nanoparticles housing molecular cargo, change based on parent cell health and contribute to cell-cell communication. Yet, mechanisms governing changes and physiological significance of ? cell EV cargo remain unclear. Autophagy is a critical intracellular degradation and (…)
• 02:00
  1699-P: The Conversion and Potential Mechanism of Conditionally Immortalized Human Classical Brown Preadipocytes from Proliferative to Adipogenic States Diabetes
  Introduction & Objective: Considering to the anti-obesity and diabetic effect of brown adipose tissue (BAT), different immortalized brown preadipocytes cell lines have been established. Notably, murine preadipocyte cell lines expressed Simian virus 40 large tumor antigen (SV40LT) possess (…)
• 02:00
  1698-P: Partial Least Squares Discrimination Analysis of Cytokine Profiles in T Cells with Inflammation in Subjects with Obesity Diabetes
  Introduction & Objective: We aims to use Partial Least Squares-Discrimination Analysis (PLS-DA) to analyze cytokine profiles in T cells in the context of obesity.Methods: PLS-DA is a robust statistical method that facilitates the identification of intricate patterns within complex cytokine (…)
• 02:00
  1697-P: Further Real-World Outcomes Using Medication and Intensive Lifestyle Intervention to Treat Obesity and Improve Diabetes at Scale Diabetes
  Introduction: More than 2/3 adults in the US have overweight or obesity. Increasing obesity rates profoundly impact diabetes and cardiometabolic disease. We established a digital metabolic health company to provide medically-supervised obesity treatment at scale.Methods: The program used the (…)
• 02:00
  311-OR: High Transepidermal Water Loss (TEWL) Associates with Failure to Maintain Wound Closure in Diabetic Foot Ulcers Diabetes
  Introduction and Objective: It’s been more than 25 years since the FDA approved becaplermin gel for diabetic wound healing. The FDA definition for wound closure is complete re-epithelialization confirmed at two consecutive clinical visits two weeks apart. Our objective was to identify (…)
• 02:00
  193-OR: Virtual Diabetes Optimization Program vs. Standard Endocrine Care for Veterans with Uncontrolled Diabetes Diabetes
  Nearly 25% of veterans have diabetes and 78% are considered overweight or obese. At the Milwaukee VA, a virtual multidisciplinary diabetes optimization program (VDOP) is available to veterans referred to endocrine specialty care. Patients above 18 years-old and with A1c ? 8% are offered (…)
• 02:00
  1939-LB: Improving Capacity for Quality Improvement in Type 2 Diabetes Primary Care Centers Diabetes
  Background: Primary healthcare centers (PHCs) caring for people with diabetes are often overwhelmed and burdened by operational challenges and low resources. The aim of this study was to increase the capacity for PHCs to implement evidence-based quality improvement (QI) projects.Methods: (…)
• 02:00
  1938-LB: Improving Screening for Retinopathy in Youth with Diabetes Mellitus Diabetes
  Introduction & Objective: Despite the rare occurrence of retinopathy in youth with diabetes (DM), routine screening is required. For type 1 diabetes (T1DM), screening starts at age 10 yrs. and DM duration of 5 yrs.; for type 2 diabetes (T2DM), at diagnosis.Methods: Retinopathy screening with (…)
• 02:00
  1937-LB: Coordinated Approach to Improve Quality of Care and Address Disparities in Patients with Cardiometabolic Disease—Analysis from the Cardiometabolic Center Alliance Registry Diabetes
  Background: The Cardiometabolic Center Alliance (CMCA) has demonstrated that its comprehensive, coordinated care model achieved statistically significant increases in the use of guideline-directed medical therapies (GDMT) as well as reductions in cardiovascular risk factors. The durability and (…)
• 02:00
  1935-LB: Integrated Model of Digital Health and Clinic Care Pathway—A Prospective Observational Study to Manage HbA1c Levels and Time in Range among Indian Type 2 Diabetes Mellitus Diabetes
  Aim: To assess the impact of Smit.fit’s CGM-powered Diabetes Care program on reducing HbA1c levels and increasing Time in Range (TIR) for T2DM patients at health clinics.Method: A single group design study of repeated measures evaluated Smit.fit’s 4-month Diabetes Care program deployed at (…)
• 02:00
  1934-LB: Evaluating the Efficacy of Decentralized Trials and Digital Marketing Tactics in Diabetes Management in Habitual’s DIGEST Study Diabetes
  Introduction/Rationale: Advances in diabetes remission programs have markedly improved type 2 diabetes (T2D) management, addressing glycemia, blood pressure, and microvascular health. However, the high demand for in-person medical consultations increases costs and decreases patient engagement. (…)
• 02:00
  1933-LB: Innovative At-Home Kidney Health Testing Program for Diabetics Diabetes
  Introduction & Objective: Chronic kidney disease, or CKD, impacts approximately one in three of these diabetic patients. An estimated 37 million people in the US have CKD and 90% are unaware due to the lack of associated symptomatology. Routine monitoring of CKD-related biomarkers such as (…)
• 02:00
  1852-LB: “I realized that I could control my health with better eating habits and exercise”—Significant Improvements in Psychosocial Health and Lifestyle in People with Prediabetes Using Dexcom rtCGM Diabetes
  CGM supports diabetes self-management and related behavior modification. We investigated the impact of CGM on psychosocial health and lifestyle behaviors in a prediabetes population.Glucose data were collected in an observational 12-week US study involving adults with prediabetes or at high risk (…)
• 02:00
  156-OR: Genome-Wide CRISPR Screen Identified That Alternative Splicing Regulates in Insulin Secretion Diabetes
  Pancreatic ? cell functionality, especially glucose-stimulated insulin secretion (GSIS), is pivotal in diabetes pathophysiology. The impairment of GSIS is not only evident in Type 2 diabetes (T2D) but also during the early stages of Type 1 diabetes (T1D). In addition, enhancing GSIS also holds (…)
• 02:00
  1488-P: A Novel Combination Therapy to Treat Autoimmune Type 1 Diabetes Diabetes
  Introduction & Objective: Type 1 diabetes (T1D) is a complex disease characterized by loss of immune tolerance to self-autoantigens and destruction of insulin-producing beta-cells. No single therapy confronts the several contributors to the disease. We developed an oral Salmonella-based (…)
• 02:00
  1489-P: GAD65 247-266 Is a Major Th1 Epitope in Japanese Patients with Acute-Onset Type 1 Diabetes Diabetes
  Introduction & Objective: Autoreactive T cell responses in type 1 diabetes (T1D) may vary depending on race. In Japan, T1D is classified into three subtypes based on disease progression: acute onset (AT1D), slowly progressive (SP1D), and fulminant (FT1D). The aim of this study was to compare (…)
• 02:00
  1577-P: CIDEB Knockdown Promotes Increased Hepatic Mitochondrial Fat Oxidation and Reverses Hepatic Steatosis and Hepatic Insulin Resistance by the PKC?-Insulin Receptor Kinase Pathway Diabetes
  Metabolic-dysfunction associated hepatic steatotic liver disease (MASLD) plays a major role in the pathogenesis of type 2 diabetes and can lead to end stage liver disease but there are currently no FDA approved treatments. CIDEB deficiency has been shown to be associated with reduced incidence (…)
• 02:00
  1576-P: Evaluation of Hepatic Steatosis and Adiposity in People with Type 1 Diabetes and Obesity Diabetes
  Introduction: Prevalence of obesity in T1D is rising, contributing to the development of hepatic steatosis (HS) with the associated risk for metabolic dysfunction associated steatotic liver disease (MASLD). While T2 D and MASLD are reliably linked, prevalence of MASLD in T1D varies by the (…)
• 02:00
  1575-P: Differential Effects of Rising Glucagon Concentrations on Hepatic Amino Acid Extraction Diabetes
  To understand the actions of glucagon on hepatic amino acid (AA) metabolism, we studied nondiabetic individuals on one occasion after an overnight fast. On the morning of the study, femoral artery (FA), femoral vein (FV) and hepatic vein (HV) catheters were placed under fluoroscopic guidance in (…)
• 02:00
  1572-P: Lipotoxicity-Induced TET1 Mediates CD36 DNA Demethylation in Liver Macrophages to Aggravate NAFLD Progression Diabetes
  Aims: DNA methylation is dysregulated in nonalcoholic fatty liver disease (NAFLD), yet the dominant genes and regulatory mechanisms remain obscure. Here, whole-genome bisulfite (WGBS) and RNA-seq revealed significantly downregulated DNA methylation and upregulated mRNA expression of Cd36 in a (…)
• 02:00
  1574-P: Catecholamine-Induced Adipose Lipolysis Drives Hepatic Steatosis in Pnpla3 I148M Knockin Mice Diabetes
  PNPLA3 (Patatin like phospholipid domain containing protein 3) I148M is the most common human genetic mutation associated with hepatic steatosis. Alterations in white adipose tissue (WAT) function are often linked to hepatic lipid accumulation, but current understanding of the effect of (…)
• 02:00
  1569-P: Quantification of Postprandial Hepatic Glucose Disposal in Roux-en-Y Gastric Bypass and Non-operated Controls Using Stable Isotope Labelling and Liver Metabolic Imaging Diabetes
  Roux-en-Y gastric bypass surgery (RYGB) alters postprandial glucose metabolism due to changes in gastrointestinal tract anatomy and large weight loss. Here, we propose a model quantifying postprandial hepatic and peripheral glucose fluxes in post-RYGB patients at steady weight loss and healthy (…)
• 02:00
  1570-P: A Human Unique Role of RNA-Binding Protein HuR in Nonalcoholic Steatohepatitis Diabetes
  Introduction & Objective: Overnutrition-induced obesity heightens the risk of cardiometabolic diseases, necessitating an understanding of how it disrupts gene expression for preventive strategies against obesity-related diseases. The RNA-binding protein human antigen R (HuR) has demonstrated (…)
• 02:00
  1571-P: CIDEB and CGI-58 Regulate Liver Lipid Droplet Size with Cholesterol Content, Linking to Inflammation and Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis Diabetes
  Metabolic dysfunction-associated steatohepatitis (MASH) is a frequent complication of type 2 diabetes. However, the molecular mechanisms responsible for the development of MASH are unknown. Loss of function mutations in the lipid droplet proteins Comparative Gene Identification-58 (CGI-58) and (…)
• 02:00
  1568-P: Liver-specific Expression of Activated G Protein G s ? Leads to Hyperglycemia with Reduced Pancreatic ?-Cell Mass and Function Diabetes
  Gs? couples hormones to stimulate intracellular cAMP generation. We previously showed that mice with liver-specific Gs? deficiency (LGsKO) have improved glucose tolerance and enlarged pancreatic islets. Here we generated mice with liver-specific expression of an activated Gs? by breeding mice (…)
• 02:00
  1567-P: Integrating Bioinformatics and Machine Learning to Identify Lactylation-Related Diagnostic Biomarkers and Characterize Immune Cell Infiltration in Nonalcoholic Fatty Liver Disease Diabetes
  Background: This study sought to explore potential lactylation-related targets for non-alcoholic fatty liver disease (NAFLD) and examine the role of immune cell infiltration in the disease's progression.Methods: Gene expression datasets were sourced from the Gene Expression Omnibus collection, (…)
• 02:00
  1566-P: Growth Hormone Replacement Treatment Improves Nonalcoholic Fatty Liver Disease in Patients with Pituitary Stalk Interruption Syndrome—A Randomized, Single-Blind, Placebo-Controlled Prospective Cohort Study Diabetes
  Background: Non-alcoholic fatty liver disease (NAFLD) commonly coexists as a comorbidity among patients with pituitary stalk interruption syndrome (PSIS) with growth hormone deficiency (GHD). This study aimed to investigate the impact of GH replacement therapy on liver fat content and metabolic (…)
• 02:00
  1565-P: Morning Hyperglucagonemia Disrupts the Priming Action of AM Insulin Diabetes
  The second meal effect describes an improvement in the glycemic response seen following the consumption of a 2nd identical meal. We previously showed that morning (AM) exposure of the liver to hyperinsulinemia can prime the liver so that there is increased hepatic glucose uptake and glycogen (…)
• 02:00
  1551-P: Impaired ß-Cell Responsiveness to Glucagon in Type 2 Diabetes Mellitus Assessed by a New C-Peptide Minimal Model Diabetes
  Glucagon (Gn) stimulates insulin secretion. However, tools to quantify ?-cell responsivity to Gn are lacking. We therefore developed a novel method that provides quantitative indexes of ?-cell function in response to a Gn bolus in people without (ND) and with type 2 diabetes (T2D).Eight ND (…)
• 02:00
  1550-P: Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D) Diabetes
  Introduction & Objective: To examine the effect of sodium-glucose co-transporter-2 inhibitor [SGLT2i] therapy alone or in combination with glucagon-like peptide-1 receptor agonist [GLP-1 RA] on beta-cell function [BCF] in T2D. HYPOTHESIS: the improvement in BCF with GLP-1 RA plus SGLT-2i (…)
• 02:00
  154-OR: Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention Diabetes
  Introduction: TrialNet TN07, a randomized controlled trial, assessed oral insulin for preventing type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. Of 560 participants, the stratum characterized by low first-phase insulin release (LFIR) (n=57) showed a positive (…)
• 02:00
  422-P: Ferritin and COVID-19 among Dialysis Patients with Diabetes Diabetes
  Early in the COVID-19 pandemic, severe hyperferritinemia, independent of inflammation, manifested as a laboratory characteristic prognostic of poor COVID-19 outcomes, including death. To determine the association between ferritin and COVID-19 infection, hospitalization and mortality in dialysis (…)
• 02:00
  424-P: Persons with Type 2 Diabetes Who Had Macroalbuminuria Prior to Impaired Glomerular Filtration Exhibited Increased Arteriolar Hyalinosis Diabetes
  There is a certain number of people with diabetes who have decreased GFR without albuminuria. Diabetic kidney disease is comprehensive concept including typical and atypical diabetic nephropathy including such cases. However, it is still unknown which histological parameters precisely predict (…)
• 02:00
  41-PUB: Pharmacy Intervention in the Management of Poorly Controlled Type 2 Diabetes Diabetes
  The prevalence of type 2 diabetes continues to increase worldwide leading to increased health and economic burden on healthcare system. Pharmacists are an essential part of healthcare delivery, play a significant role in patient outreach and can assist with medication titration. Our study was a (…)
• 02:00
  420-P: Effects of Nonalbuminuric Type 2 Diabetes Mellitus on Renal Outcomes Diabetes
  Introduction & Objective: The classic pattern of diabetic kidney disease is typically followed by microalbuminuria. However, the pure impact of type 2 diabetes mellitus (T2D) without albuminuria on renal outcomes is not fully understood. This study aimed to investigate the renal outcomes in (…)
• 02:00
  421-P: Ferritin and COVID-19 Infection and Outcomes in American Indian and Alaska Native Dialysis Patients with Diabetes Diabetes
  American Indians/Alaska Natives (AIAN) bear the greatest burden of diabetes and are overrepresented in the dialysis population. They were also hardest hit by COVID-19, w/higher mortality rates than any U.S. racial/ethnic group. Early in the pandemic, hyperferritinemia was prognostic of poor (…)
• 02:00
  419-P: Association of Remnant Cholesterol (rem-C) with Kidney Disease Progression in People with Type 2 Diabetes (T2D) Diabetes
  Objective: A study using diabetic mice demonstrated that cholesterol deposition in the kidneys provokes apoptosis of podocytes and albuminuria; however, most studies in people with diabetes have failed to demonstrate significant association of higher LDL cholesterol (LDL-C) levels with (…)
• 02:00
  41-OR: Insulin Regulates Exosomal MicroRNA Secretion from Adipocytes Completing a Novel Feedback Loop Diabetes
  MicroRNAs (miRNAs) are critical regulators of gene expression. MiRNAs are also secreted by tissues in small extracellular vesicles known as exosomes and can act at a distance. We have shown that adipose tissue is a major source of circulating exosomal miRNAs and that some of these are taken up (…)
• 02:00
  417-P: Diabetic Foot Ulcer Amputation Increases the Risk of Severe Renal and Retinal Microvascular Complications—A Korean National Health Information Database Study Diabetes
  Diabetic foot ulcer (DFU) and subsequent amputation represents significant health burden associated with diabetes. It is widely recognized that individuals with diabetic end stage kidney disease (ESKD) and proliferative diabetic retinopathy (PDR) face an elevated risk of limb amputation, but (…)
• 02:00
  418-P: Rosuvastatin vs. Atorvastatin on Cardiorenal Outcomes in Chinese People with Diabetes With and Without Chronic Kidney Disease Diabetes
  Introduction: Rosuvastatin compared with atorvastatin has been associated with worse renal outcomes in people with diabetes and chronic kidney disease (CKD). There are interethnic differences in statin metabolism and dosage. We compared the risk associations of rosuvastatin and atorvastatin with (…)
• 02:00
  415-P: Different Diabetic Kidney Disease (DKD) Phenotypes and Urinary Fetuin-A Levels in Subjects with Type 2 Diabetes Diabetes
  Introduction & Objective: The hepatokine fetuin-A is associated with insulin resistance and promotes inflammation in T2D, contributing to the development of DKD. In this observational, single-center study, we evaluated the potential of this novel urinary biomarker in differentiating DKD (…)
• 02:00
  416-P: Variability of Metabolic Risk Factors for Kidney Function Decline in Diabetes Compared with Nondiabetes—A Cluster Analysis of Community-Based Prospective Cohort Study Diabetes
  Introduction & Objective: We aimed to identify different patterns of estimated glomerular filtration rate (eGFR) trajectories depending on diabetes status using long-term prospective cohort and to find the association and variability between risk factors, and patterns of eGFR (…)
• 02:00
  413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk Diabetes
  Introduction & Objective: Guideline-directed care of people with type 2 diabetes (T2D) and high risk of cardiovascular disease (CVD) is informed by robust outcome trials. Little is known about the impact of T2D drugs in adults with T2D with moderate CVD risk, particularly on key kidney (…)
• 02:00
  414-P: A Novel Mutation in HNF1B Promotes Ferroptosis-Mediated Renal Mesangial Cells Fibrosis Diabetes
  Objective: In this study, we identified a novel HNF1B gene mutation (c.445C>A) in a young male MODY5 patient with and elevated serum creatinine levels and albuminuria.Method: We constructed the HNF1B wild type (HNF1B-WT) and the novel missense mutation (c.445C>A) Mutant (HNF1B-Mut) plasmid and (…)
• 02:00
  411-P: Extended Generalized Metabolic Fluxes (GMF) Based Digital Twins for Predicting CKD Diabetes
  Introduction: CKD is a prominent complication in diabetes patients. Our regulatory-approved digital twin model, HealthVector Diabetes (HVD), leverages generalized metabolic fluxes (GMF) to predict CKD within a 3-year timeframe using common biochemical and physiological parameters. HVD achieved (…)
• 02:00
  412-P: Kidney Shape in Magnetic Resonance Imaging—A Possible Biomarker for Diabetic Kidney Disease? Diabetes
  Introduction: With advancement in medical imaging, magnetic resonance imaging (MRI) is considered as an alternative source of biomarkers. The aim of this study was to explore the potential of kidney shape factors measured by MRI as biomarkers for DKD progression as early DKD tends to have larger (…)
• 02:00
  410-P: Evaluating the Performance of the 2021 CKD–EPI Equation in People with Diabetes Diabetes
  Introduction: In 2021, CKD-EPI equation without the race coefficient (2021 CKD-EPI equation) was recommended for use in clinical practice by international guidelines. The performance of the 2021 equation in people with diabetes is unknown. This study aims to assess and compare the performance of (…)
• 02:00
  40-OR: The Association of Continuous Glucose Monitoring Metrics with Hospital-Related Clinical Outcomes Diabetes
  Introduction: Few studies have examined the association between continuous glucose monitoring (CGM) metrics and hospital-related clinical outcomes in the inpatient setting.Methods: In this prospective observational study, patients admitted on non-intensive care floors receiving fingerstick (…)
• 02:00
  40-PUB: Impact of the Initiation of is-CGM Soon after Type 1 Diabetes Mellitus Diagnosis in Adults on Glycemic Indices and Fear of Hypoglycemia—Data from RCT Diabetes
  Use of CGMS has become the standard of glucose control in patients with T1DM. It was shown that use of CGM improves TIR and TBR, and QoL. We aimed to assess the impact of soon after diagnosis (within 1-6 months) initiation of is-CGM on glycemic indices and fear of hypoglycemia (FoH) in adults (…)
• 02:00
  409-P: Evaluating the Agreement between CKD-EPI Calculated eGFR and mGFR in People with Diabetes—An International Individual Participant Data Meta-analysis Diabetes
  Introduction: Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide. We and others have shown that CKD-EPI equation is less accurate in estimating glomerular filtration rate (eGFR) in people with diabetes. This study aimed to assess the agreement between directly (…)
• 02:00
  407-P: Kidney Transplant Infection Risks—CGM Parameters Insights and Glucagon-Like Peptide-1 Receptor Agonist (GLP1-RA) Strategies Diabetes
  Introduction: Cytomegalovirus (CMV) and BK are common viral infections in kidney transplant (KT) recipients that tend to appear within the first year after KT. Uncontrolled post-transplant diabetes mellitus (PTDM) and Type 2 diabetes mellitus (T2DM) have been associated with an increased risk (…)
• 02:00
  408-P: Long-Term Improvement in Renal Function following Intensive Lifestyle Intervention in Patients with Diabetes and Obesity—A 15-Year Longitudinal Study Diabetes
  Nearly 30% of patients with diabetes mellitus (DM) develop diabetic nephropathy over time. The long-term effect of weight loss, through lifestyle intervention, on kidney function remains unknown.We evaluated 94 patients with obesity and DM (12.8% type 1 DM and 87.2% type 2 DM, age 53.9±9.9 (…)
• 02:00
  405-P: Pharmacological Activation of Kidney AMPK Promotes Diuresis and Natriuresis in Rats Diabetes
  Introduction: In vitro and in vivo genetic studies have demonstrated that AMP-activated protein kinase (AMPK) controls renal epithelial electrolyte transport stimulating renal sodium and water reabsorption. Using a selective small molecule pan AMPK activator, cpd 1, we characterize the (…)
• 02:00
  406-P: Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes Diabetes
  Introduction & Objective: Sodium glucose linked transporter inhibitors (SGLTi) in T1D raise DKA risk but hold potential for kidney protection, especially with impaired renal function [eGFR 2]. We aimed to determine if those with eGFR impairment have higher DKA risk, perhaps owing to lower (…)
• 02:00
  403-P: Body-Weight Cycling and Risk of Diabetic Kidney Disease in People with Type 1 Diabetes Diabetes
  Introduction & Objective: Chronic kidney disease (CKD) is a major issue in the management of people with type 1 diabetes (T1D). Intraindividual body weight variability (BWV) or cycling is associated with increased risk of cardiovascular events and all-cause death in T1D. We conducted a (…)
• 02:00
  404-P: Characterization of the Differential Effects of Oxyntomodulin (GLP-1/Glucagon) and GLP-1 on Body Weight, Glucose Metabolism and Renal Function in db/db Mice Diabetes
  Introduction: Oxyntomodulin (OXM) is a peptide hormone released from the gut in post-prandial state that activates both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). Because GLP-1 agonism has been reported to have a renoprotective effect in animal models and (…)
• 02:00
  401-P: Fibrosis-4 Index Independently Predicts CKD Progression in Patients with Type 2 Diabetes and MAFLD Diabetes
  Background: Fibrosis-4 (FIB-4) index is recommended by the American Diabetes Association Standard of Care 2024 for liver fibrosis screening in T2D. While the association between FIB-4 and increased cardiovascular disease has been established, its impact on the progression of chronic kidney (…)
• 02:00
  402-P: Effect of Serum 25-Hydroxyvitamin D on CKD Progression in Type 2 diabetes Diabetes
  Background: It has been established that there was an inverse association between baseline serum 25-hydroxyvitamin D (25OHD) and new-onset chronic kidney disease (CKD) in patients with type 2 diabetes (T2D). However, the prospective relationship between vitamin D status and CKD progression (…)
• 02:00
  1564-P: Hepatic Lipid Content Associates with Fasting and Prandial Glucagon Secretion in Recent-Onset Type 2 Diabetes Diabetes
  Hyperglycemia in type 2 diabetes (T2D) associates with higher glucagon secretion, which may be further promoted in the presence of metabolic dysfunction-associated steatotic liver disease (MASLD). Thus, we compared fasting and prandial glucagonemia in people with and without recent-onset T2D and (…)
• 02:00
  604-P: Different Exercise Exposures May Protect against Developmental Programming of MASLD in Male Mice? Diabetes
  Introduction: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is a chronic liver disease that affects up to a fourth of the adults in the US. Maternal obesogenic diet exposure (MODE) programs worse MASLD in offspring. The beneficial effects of exercise on metabolic disease are (…)
• 02:00
  603-P: In Type 1 Diabetes, Meta-analysis Identifies Variable Glucose Response to Exercise Based on Intensity Diabetes
  Introduction & Objective: For people with Type 1 diabetes, changes in sugar levels in response to exercise can be highly variable. A meta-analysis of recent continuous glucose monitoring (CGM) studies was conducted to identify glucose changes in response to exercise.Methods: A literature (…)
• 02:00
  602-P: Relationships between Diagnosis Duration, Motor Proficiency, and Physical Fitness in Youth with Type 1 Diabetes Diabetes
  Introduction & Objective: Individuals with T1D encounter unique challenges regarding physical activity, glucose control, and chronic health conditions. Understanding the connection between diagnosis duration, motor proficiency (MP), physical fitness, and glycemic control is crucial for (…)
• 02:00
  601-P: Exploring Strategies to Manage Hyperglycemia-Related Anxiety during Competition in Elite Athletes with Type 1 Diabetes—A Qualitative Analysis Diabetes
  Introduction & Objective: Elite athletes with type 1 diabetes (T1D) face unique challenges managing their blood glucose levels, as competitions can cause unpredictable fluctuations. The impact of hyperglycemia-related anxiety on their performance and diabetes management is important, yet (…)
• 02:00
  5-PUB: Retrospective Study of Patients with Dyslipidemia With and Without Type 2 Diabetes Mellitus Treated with a Fixed-Dose Combination of Rosuvastatin/Ezetimibe Diabetes
  Introduction and Objective: Currently, dyslipidemia is one of the most common comorbidities in patients with Type 2 Diabetes Mellitus (T2DM), for which cardiovascular risk (CVR) is usually underestimated, being this the case where the use of combined therapy of statins and ezetimibe is (…)
• 02:00
  5-OR: Renal Hypermetabolism in Youth-Onset Type 2 Diabetes (T2D)—A C-11 Acetate PET Scan Analysis Diabetes
  Introduction & Objective: Renal hypermetabolism in youth-onset T2D presents a critical area of study due to potential metabolic implications. Prior kidney biopsy research indicated upregulated metabolic pathways, such as the TCA cycle and oxidative phosphorylation, in the proximal tubules of (…)
• 02:00
  59-PUB: Leveraging Machine Learning for Precise Prediction of Type 2 Diabetes Diabetes
  Introduction: Diabetes, a global chronic ailment, necessitates advanced predictive models.Methods: This study leverages the Pima Indian dataset, implementing Logistic Regression (LR), Naïve Bayes, Random Forest, and Decision Tree algorithms. Algorithmic performance is assessed using accuracy, (…)
• 02:00
  59-OR: Improving Diabetic Kidney Disease Screening in a Veterans Affairs Primary Care Clinic Diabetes
  Introduction & Objective: Diabetic Kidney Disease (DKD) is a major cause of end stage renal disease. Up to half of Americans with DKD are unaware of the diagnosis and community screening rates for albuminuria varies widely. Using Lean quality improvement methods, we aimed to improve our DKD (…)
• 02:00
  599-P: Automated Insulin Delivery Systems and Physical Activity—Management and Outcomes Diabetes
  Introduction: Physical activity (PA), along with insulin adjustments and food intake for its purpose, can cause dysglycemia for people with type 1 diabetes (PWT1D), acting as a major barrier to activity. It is unclear if automated insulin delivery (AID) systems improve this situation.Methods: (…)
• 02:00
  598-P: Sex-Specific Differences of Human Skeletal Muscle—A Multiomics Exercise Study Diabetes
  Exercise is a potent skeletal muscle stimulus and one of the most effective strategies to prevent muscle loss and type 2 diabetes. Biological sex-based differences are reported for aerobic capacity, muscle mass, and exercise performance. We aimed to provide a yet missing comprehensive picture of (…)
• 02:00
  597-P: Wearable Device Use and Physical Activity among Individuals with Diabetes—The 2022 Health Information National Trends Survey Diabetes
  Introduction & Objective: Wearable devices have demonstrated potential in encouraging physical activity (PA) in the general population. This study is to investigate sociodemographic factors linked to the use of wearable devices and assess the influence of the wearable device use on PA among (…)
• 02:00
  1778-LB: Comparing a Somatostatin Receptor 2 Antagonist (SSTR2a) to Exogenous Glucagon (EG) for the Treatment of Severe Insulin-Induced Hypoglycemia Diabetes
  Introduction & Objective: Treatment of severe hypoglycemia (SH) with EG causes hyperglucagonemia, resulting in gastrointestinal distress that limits its real-world utility. Prophylactic dosing of SSTR2a augments glucagon counterregulation during insulin-induced hypoglycemia in diabetic rats. (…)
• 02:00
  855-P: GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Reduces Glucose and Bodyweight in Patients with Type 2 Diabetes Diabetes
  Background: GLY-200 is an investigational oral non-absorbed polymer drug designed to bind to and enhance the barrier function of gastrointestinal mucus as a non-invasive alternative to metabolic surgery and duodenal exclusion devices. In healthy volunteers, GLY-200 lowered glucose and increased (…)
• 02:00
  854-P: Global, Multicenter Registry of Prospectively-Enrolled Patients Utilizing SCS for Chronic Pain—Long-Term Outcomes from a Subcohort Diagnosed with Painful Diabetic Peripheral Neuropathy Diabetes
  Introduction & Objective: The American Diabetes Association recommends referring DPN patients to interventional pain management care when pharmacological therapies have no meaningful effect. Recent burgeoning of advances in neuromodulatory-based systems has thus spurred interest in (…)
• 02:00
  853-P: Efficacy and Safety of HD-6277, a Novel GPR40 Agonist, in Patients with Type 2 Diabetes—A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Trial Diabetes
  Objective: To assess the efficacy and safety of HD-6277, the first candidate of GPR40 in a new oral antidiabetic agent, in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus (T2DM)Research Design & Methods: A double-blind, randomized, placebo-controlled phase 2 trial (…)
• 02:00
  852-P: Effect of Metformin on Intestinal Flora in Patients with Polycystic Ovary Syndrome Diabetes
  Objective: To analyze the characteristics of the intestinal flora of patients with polycystic ovary syndrome (PCOS) in reproductive age, and to explore the effect of metformin on the intestinal flora of PCOS patients.Methods: Thirty-six PCOS patients attending Wuxi People's Hospital affiliated (…)
• 02:00
  851-P: Whole Body Digital Twin (WBDT) Enabled Diabetes Reversal—U.S. Real-World Findings Diabetes
  The WBDT is a digital model of metabolism, created using sensors, the Internet of Things, artificial intelligence and machine learning, providing an individualized comprehensive lifestyle intervention to improve and reverse T2D and its comorbidities. With an easy-to-use app, patients (pts) and (…)
• 02:00
  850-P: Trends in GLP-1RA Use among Individuals with Type 2 Diabetes (T2D) and/or Obesity—Insights from a Nationwide Electronic Health Record System, 2010–2023 Diabetes
  New evidence highlights GLP-1 RAs' significant benefits in blood glucose and weight control for those with T2D and/or obesity, yet their real-world use and related disparities are unexplored. We conducted a pooled cross-sectional study using electronic health records from the Epic Cosmos (…)
• 02:00
  84-OR: Performance of FIB-4 Score in Predicting Mortality among Patients with Nonalcoholic Diabetes
  Introduction & Objective: T2D in NAFLD is associated with adverse outcomes. FIB-4 score identifies high-risk NAFLD. The association of FIB-4 with mortality among NAFLD with T2D was assessed.Methods: NHANES III-linked mortality data were used. NAFLD is defined by ultrasound without other (…)
• 02:00
  849-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects—A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study Diabetes
  Background: BGM0504 is an optimized dual GIP and GLP-1 receptor agonist with greater in vitro potency, and similar GLP-1R/GIPR activity ratio as Tirzepatide. Here we report the results of a phase Ia study of BGM0504 in healthy subjects (CTR20230120).Methods: In a clinical study of 40 healthy (…)
• 02:00
  3-PUB: Prevalence and Associated Factors of Diabetic Retinopathy among Type 2 Diabetes in Beijing, China—A Cross-Sectional Study Diabetes
  Objective: Diabetic retinopathy (DR) is the main cause of blindness in diabetic patients. The worldwide prevalence of Diabetic Retinopathy was recently estimated to be 34.6%. However, the prevalence and contributing factors of diabetic retinopathy remains controversial in the study areas. The (…)
• 02:00
  400-P: KidneyIntelX Impact on ADA DKD Prevention Model Metrics Diabetes
  The ADA DKD Prevention Model was developed to define key concepts for DKD prevention and treatment. We sought to describe and quantify specific outcome measures outlined in the ADA model following deployment of a system-wide interdisciplinary approach that centered around KidneyIntelX, a (…)
• 02:00
  39-PUB: A Comprehensive Tool for Analyzing Continuous Glucose Monitoring Data Diabetes
  Introduction & Objective: While existing software packages are available for Continuous Glucose Monitoring (CGM) data analysis, they lack the incorporation of novel CGM-based metrics, specifically focusing on the dynamics of health status, Shannon entropy, and fractal analysis.Methods: We (…)
• 02:00
  3-OR: Lipoprotein(a) Levels and Epicardial Adipose Tissue in Diabetes—Unraveling Novel Connections Diabetes
  Introduction & Objectives: While extremely high levels of lipoprotein (a) [Lp(a)] are associated with an increased risk of cardiovascular disease, very low levels of Lp(a) have been associated with an increased risk of diabetes. The underlying mechanisms explaining this association are still (…)
• 02:00
  1948-LB: Effect of N-Acetyl Cysteine on Thrombo-inflammation in Children with Metabolic Dysfunction–Associated Steatotic Liver Disease Diabetes
  Background: Obesity (OB)-related pro-thrombo-inflammatory state sets the basis for cardiometabolic disease including type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) in children. The aims were to explore in children with OB and MASLD (i) the role of (…)
• 02:00
  1949-LB: Clinical Characteristics and Dosing Patterns of Tirzepatide among Adults without Type 2 Diabetes—Real-World Results Diabetes
  Objective: Tirzepatide is a once weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes (T2D) and obesity. This study aimed to understand characteristics and dosing patterns of tirzepatide in adults without T2D (…)
• 02:00
  1946-LB: Patterns of Insulin Discontinuation in Youth with New-Onset Type 2 Diabetes Diabetes
  Heterogeneity in the clinical course of T2D in youth presenting with and without diabetic ketoacidosis (DKA) at diagnosis is not well described. In this study, we aimed to characterize if presentation with DKA affects rates of insulin discontinuation compared to T2D without ketosis (non-DKA). (…)
• 02:00
  1947-LB: Trends of Diabetes in Youth (TrenDY) during COVID-19 across the United States Diabetes
  Introduction and Objective: Reports from year 1 of the COVID-19 pandemic showed an increase in frequency and acuity of type 1 diabetes (T1D) and type 2 diabetes (T2D) in youth at diagnosis. It is unclear whether this changed as the pandemic progressed. This study aims to describe the US national (…)
• 02:00
  1944-LB: Control of Impatient Hyperglycemia Using a Decision Support System Diabetes
  Introduction: Hyperglycemia is an independent marker of hospital mortality, regardless of the previous diagnosis of diabetes. insulin is the clear choice for the hospitalized patient. Insulin should be administered using validated protocols that allow predefined adjustments in insulin doses (…)
• 02:00
  1945-LB: Evaluation of Proactive Targeting Models Used to Identify People with Diabetes at Risk of Being Uncontrolled during Participation in a Digital Diabetes Management Program (DDMP) Diabetes
  Introduction & Objective: Predictive machine learning models were developed for each month during DDMP to predict individual risk of having an estimated A1c (eA1c) ?7.5% at 12 months for personalized Health Nudges to be deployed for improved fingerstick blood glucose monitoring (FBGM) and (…)
• 02:00
  1941-LB: Effect of the Community-Based Multicomponent Strategy for Diabetes Self-Care Diabetes
  Introduction & Objective: Although there are many studies to confirm the effectiveness of single interventions for diabetes self-care, but patients’ real world experiences are complex, including education, counseling, and access to mHealth. The purpose of this study is to identify the effect (…)
• 02:00
  1942-LB: Detecting Unmet Psychosocial Needs in Adult Persons with Diabetes—First Data from Our National Danish Diabetes PROMS Questionnaire DiaProfil Diabetes
  Introduction & Objectives: Persons with diabetes (PwD) and our VBS-PRO-DIA research team developed the national Danish Patient-Reported Outcome (PRO) fully digital questionnaire (#DiaProfil). It is now fully implemented in all 4 hospitals in our region (uptake 600.000 inhabitants). DiaProfil (…)
• 02:00
  1943-LB: The Fresh Start Program—Refreshing Management of Type 2 Diabetes Mellitus Diabetes
  Objective: Intensive type 2 diabetes mellitus (T2DM) intervention programs can improve clinical outcomes for patients and reduce costs to patients, insurance providers, and health care systems. We piloted an intensive T2DM intervention program consisting of a multidisciplinary team of diabetes (…)
• 02:00
  15-OR: Diabetic Retinopathy (DR) Is Associated with Markers of Alzheimer's Disease (AD) in Type 1 Diabetes (T1D) Diabetes
  Introduction & Objective: DR is shown to predict AD in type 2 diabetes, but less is known in T1D where DR burden is significant. This study examined differences in levels of phosphorylated tau-181 (pTau181), a validated preclinical biomarker of AD neuropathology, between adults with and (…)
• 02:00
  1940-LB: Implementation of an Inpatient Glucose Management Program in a Large U.S. Health System Diabetes
  Introduction: Translation of inpatient glycemic recommendations has been slow to occur. The recent consolidation of two large healthcare systems provided a unique opportunity to harmonize all ordersets and examine the impact on glycemic control.Methods: A comprehensive revision of glycemic (…)
• 02:00
  1599-P: Understanding the Paradoxical Rise in Blood Glucose in the Context of a Low-Carbohydrate Diet Diabetes
  Introduction and Objective: Conventional medicine places markers of glycemic control as a key diagnostic and therapeutic target for metabolic disorders. Long-term adherence to a low-carbohydrate diet may improve glycemic control but may also cause a unique hormonal response to macronutrients (…)
• 02:00
  159-OR: Sequential Measurements of Insulin Resistance in the Assessment of Individuals Participating In Diabetes Prevention Programs Diabetes
  A number of studies have found that programs such as the Diabetes Prevention Program (DPP) delay or prevent the progression from prediabetes to type 2 diabetes mellitus. However, a substantial proportion of the participants in these programs eventually develop type 2 diabetes. To explore (…)
• 02:00
  1597-P: High Fat and Fructose Diet Dysregulates Postprandial Gut and Hepatic Metabolism in a Canine Model Diabetes
  Diets high in fat and sugar are associated with the development of metabolic disease, but pathogenic changes in the gut and downstream metabolic organs are not well understood. In the dog, we sought to assess 9 weeks of chow (n=5) versus high-fat, high-fructose diet (HFFD) (n=5) on the gut (…)
• 02:00
  1598-P: Transcriptional Profiling of the Intestinal Tract in Type 2 Diabetes—Unraveling Pathophysiological Pathways for Therapeutic Insights Diabetes
  Introduction and Objective: Investigating the intestinal gene expression in type 2 Diabetes (T2D) may reveal novel insights into its pathophysiology. We conducted a comprehensive investigation to compare gene expression profiles along the entire human intestinal tract of individuals with T2D and (…)
• 02:00
  1595-P: Differential Effects of Carbohydrate Overfeeding on Postprandial Glucose Metabolism in Individuals with Low Compared with Normal Birthweight Diabetes
  Introduction & Objective: Individuals born with low birthweight (LBW) are at elevated risk of developing type 2 diabetes (T2D). We studied postprandial (pp) glucose metabolism during a mixed meal-test in healthy LBW compared with normal birthweight (NBW) men before and after carbohydrate (…)
• 02:00
  1596-P: Personalized Glycemic Response to Carbohydrates and Associated Physiological Signatures in Multiomics Diabetes
  Introduction & Objective: Individuals with type 2 diabetes (T2D) exhibit heterogeneous metabolic dysfunction (e.g., muscle insulin resistance (IR), beta-cell dysfunction) and varying intervention needs. People also have different dynamic responses to daily activities (e.g., exercise and (…)
• 02:00
  1594-P: Deciphering Postprandial Hypoglycemia—Dominant Influence of Insulin Sensitivity in Patients without Diabetes Diabetes
  Introduction & Objective: Postprandial hypoglycemia describes a condition with abnormally low glucose within a few hours after carbohydrate-rich meals. Underlying mechanisms are still unclear, with hypotheses including an unusually rapid increase in blood glucose, excessive insulin release, (…)
• 02:00
  610-P: Effect of Butyrate on GI signs, SIBO, and Diabetes Control—Randomized, Placebo-Controlled Study in Patients with Type 2 Diabetes Diabetes
  Introduction & Objective: Patients with type 2 DM have frequently GI signs/symptoms and small intestinal bacterial overgrowth (SIBO), which may impair beta cell function and diabetes control. The study aimed to evaluate the influence of microencapsulated oral sodium butyrate on GI signs, (…)
• 02:00
  611-P: Effect of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) during a Nutrition Intervention on Time in Range (TIR) Diabetes
  Introduction: Reducing carbohydrate intake improves glycemia in people with T2D. Data on nutrition interventions using CGM are sparse. IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE) compared differences in change in CGM-derived TIR (% time with glucose 70?180 mg/dL) from (…)
• 02:00
  612-P: Impact of Continuous Glucose Monitoring (CGM) vs. Blood Glucose Monitoring (BGM) on Dietary Adherence and Weight during a Medically Supervised Ketogenic Diet Program (MSKDP) in People with Type 2 Diabetes (T2D) Diabetes
  Introduction: Lifestyle-based interventions that promote nutritional ketosis can be effective for T2D management. This three-month trial compared use of CGM or BGM to support a MSKDP delivered via continuous remote care.Methods: In this randomized trial, CGM (N=81) or BGM (N=82) data were used (…)
• 02:00
  60-PUB: Simultaneous Analysis of Serum Monosaccharides Levels among Adults of Self-Reported Diabetes Status using Non-Derivatized LC-MS/MS Method Diabetes
  Introduction and Objective: Glucose is the major biomarker for diagnosis and management of diabetes. Fructose is sometimes used to replace glucose and reduce glucose intake. Increased consumption of fructose was shown to contribute to non-alcoholic fatty liver disease (NAFLD). To better (…)
• 02:00
  609-P: Effects of Oligomalt (OM), a New Slowly Digestible Carbohydrate (SDC), on Postprandial (PP) Glucose, Insulin, and GLP-1 Trajectories Compared with Maltodextrin (MD) in People with Obesity (PwO) or Type 2 Diabetes (T2D)—A Double-Blind RCT Diabetes
  Introduction & Objective: to assess glucometabolic effects of OM, a novel fully digestible SDC.Methods: In a cross-over RCT, we tested 33g and 50g of OM/MD in PwO (n=26, mean age 44 yrs, BMI 29.9 kg/m2, HbA1c 5.3%), and 50g in people with T2D (n=22, age 61 yrs, BMI 31.8 kg/m2, HbA1c 7.4%). (…)
• 02:00
  60-OR: Implementing a Machine-Learning Model to Predict Risk of Chronic Kidney Disease (CKD) Progression Diabetes
  Introduction & Objective: Early identification of at-risk CKD can facilitate timely interventions and improve patient (pt) outcomes. This study applied a previously published and validated machine learning model, Klinrisk, to predict CKD progression risk in a US population.Methods: A (…)
• 02:00
  607-P: Associations of Gut Microbiome with Glycemic Control in a Carbohydrate-Restricted, High-Protein Diet for Type 2 Diabetes Mellitus Diabetes
  Objective: The Low Biologically Available Glucose (LoBAG) diet was designed to improve glycemic control of type 2 diabetes mellitus (T2D). We evaluate changes in the gut microbiome when participants with T2D are given the LoBAG diet.Methods: Thirty-six participants with T2D taking metformin or (…)
• 02:00
  608-P: Carbohydrate Intake, Glycemic Control, and Cardiometabolic Risk Factors in Type 1 Diabetes—A Systematic Review and Meta-regression Diabetes
  The relationship between carbohydrate intake and cardiometabolic risk remains controversial in people with type 1 diabetes (T1D). In a systematic review of dietary carbohydrate (CHO) content [ranging from very-low (p) and TDD (+0.12 IU/kg/day per 50 g, p). Above the knot, CHO intake was (…)
• 02:00
  606-P: Mitigating Type 2 Diabetes Risks—A 12-Week At-Home Physical Activity Intervention for Improving Metabolic Health in the Growing Asian Immigrant Community Diabetes
  Introduction & Objective: As the immigrant community experiences rapid growth in the U.S., Asians encounter diverse health challenges, with a notable focus on addressing type 2 diabetes (T2D). Enhancing muscle mass has been identified as a means to alleviate insulin resistance and, (…)
• 02:00
  605-P: Barriers of Exercise in Children and Adolescents with Diabetes Mellitus in Hong Kong Diabetes
  Objective: According to World Health Organization (WHO), children and adolescents are recommended to exercise at least 150 mins per week to maintain good physical and psychosocial health. This study aimed to determine the barriers of exercise among children and adolescents with diabetes.Methods: (…)
• 02:00
  848-P: Comparing Generative AI to Human Responses for Personalized Diabetes Drug Selection Diabetes
  Introduction and Objective: Generative artificial intelligence (AI) offers great promise for clinical decision support (CDS). When there is a single right answer to a clinical question, assessing whether a generative AI is appropriate for CDS may be simple: does it give the correct answer often (…)
• 02:00
  770-P: Efficacy and Safety of Tirzepatide in Participants Who Achieved Fasting Serum Glucose Targets at 52 Weeks in SURPASS-3 and SURPASS-4 Diabetes
  Introduction & Objective: In the SURPASS-3 (S-3) and -4 (S-4) trials, tirzepatide (TZP) reduced HbA1c and body weight (BW) in participants with type 2 diabetes (T2D) vs. basal insulin (BI). We assessed the efficacy and safety of TZP and BI in those who did or did not achieve fasting serum (…)
• 02:00
  76-OR: Diabetes Technology and Waste—A Real-World Study in a Specialized Practice in Germany Diabetes
  Introduction & Objective: Diabetes technology is a pillar of modern diabetes therapy. No real-world data about the amount of waste generated was published before. The aim of our study was to quantify this “diabetes technology waste” in a real-world situation in a specialized diabetes (…)
• 02:00
  769-P: Efficacy and Safety of GLP1RAs in Liver-Transplanted People with Diabetes—Ad Interim Results of a 24-Month Trial Diabetes
  GLP1 RAs are first line drugs for DM2, due to their effects on glycemic control, cardiorenal protection and weight-loss action. However, consistent data about efficacy and safety in patients with liver transplant (LT) are lacking.Aim: to assess the efficacy and safety of GLP1RAs in people with (…)
• 02:00
  768-P: A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity Diabetes
  Introduction: PB-718 is a fixed dose combination of PB-119 (GLP-1 receptor agonist) and PB-722 (glucagon receptor agonist in clinical development. Compared with a single molecule approach, PB-718 may offer the balance between GLP-1 and GCGR through adjusting the molar ratio of PB-119 and PB-722 (…)
• 02:00
  767-P: A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Participants with Type 2 Diabetes Mellitus (T2DM) Diabetes
  Introduction: GSBR-1290 is a novel, oral, non-peptide GLP-1RA and a potential alternative to injectable or oral peptides used for the treatment of T2DM and obesity. These studies were designed to evaluate the safety, tolerability, and efficacy of GSBR-1290.Methods: Phase 1b: The safety and (…)
• 02:00
  766-P: Long-Term Effectiveness Associated with Maintenance Doses of Once-Weekly Semaglutide in U.S. Adults with Poorly Controlled Type 2 Diabetes Diabetes
  Introduction & Objective: To evaluate long-term effectiveness associated with maintenance doses of once-weekly semaglutide (sema) in US adults with poorly controlled type 2 diabetes (T2D).Methods: Observational cohort study (Optum Clinformatics® Data Mart, Jan 2017-Dec 2022). Eligibility (…)
• 02:00
  765-P: Efficacy and Safety of Switching to iGlarLixi from Premixed Insulin (PI) in South Korean People Living with Type 2 Diabetes (T2D)—Subanalyses of Soli-SWITCH Study Diabetes
  Introduction & Objective: iGlarLixi is a once-daily injectable fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide and may be a simplified treatment option vs PI. This sub-analysis of the Soli-SWITCH study (EudraCT number 2021-003711-25) assessed the efficacy and safety of (…)
• 02:00
  764-P: Discovery of ASC30, a Highly Potent and Orally Available Novel Nonpetide GLP-1 Receptor Biased Agonist Diabetes
  Introduction & Objective: Injectable peptidic GLP-1 receptor (GLP-1R) agonists are established treatments for Type 2 Diabetes Mellitus (T2DM) and obesity. An nonpeptide oral GLP-1R agonist without injection and cold chain storage offers many benefits for patients. Here we report the (…)
• 02:00
  763-P: CagriSema Improves Insulin Sensitivity in Diet-Induced Obese Rats Diabetes
  Introduction & Objective: CagriSema (CS), a combination of the long-acting analogues of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide), is in clinical development for treatment of obesity and type 2 diabetes. Rodent studies have shown that CS treatment results in weight (…)
• 02:00
  762-P: Semaglutide Awareness among Clinical-Year Medical Students Diabetes
  Introduction & Objective: Semaglutide, a novel type 2 diabetes (T2D) medication, offers significant advantages over other antidiabetic drugs by facilitating weight reduction, preventing cardiovascular complications, and minimizing hypoglycemic risks. Prescriptions for Semaglutide, to treat (…)
• 02:00
  761-P: Use of Tirzepatide in Type 1 Diabetes Diabetes
  In a retrospective chart review, we assessed the efficacy and safety of GLP1/GIP agonists, specifically tirzepatide, in managing Type 1 Diabetes (T1D). The study involved 15 patients (7 males, 8 females; average age 48 years; average diabetes duration 34 years), using Continuous Glucose Monitors (…)
• 02:00
  760-P: TERN-501 Enhances Weight Loss Efficacy of a GLP-1R Agonist in Obese Mice via Increased Fat Mass Loss without Additional Loss of Lean Mass Diabetes
  Introduction & Objective: GLP-1R agonists suppress food intake resulting in weight loss but efficacy is limited by metabolic adaptation, a compensatory process that lowers energy expenditure (EE). Thyroid hormone receptor beta (THR?) regulates EE providing a potential mechanism to mitigate (…)
• 02:00
  75-PUB: The Sartorius Fat Fraction Is Independently Associated with Myocardial Fibrosis in Chinese Patients with Obesity Diabetes
  Objective: The study aimed to investigate the correlation between intramuscular adipose tissue (IMAT) accumulation in lower extremities and the myocardial tissue-level characteristics detected by MRI in Chinese individuals with obesity.Methods: A cross-sectional analysis was performed in 51 (…)
• 02:00
  75-OR: In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes Diabetes
  Introduction & Objective: The UVLab platform - equipped with a metabolic model and 6062 virtual subjects (VS) with type 2 diabetes (T2D) - describes T2D heterogeneity. This work evaluates UVLab's ability to replicate the findings from a 26-week phase 3 clinical trial (NCT01336023) comparing (…)
• 02:00
  758-P: PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to -6 by Age, Gender, BMI, and Weight Loss Diabetes
  Tirzepatide treatment statistically and meaningfully reduced HbA1c, and substantially reduced weight, in adults with T2D in the Phase 3 SURPASS studies. PROs in adults treated with tirzepatide 5, 10, or 15 mg in SURPASS-1 to -6 were explored by age, gender, BMI, and weight loss.Data from all (…)
• 02:00
  757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes Diabetes
  Introduction & Objective: In the SURPASS-6 trial, addition of tirzepatide (TZP) to basal insulin glargine U100 in participants with inadequately controlled long-standing type 2 diabetes (T2D), substantially improved HbA1c and body weight. We evaluated degrees of insulin dose reductions and (…)
• 02:00
  1968-LB: Early Prediction of Gestational Diabetes Mellitus Using Electronic Health Records and Machine Learning Diabetes
  Introduction: The objective of this study is to assess the efficacy of machine learning models in gestational diabetes mellitus (GDM) prediction using electronic health record (EHR) data collected in the first trimester.Methods: Data were extracted from The Coombe Hospital EHRs, Dublin, spanning (…)
• 02:00
  1965-LB: Metabolomic and Transcriptomic Signatures of Gestational Diabetes Mellitus (GDM) Suggest Nutritional and Inflammatory Pathways in Intergenerational Transfer of Risk Diabetes
  Introduction & Objective: GDM impacts intergenerational transfer of metabolic risk. The underlying mechanisms could inform intervention strategies. The placenta nourishes the developing fetus and is influenced by the maternal milieu. We assessed placental transcriptome and cord blood (…)
• 02:00
  1964-LB: Association between Fasting Venous Lactate Level and Development of Preeclampsia in Pregnant Individuals with Gestational Glucose Intolerance Diabetes
  Introduction & Objective: Pre-eclampsia (PE) is a hypertensive disorder in pregnancy thought to result from abnormal vascular placentation that is associated with metabolic dysfunction. Blood lactate is also associated with metabolic dysfunction. Few studies have explored if lactate is (…)
• 02:00
  1963-LB: Prenatal Treatment of Glucagon-Like Peptide 1 Agonist Mitigates Cognitive Deficits in Offspring of Mothers with Diabetes by Modulating Placental Development Mediated by ADGRL3 Diabetes
  Hyperglycemia during pregnancy is associated with increased neurobehavioral risks in offspring, even with insulin control. We hypothesized that prenatal administration of Glucagon-like peptide 1 (GLP-1) agonist to diabetic mothers could alleviate cognitive deficits in offspring. A pregestational (…)
• 02:00
  1962-LB: Intrauterine Exposure to Gestational Diabetes and the Developing Brain Diabetes
  Intrauterine exposure to gestational diabetes mellitus (GDM) is associated with an increased risk for adverse metabolic and cognitive outcomes, but the mechanisms are not clear. We tested the hypothesis that exposure to GDM is associated with changes in adiposity and brain trajectories during (…)
• 02:00
  1961-LB: Evaluation of Two Behavioral Economic Interventions for Youth with Type 1 Diabetes—A Randomized Controlled Trial Diabetes
  Introduction & Objective: Mealtime insulin dosing behavior is critical to glycemic control in youth with type 1 diabetes (T1D). Behavioral Economic Incentives (BEI) have been shown to improve self-management behaviors. We report interim results of a randomized trial evaluating 2 forms of a (…)
• 02:00
  1960-LB: A 3D Analysis of CD8+ Leukocytic Infiltration in Human Endocrine and Exocrine Pancreas at Type 1 Diabetes Onset Diabetes
  Introduction: Elevations in immune cell numbers are well documented in both the endocrine and exocrine pancreas in type 1 diabetes (T1D), with CD8+ T cells representing the predominant cell type in islet inflammation (insulitis). To expand on previous 2D characterizations, we used 3D light sheet (…)
• 02:00
  195-OR: Efficacy and Feasibility of a Telemedicine Program for Institutionalized Elderly People with Insulin-Treated Diabetes Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap—The Trescasas Study Diabetes
  Introduction & Objective: Investigate the feasibility and efficacy of a telemedicine program in institutionalized elderly people with insulin-treated diabetes.Methods: This multicenter, prospective study comprised of three two-week phases: Phase 1 (baseline): blind CGM (Freestyle Libre (…)
• 02:00
  1959-LB: An Insulin-Modified Oral Glucose Tolerance Test (OGTT) to Assess Insulin Resistance (IR) in Type 1 Diabetes (T1D) Diabetes
  IR is a key contributor to cardiovascular disease in T1D and increasingly so with increased rates of obesity in T1D. IR is difficult to measure in T1D due to absent insulin secretion. The hyperinsulinemic euglycemic clamp (HEC) is the gold-standard method for assessing IR in T1D, but is (…)
• 02:00
  1958-LB: Overnight Glycemia’s Relevance to Insulin Resistance (IR) in Type 1 Diabetes (T1D) Diabetes
  IR is a key contributor to cardiovascular disease in T1D but is difficult to measure. The relevance of mean overnight glycemia (MOG) in IR assessments by gold-standard hyperinsulinemic-euglycemic clamps (HEC) in T1D is unclear. We assessed the relationship between pre-HEC MOG and HEC-assessed IR (…)
• 02:00
  1957-LB: Transition between Pediatric and Adult Diabetes Services—The Experiences and Perceptions of Health Care Professionals Worldwide Diabetes
  Introduction: Youth with diabetes should transition from paediatric to adult diabetes services in a deliberate, organized and cooperative way. International diabetes specific consensus guidelines are currently lacking. We sought to identify the experiences of healthcare professionals (HCPs) (…)
• 02:00
  1956-LB: Altered Gut Microbiota and Short-Chain Fatty Acids in Children with Diabetic Ketoacidosis at Onset of Type 1 Diabetes Diabetes
  Objective: Diabetic ketoacidosis (DKA) stands as the most common acute hyperglycaemic complication with relatively high mortality rate among children diagnosed with type 1 diabetes (T1D). Previous studies have shed light on gut dysbiosis in newly-onset T1D children, but research specifically (…)
• 02:00
  1954-LB: Health Care Resource Utilization in Newly Diagnosed Children with Type 1 Diabetes in U.S. Clinical Practice Diabetes
  Introduction & Objective: There are limited contemporary data available on healthcare resource utilization (HCRU) in children newly diagnosed with type 1 diabetes (T1D). This study estimated HCRU in newly diagnosed pediatric patients with T1D in US clinical practice.Methods: Merative (…)
• 02:00
  1953-LB: Assessing Continuous Glucose Monitor Accuracy for Diabetes Management in Hospitalized Children Diabetes
  Introduction & Objectives: The adoption of continuous glucose monitors (CGM) in inpatient settings in the pediatric population has remained slow due to a scarcity of data on their reliability in hospitalized children.Methods: We retrospectively reviewed the accuracy of the Dexcom G6 CGM (…)
• 02:00
  1952-LB: Impact of Automated Insulin Delivery Systems by Baseline HbA1c in Emerging Adults with Type 1 Diabetes Diabetes
  Introduction & Objectives:Use of automated insulin delivery (AID) systems can improve HbA1c in people with type 1 diabetes (T1D). Data are limited on the impact in emerging adults with higher baseline HbA1cs.Methods:Retrospective chart review performed on 14-30 year olds with T1D ? 1 year (…)
• 02:00
  1951-LB: Impact of Discontinuation of Automated Insulin Delivery Systems in the Emerging Adult with Type 1 Diabetes Diabetes
  Introduction & Objectives: Automated insulin delivery (AID) systems can improve HbA1c in people with type 1 diabetes (T1D). Data are limited on rates and impact of discontinuation of newer AID in the emerging adult population.Methods: Retrospective chart review was performed on 14-30 year (…)
• 02:00
  1950-LB: Real-World Use of Tirzepatide among People without Type 2 Diabetes—Results from Optum’s Deidentified Clinformatics Data Mart Database Diabetes
  Objective: Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagonlike peptide-1 (GLP-1) receptor agonist (RA) approved for treatment of adults with type 2 diabetes (T2D) and obesity. This study aimed to understand the real-world use of tirzepatide among people (…)
• 02:00
  194-OR: Improved Linkage to the Health System and Better Diabetes Control Due to Community-Based m-Health–Enabled Screening and Follow-up in India Diabetes
  Introduction: India faces a huge burden of undiagnosed and uncontrolled diabetes, resulting in a significant challenge to the healthcare system.Methods: To improve linkage to the primary healthcare system and blood glucose control among diabetics, we conducted a large community-based screening (…)
• 02:00
  1775-LB: Role for Glucagon-Like Peptide 1 Receptor Agonists in Symptomatic Post-bariatric Hypoglycemia Diabetes
  Introduction & Objectives: Post-bariatric surgery patients suffer from weight gain and hypoglycemia. Role of GLP-1 in such patients is not established. We studied the effects of GLP-1 agonists on hypoglycemia, weight and hypoglycemic attitudes and behavior among patients who had bariatric (…)
• 02:00
  1774-LB: The Glucagon Stimulating Effect in Hypoglycemia of Somatostatin Receptor 2 Antagonist (SSTR2a) Is Maintained with Repeat Dosing Diabetes
  Introduction: A single dose of SSTR2a, ZT-01, reduces hypoglycemia exposure in diabetic rat models. However, the pharmacology of daily dosing in type 2 diabetes (T2D) rats has not been reported. The purpose of this study was to determine the effects of repeat ZT-01 dosing in a rat model of T2D (…)
• 02:00
  1773-LB: Impact of SSTR2a Treatment in Hypoglycemia in Male (M) and Female (F) Rat Models of Type 2 Diabetes (T2D) Diabetes
  Introduction: This study characterized a F rodent model of T2D and examined SSTR2a treatment in hypoglycemia in M and F rats with T2D.Methods: A high fat fed streptozotocin-treated (35 mg/kg) T2D model (n=8-10/group) with impaired glucagon (GNC) counterregulation to hypoglycemia was (…)
• 02:00
  1772-P: Monocarbonyl Analogs of Curcumin C66 and B2BrBC Modulate Diabetes-Related Gene Expression in Rat Pancreatic Cells Diabetes
  Monocarbonyl analogs of curcumin (MACs) lacking a ?-diketone moiety have been shown to exhibit improved stability and better bioavailability than curcumin. This study aimed to evaluate the effects of two MACs (C66 and B2BrBC) on the expression of genes related to the onset, development, and (…)
• 02:00
  1771-P: Comprehensive Characterization of Individual Extracellular Vesicles from Beta-Cell Model Systems Diabetes
  In the United States, type II diabetes is prevalent in approximately 34-36 million Americans. To improve patient outcomes, extracellular vesicles (EVs) have emerged as an exciting potential modality. EVs are nano-scale particles released from all types of cells; they contain metabolites, nucleic (…)
• 02:00
  1770-P: Gymnemic Acid Functions as NFE2L2 Activator to Enhance Antioxidant Defense against Cellular Stress Caused by Inflammation and Hypoxia in Human Pancreatic Islets Diabetes
  Introduction & Objective: Increasing the mass of pancreatic beta cells through neogenesis and proliferation while protecting islets from oxidative stress and inflammation is a possible therapeutic strategy for treating all types of diabetes. We examined the effect of the natural (…)
• 02:00
  176-OR: Association between Clustering of Hypoglycemic Symptoms, Psychological Traits, and Problem-Solving Abilities in Adults with Type 1 Diabetes Diabetes
  Background: Precision medicine in diabetes care requires a dedicated focus on hypoglycemic symptoms. This study aimed to explore the interrelationship between the clustering of hypoglycemic symptoms, psychological characteristics, and problem-solving capabilities in adults with type 1 diabetes (…)
• 02:00
  1769-P: Empowering Islet Biology—Advancing Scientific Rigor and Reproducibility, Resource Discoveries, and Effective AI/ML Collaboration via dkNET Diabetes
  The NIDDK Information Network (dkNET; dknet.org) is an open community resource for researchers supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), including islet biology investigators. The primary objective is to provide tools, access to diverse resources, (…)
• 02:00
  1768-P: The Impact of IL-1 in Islet Antiviral Responses Diabetes
  Introduction & Objective: Viruses, particularly members of the picornavirus family, are correlated with the onset of T1D. For this reason, viral infection has been identified as an environmental trigger for T1D onset, specifically due to its ability to stimulate the production and release of (…)
• 02:00
  1767-P: A Modifying Effect of Genetic Background on S64F MAFA-Induced Dysglycemia Diabetes
  Introduction & Objective: The MAFA transcription factor is an essential regulator of mature pancreatic islet ? cell function. A rare missense variant of human MAFA, Ser64Phe (S64F), was identified as a MODY gene in patients with familial insulinomatosis or diabetes mellitus (1). S64F MAFA (…)
• 02:00
  1765-P: Inhibition of NLRP3 Inflammasome Activation and Reduction in T-Cell Migration Are Key Mechanisms by Which PAHSAs Protect against Type 1 Diabetes Diabetes
  Palmitic acid esters of hydroxy stearic acids (PAHSAs) are bioactive lipids with anti-inflammatory and anti-diabetic effects. PAHSAs markedly reduce the incidence and delay the onset of autoimmune T1D in NOD mice. PAHSAs attenuate autoimmune responses by lowering mature T helper cell activation (…)
• 02:00
  1764-P: Cross Talk between Pancreatic Mesenchymal Stem Cells and Macrophages Facilitates ß-Cell Decompensation in Obesity Diabetes
  Introduction & Objective: Obesity has long been recognized as a significant risk factor for developing type 2 diabetes mellitus (T2DM), the mechanisms triggering ?-cell compensation and subsequent decompensation are still not fully understood. Our research has brought to light that in (…)
• 02:00
  967-P: The Use of Hybrid Closed-Loop Insulin Delivery in Adolescents and Young Adults with High-Risk Acute Lymphoblastic Leukemia during Induction Chemotherapy Diabetes
  Introduction & Objective: Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) are at risk of iatrogenic hyperglycemia during induction chemotherapy due to exposure to high dose corticosteroids and asparaginase, two cornerstones of ALL therapy. While hyperglycemia has (…)
• 02:00
  966-P: Diabetes Technology Outcomes in the Vulnerable Early Childhood Population at a Large Diabetes Clinic Diabetes
  Intro: As more diabetes technology is approved for children down to age 2 and off-label use expands, clinical outcomes data for young children on these devices are sparse. We evaluated real-world device usage and the glycemic results in this vulnerable population.Methods: Retrospective data were (…)
• 02:00
  965-P: Data Driven Dosing Formulas in Early Childhood Type 1 Diabetes Diabetes
  Intro: As T1D technology use expands for children down to age 2, fine tuning dosing has become easier. Traditional dosing formulas for insulin-carb ratios (ICR) and insulin sensitivity factor (ISF) are derived from older patients prior to intro of AID. We seek to determine how ICR and ISF differ (…)
• 02:00
  964-P: Real-World Access to Diabetes Technology and Achieved HbA1c Levels in Type 1 Diabetes by Race and Ethnicity Diabetes
  Introduction: Recent research from specialist endocrine centers has highlighted racial disparities in access to care for individuals with type 1 diabetes (T1D). The aim of this study was to use real-world data to determine outcomes, including the use of technology, and achieved HbA1c levels for (…)
• 02:00
  963-P: Is Using an Automated Insulin Delivery System Associated with a Higher Physical Activity Frequency? A BETTER Registry Analysis Diabetes
  Introduction & Objective: To explore the association between using an automated insulin delivery (AID) system and physical activity (PA) frequency among people with type 1 diabetes (T1D).Methods: Cross-sectional study using the Canadian BETTER T1D registry. Inclusion criteria: T1D; aged ? 18 (…)
• 02:00
  962-P: Assessment of Hybrid Closed-Loop Impact upon Glycemic Control, Weight, and Retinopathy Diabetes
  Background: We sought to assess real-world outcomes in adults with type 1 diabetes commenced on hybrid closed loop (HCL).Methods: Observational study of 254 adults following conversion from CSII to HCL in a secondary care setting. Outcomes included change in CGM metrics, HbA1c, weight and eye (…)
• 02:00
  961-P: Significant Reduction in Real-World Nighttime Burden with the MiniMed 780G System (MM780G) Diabetes
  Introduction: Nighttime burdens of T1D include responding to CGM-generated alerts and delivering manual boluses which interrupt sleep. First-generation automated insulin delivery (AID) systems without autocorrection (e.g., MM670G/770G) have improved overnight glycemic outcomes, but sleep (…)
• 02:00
  960-P: Perceived Consequences of AID Systems for the Care of People with Diabetes in Switzerland, Austria, and Germany Diabetes
  AID systems are becoming increasingly popular among people with type 1 diabetes (pwt1d). As part of the Diabetes Report, we asked Pwt1d (n=1920) and parents of children with type 1 diabetes (n=210) in three countries (Germany, Austria and Switzerland) about the expected consequences of the (…)
• 02:00
  95-OR: Diurnal Variation of Islet Autoantibodies in Established Type 1 Diabetes Diabetes
  Introduction: Accurate pancreatic islet autoantibody (Aab) measurement is vital for risk-screening, early-stage treatment, and prevention study eligibility assessment in persons with and at risk of type 1 diabetes (T1D). Although Aab measurement has been standardized by addressing lab assay (…)
• 02:00
  959-P: Multiple Daily Injection (MDI) to Automated Insulin Delivery (AID) vs. Non-AID Insulin Pump for Newly Diagnosed People with Type 1 Diabetes Offers Improvement in Glycemic Control Diabetes
  Automated insulin delivery relates to lower HbA1c values in people with type 1 diabetes (PwT1D) participating in clinical trials, but real-world evidence is lacking.This observational crossover study used medical record data from PwT1D newly diagnosed between 2019-2023 from 32 centers in the T1D (…)
• 02:00
  958-P: High User Satisfaction and Ease-of-Use Scores with Six Months Use of the Tandem t:connect Mobile Application Diabetes
  Objective: People with diabetes who use the t:slim X2 with Control-IQ technology (CIQ, Tandem Diabetes Care) in the United States also have the option to use the smartphone app (t:connect mobile), which includes the ability to bolus from the app, and continuously upload data to the cloud. This (…)
• 02:00
  957-P: Feasibility Study of Use of the iLet Bionic Pancreas in Primary Care and Telehealth Diabetes
  Introduction & Objective: While about half of US adults with T1D are managed by primary care (PC), automated insulin delivery (AID) use is rare in PC compared to endocrinology (EN). The iLet Bionic Pancreas (BP) has a unique initiation process of simply entering the user’s weight, followed (…)
• 02:00
  956-P: Successful Use of U-500 Insulin with the Tandem X2 Pump with Control IQ (CIQ) Diabetes
  Objectives: The American Diabetes Association recommends the use of U-500 insulin for individuals with insulin dose requirements over 200 units per day. Commercially available insulin pumps are FDA-approved for U-100 insulin. Patients requiring high daily insulin doses must frequently refill (…)
• 02:00
  955-P: Effective Use of U-200 Insulin in OmniPod 5, Medtronic 780G, and Tandem X2 Systems Diabetes
  Objectives: Commercially available insulin pumps are approved for U-100 insulin. Patients with high insulin dose requirements need to change infusion sets every 1-2 days, creating inconvenience and increasing costs. We evaluated the safety and feasibility of using U-200 insulin in hybrid (…)
• 02:00
  954-P: Effect of Automated Insulin Delivery on Diabetes Distress in People with Type 1 Diabetes—A Systematic Review and Meta-analysis Diabetes
  Introduction & Objective: Diabetes distress (DD) is prevalent among people with diabetes (PwD). While automated insulin delivery systems (AID) improve glycemic control and are expected to alleviate diabetes burden, their impact on DD is unclear.Methods: Adhering to PRISMA guidelines, we (…)
• 02:00
  953-P: Changes in Time in Range (TIR) among Youth with Type 1 Diabetes (T1D) Initiating Different Automated Insulin Delivery (AID) Systems Diabetes
  Introduction & Objective: Glycemic outcomes in youth with T1D have not been compared between the two most commonly used AID systems in the United States, Insulet Omnipod 5 (OP5) and Tandem Control IQ (CIQ). Our aim is to perform the first head-to-head analysis of changes in TIR in youth (…)
• 02:00
  952-P: What Happens When People Don’t Bolus for Extended Periods of Time while Using the t:slim X2 with Control-IQ Technology? Diabetes
  Objective: The t:slim X2 with Control-IQ technology (CIQ) predicts future hyperglycemia and delivers automatic correction boluses to help improve time-in-range (TIR, 70-180 mg/dl). This is thought to help improve glycemia when users do not initiate boluses for meals. The purpose of this analysis (…)
• 02:00
  951-P: The t:slim X2 with Control-IQ Technology Overcomes Missed Boluses for Moderate Meals Diabetes
  Introduction & Objective: People with diabetes frequently miss mealtime insulin boluses. The t:slim X2 pump with Control-IQ technology (CIQ) delivers automatic correction insulin, which is thought to help improve glycemia when users do not consistently bolus for meals. This study uses (…)
• 02:00
  950-P: Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding—Real-World Outcomes by Training Type Diabetes
  Users new to the Omnipod 5 AID System can complete training and onboarding via personalized trainer-led education, virtually or in-person, or for those upgrading from an earlier Omnipod System, online, self-guided training modules can be completed. This study aimed to evaluate outcomes by (…)
• 02:00
  94-OR: Pathogenic Action of GAD65 Autoantibodies on Islet Function in Type 1 Diabetes Diabetes
  A hallmark of T1D is the appearance of autoantibodies directed against islet cell antigens including insulin and the 65kDa isoform of glutamate decarboxylase (GAD65). Based on unsuccessful attempts to trigger diabetes in mice using autoantibodies isolated from T1D patients, autoantibodies are (…)
• 02:00
  949-P: Android Artificial Pancreas System Use among Patients with Type 1 Diabetes Mellitus in China—A Real-World Study Diabetes
  Objective: The real-world study aimed to investigate the current status of Android artificial pancreas system (APS) use among patients with type 1 diabetes mellitus (T1DM) in China, where market-approved commercial APS is unavailable.Methods: The healthcare providers of China’s largest online (…)
• 02:00
  948-P: Glycemic and CGM Outcomes Are Nearly Independent of the Frequency of User Engagement with the Bionic Pancreas during 13 Weeks of Use in Adults and Children with Type 1 Diabetes Diabetes
  It is well established that glycemic and continuous glucose monitoring (CGM) outcomes improve with increasing user engagement for both therapeutic devices (insulin pumps and pens) and diagnostic devices (CGMs, flash-glucose monitors, and blood-glucose monitors) used in the management of type 1 (…)
• 02:00
  652-P: Impact of a Six-Month Digital Health Coaching Program on Individuals with Type 2 Diabetes Mellitus Experiencing Food Insecurity in Rural Areas Diabetes
  Individuals with type 2 diabetes mellitus (T2DM) experiencing food insecurity often have worse health outcomes than those not experiencing food insecurity. These poor outcomes are often exacerbated among individuals who live in rural areas. Current studies have evaluated the impact of digital (…)
• 02:00
  651-P: Group Matching Preferences for Emerging Adults with Type 1 Diabetes Diabetes
  Introduction & Objective: D-COPES (Diabetes - Connecting Online Peers to Enhance Support) is a social support intervention that matches emerging adults (EA) into small groups led by a trained peer connector (PC) who engage virtually over 12 weeks. The purpose of this pilot was to evaluate (…)
• 02:00
  28-OR: Posttranslational Modifications in Skeletal Muscle Direct Divergent Metabolic Responses to Different Exercise Training Modes Diabetes
  Different exercise modes yield distinct metabolic outcomes, yet the underlying molecular mechanisms driving these exercise responses remain unclear. Here, we investigated the impact of post-translational modifications (PTM) to skeletal muscle proteins in response to 3 months of high intensity (…)
• 02:00
  289-OR: Autophagy Promotes Islet ?-Cell Function by Maintaining ER Proteostasis and Glucagon Production Diabetes
  Introduction & Objective: Islet ? cells have traditionally been maligned for contributing to hyperglycemia in diabetes but are increasingly recognized for their potential to promote ? cell mass and function. The cellular mechanisms regulating proglucagon production and its subsequent (…)
• 02:00
  288-OR: Inflammation-Induced Repression of Insulin Production by Targeting Its mRNA to Stress Granules via ADP-Ribosylation Machinery Diabetes
  ADP-ribosylation has been shown to contribute to the development of Type 1 diabetes (T1D); however, the mechanism through which each component of the ADP ribosylation machinery contributes to the disease is poorly understood. Here, we aimed to investigate the contribution of specific (…)
• 02:00
  2008-LB: Identification of Genome-Wide Significant Loci for Childhood Glycemic Traits in HAPO Follow-up Study Diabetes
  Introduction & Objective: Type 2 Diabetes (T2D) among children is increasing. Compared to T1D and adult-onset T2D, it is more aggressive with more rapid disease progression. The genetic risk associated with youth-onset T2D has not been elucidated. We performed a GWAS of childhood dysglycemia (…)
• 02:00
  2006-LB: Polygenic Scores for Metabolic Diseases Are Associated with Gene Expression Networks across Tissues Diabetes
  Genetic risk for type 2 diabetes (T2D), coronary artery disease (CAD), and obesity can be estimated with global extended polygenic scores (gePS), which capture risk across thousands of genetic variants. Nevertheless, knowledge of underlying disease pathways remains limited. Expression (…)
• 02:00
  2005-LB: Optimization of Single Nuclei Isolation from Frozen Human Skeletal Muscle and Pancreatic Tissue Samples for Single Nuclei Multiome ATAC + Gene Expression Diabetes
  Background: Dysfunctional pancreatic islets beta cells are a well established hallmark of type 2 diabetes. Despite intense research, we still lack understanding of the underlying gene dysregulation mechanisms, including gene regulatory pathways driving the shift between normal and diabetic (…)
• 02:00
  2004-LB: Elucidating Causal Genes of Severe Insulin Resistance Diabetes through Polygenic Exploration of Type 2 Diabetes Heterogeneity Diabetes
  Background: Severe insulin resistance diabetes (SIRD) is a subgroup of type 2 diabetes (T2D) with particularly high risk of cardiovascular complications. A subset of T2D genome-wide association study (GWAS) associations are suggested to act through pathways underlying SIRD, but the number of (…)
• 02:00
  2003-LB: Dissecting Ancestry-Aware Molecular Causal Paths of Type 2 Diabetes Diabetes
  Multiple molecular mechanisms are involved in the pathogenesis of type 2 diabetes (T2D), with potentially different effects across ancestries. Recent large-scale efforts by the Type 2 Diabetes Global Genomics Initiative (T2DGGI) have broadly described the genetic architecture of T2D, data that (…)
• 02:00
  2077-LB: Regional Differences in Obesity Awareness, Prevalence, and Management in India Diabetes
  Introduction & Objective: India is a large country that can be broadly categorized into regions based on geography with diverse lifestyle and cultural habits. The current observational study explores the disparities in the prevalence of metabolic disturbances and the role of lifestyle habits (…)
• 02:00
  2076-LB: Physician Views on Management of Patients with Both Obesity and Type 2 Diabetes (PwOT2D) in the U.S. and Germany Diabetes
  Obesity is a key risk factor for developing type 2 diabetes (T2D) and treating obesity is central to its management. In our study, we aimed to understand how anti-obesity medications (AOMs) impact US and German healthcare professionals’ (HCPs) views on managing patients with both obesity and (…)
• 02:00
  2075-LB: Identification and Characterization of Two Novel Data-Driven Subtypes of Human Obesity Diabetes
  Introduction & Objective: Obesity affects ~890 million adults and causes an estimated 5 million deaths each year. However, other than BMI and several clinical severity scales, there is no accepted framework for stratifying obesity into clinically actionable or etiologically distinct (…)
• 02:00
  2074-LB: Metabolic Heterogeneity of Adipocytes during Obesity Revealed by Single Nucleus RNA-seq Diabetes
  Objective: The prevalence of obesity continues increasing nowadays, but the understanding on the pathogenesis of obesity and its complications remains obscure. Adipocytes are the main components of metabolic homeostasis, involved in glucose and lipid metabolism, hormone and adipokine secretion. (…)
• 02:00
  2073-LB: Unveiling the Hidden—Insulin Resistance and Cardiometabolic Risks in Overweight Adolescents Diabetes
  Introduction and Objectives: Adolescent obesity escalates cardiometabolic complications and insulin resistance (IR). While adult IR criteria are clear, their adaptation for adolescents is inconsistent due to standardization challenges. The study aimed to determine the prevalence of insulin (…)
• 02:00
  2072-LB: Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease Diabetes
  Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in China, especially in patients with type 2 diabetes mellitus (T2DM). Weight loss strategies have been shown to treat NAFLD effectively. We conducted a 24-week, prospective, randomized study in T2DM (…)
• 02:00
  2070-LB: Enhancing Metabolic Health in Obesity via Testosterone Replacement—Insights from a Meta-analysis of Controlled Trials Diabetes
  Objective: This systematic review aimed to assess the efficacy and safety of testosterone replacement therapy (TRT) in obese men with testosterone deficiency.Materials and Methods: A comprehensive computer-based search was conducted in Cochrane Library, PubMed, Embase, Web of Science, Scopus, (…)
• 02:00
  206-OR: Assessing Connection to Outpatient Care among Patients Screening Positive for Previously Undiagnosed Diabetes in the Emergency Department Diabetes
  Introduction & Objective: Patients with frequent emergency department (ED) use often have poor connection to primary care, which limits their access to the preventive screening necessary to diagnose diabetes early. Our objective was to assess how frequently patients connected with outpatient (…)
• 02:00
  1817-LB: Association between the Neutrophil Percentage–to–Albumin Ratio and Mortality in Patients with Diabetic Foot Ulcer Diabetes
  Objective: Diabetic foot ulcer (DFU) is a common complication of diabetes mellitus, and it is also the main cause of infection, hospitalization, amputation and even death in patients with DFU. Neutrophil percentage-to-albumin ratio (NPAR) has been proved to be a predictor of death in many (…)
• 02:00
  1816-LB: Examining the Human Diabetic Bone Marrow Niche Diabetes
  Introduction & Objective: Patients with diabetes mellitus (DM) have a 30-fold increased risk of developing diabetes foot ulcers (DFUs), with 43% requiring lower extremity amputations (LEAs). While the underlying cause of non-healing DFUs is not known, abnormalities in bone marrow (…)
• 02:00
  1815-LB: Lower Limb Vascularity Indices for Major Adverse Limb Events and Mortality in Individuals with Diabetic Foot Ulcer Diabetes
  Objectives: We aimed to assess correlation between baPWV and ABI, specifically role of baPWV in participants with normal ABI for major adverse limb events (MALE) and mortality in people with diabetes and first diabetic foot ulcer (DFU).Research Design and Methods: A total of 16000 patients with (…)
• 02:00
  1814-LB: Hypertriglyceridemic-Waist Phenotype Is Associated with Diabetic Foot Ulcer in Chinese Patients with Type 2 Diabetes Diabetes
  It is still unclear whether the hypertriglyceridemic-waist (HTGW) phenotype is related to increased risk of diabetic foot ulcer (DFU) in Chinese patients with type 2 diabetes. A total of 2651 consecutive in-patients with type 2 diabetes (mean age 56±11 years, 58% women), with a mean duration of (…)
• 02:00
  1813-LB: Serum 25-hydroxyvitamin D Levels in Relation to the Risk of Diabetic Foot Ulcer in Chinese Patients with Type 2 Diabetes Diabetes
  Vitamin D deficiency is not only related to bone-related diseases but also associated with cardiovascular disease, diabetes, cancer and autoimmune diseases. Previous studies show that vitamin D deficiency increases risk of macrovascular diseases and different type of infections in patients with (…)
• 02:00
  1812-LB: Association of Plasma Ceramides with Progression to Diabetes in the Diabetes Prevention Program (DPP) and Outcomes Study (DPPOS) Diabetes
  Objective: Ceramides (CER) have been implicated in the pathogenesis of type 2 diabetes (T2D). Here, we assessed baseline plasma CER profiles in relation to incident T2D in the DPP/DPPOS.Methods: Adults at high risk for T2D were randomized in DPP to intensive lifestyle, metformin, or placebo to (…)
• 02:00
  1811-LB: Improvement in Diabetic Retinopathy and Achieving Remission of Type 2 Diabetes Mellitus through Digital Twin Technology—A One-Year Intervention Study Diabetes
  Introduction and Objectives: Digital twin (DT) platform uses Artificial Intelligence (AI) and Internet of Things, to integrate multi-dimensional data to give precision nutrition and health recommendations via the mobile app and by coaches. Remission was defined as A1C levels less than 6.5% (…)
• 02:00
  1810-LB: Diagnostic Accuracy of Automated Pupillometry for Diabetic Retinopathy Screening Diabetes
  Introduction: Diabetic retinopathy (DR) is a major and preventable cause of blindness. Although regular fundoscopic examination (FE) is recommended to detect DR, screening coverage remains low in Latin America, the USA, and other regions, supporting the need for new screening tools. Because (…)
• 02:00
  180-OR: Glycemic Markers Are Differentially Associated with Cardiovascular Imaging and Outcomes in Long-Duration Type 1 Diabetes Diabetes
  Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes (T1D). While glycemic control is related to CVD outcomes in T1D, there is a lack of information on the risk of glycemic excursions and comparative contributions of glycemic markers to CVD in aging populations with T1D. (…)
• 02:00
  1809-LB: Hyperglycemia Activated the STING Pathway to Induce Retinal Vascular Endothelial Inflammation and Breakdown of Retinal Tight Junctions Diabetes
  Introduction & Objective: Diabetic retinopathy is a common microvascular complications of diabetes mellitus characterized by hyperglycemia and chronic inflammation. Retinal endothelial cells are the primary target cells for diabetes-induced vascular damage causing acellular blood capillary (…)
• 02:00
  1808-LB: NIK-Mediated Microglia Polarization Induces Endothelial Dysfunction in Diabetic Retinopathy Diabetes
  Introduction & Objective: Chronic inflammation significantly contributes to endothelial dysfunction in diabetic retinopathy (DR). NIK, a central and specific signal component that regulates the activation of noncanonical NF-?B pathway, is overexpressed in inflammatory diseases, metabolic (…)
• 02:00
  1807-LB: Comparison between Normal and Diabetes Patients’ Foot Neuro Activity Diabetes
  One simple diagnostic method to determine foot insensitivity is a nanofilament test or sending a weak electric shock to the patient to detect their response. However, accuracy is an issue due to controlling neurostimulation in the patient. We have developed a device that can detect neuro signals (…)
• 02:00
  1806-LB: Improvement in Sensory Function and Achieving Remission of Type 2 Diabetes Mellitus through Digital Twin Technology—A One-Year Intervention Study Diabetes
  Introduction and Objectives: Digital twin (DT) platform uses Artificial Intelligence (AI) and Internet of Things, to integrate multi-dimensional data for precision nutrition and health recommendations via the mobile app and by coaches. Remission was defined as A1C levels less than 6.5% without (…)
• 02:00
  1805-LB: Attenuation of Niacin-Induced Skin Flushing Response—A Potential Clinical Adjunctive Diagnostic Instrument for Diabetic Peripheral Neuropathy Diabetes
  Objectives: Explore the potential of using niacin-induced skin flushing response (NSFR) as a diagnostic method for diabetic peripheral neuropathy (DPN) based on the microangiopathic characteristics of DPN.Methods: This study involved 114 diabetic patients (51 with DPN, 59 without DPN, and 4 with (…)
• 02:00
  1804-LB: Serum Spexin Level Is Negatively Associated with Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes Diabetes
  Background: Spexin is a novel peptide hormone and has shown anti-nociceptive effects in experimental mice. This study aimed to evaluate the association of serum spexin level with diabetic peripheral neuropathy (DPN) and related pain in a Chinese population.Methods: We enrolled 167 type 2 (…)
• 02:00
  1803-LB: Improving Diabetic Foot Ulcer Management with Electrochemical Skin Conductance Diabetes
  Introduction: Addressing the challenges in diabetic foot ulcer (DFU) management is critical, given the high morbidity, mortality, and healthcare costs associated with this devastating complication of diabetes. This study introduces an innovative strategy for DFU risk stratification using (…)
• 02:00
  783-P: Efficacy of GLP-1RA according to Type 2 Diabetes Phenotypes—A Monocentric Retrospective Study Diabetes
  Introduction & Objective: Type 2 diabetes (T2D) is considerably heterogeneous due to different pathogenetic mechanisms that may affect response to treatment. We aimed to assess the efficacy of GLP-1RA according to the phenotypes described by Ahlqvist et al. (Diabetes, 2000).Methods: In this (…)
• 02:00
  782-P: Insulin Therapy Deintensification with iGlarLixi—The IDEAL Randomized Controlled Trial Diabetes
  Introduction: Multiple daily injection (MDI) insulin therapy in people with type 2 diabetes (PwT2D) often leads to weight gain, increased risk of hypoglycemia and lower QoL. The Insulin therapy DE-intensificAtion with iglarLixi (IDEAL) trial examined the efficacy and safety of MDI (…)
• 02:00
  781-P: Efficacy and Safety of Switching to iGlarLixi from Twice-Daily (BID) Premixed Insulin (PI) Administration in People with Type 2 Diabetes (T2D)—Subanalysis of Soli-SWITCH Study Diabetes
  Introduction & Objective: iGlarLixi is a once-daily injectable fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide. This sub-analysis of Soli-SWITCH (EudraCT number 2021-003711-25) assessed the efficacy and safety of switching from BID administration to once-daily (…)
• 02:00
  780-P: Soli-SWITCH—Efficacy and Safety of Switching to iGlarLixi from Premixed Insulins (PI) in People with Type 2 Diabetes (T2D) Diabetes
  Introduction & Objective: iGlarLixi, a once-daily injectable fixed-ratio combination of insulin glargine 100 U/mL + lixisenatide, has demonstrated improved glycemic control in people with T2D vs its monocomponents and may be a simplified treatment option vs PI. The Soli-SWITCH study (EudraCT (…)
• 02:00
  77-PUB: Deep Learning–Powered Islet Quantification for Type 1 Diabetes Diabetes
  Introduction & Objective: Islets in patients with type 1 diabetes (T1D) display a high degree of heterogeneity in sizes, numbers, architecture, endocrine and immune cell type compositions, and capillary density, compared to nondiabetic controls (ND). Extensive whole slide imaging (WSI) data (…)
• 02:00
  77-OR: Time in Range Is Associated with Glucagon/C-Peptide Index Ratio in Type 2 Diabetes Patients Diabetes
  Introduction & Objective: Paradoxical increase of postprandial glucagon is considered to be a factor inducing hyperglycemia in type 2 diabetes (T2D). Although continuous glucose monitoring (CGM) is often used to evaluate glycemic control in T2D patients, no studies on the association between (…)
• 02:00
  779-P: Clinical Characteristics and Treatment Patterns among Glucagon-Like Peptide Receptor Agonist (GLP-1RA) Users in a U.S. EHR and Claims Linked Database Diabetes
  Introduction & Objective: Certain glucagon-like peptide receptor agonists (GLP-1RA) are indicated in different formulations for the treatment of obesity and diabetes. The study objective was to describe real-world demographics, clinical characteristics, and treatment patterns among GLP-1RA (…)
• 02:00
  778-P: Changes in HbA1c with GLP-1 Use in People with Type 1 Diabetes—Data from the T1D Exchange QI Initiative Diabetes
  Background: Glucagon-like peptide 1 receptor agonists (GLP-1RA) are currently not approved for use in people with T1D (PwT1D). At present there is limited safety and efficacy data using these agents in PwT1D. We analyzed the association of GLP-1RA on HbA1c levels and weight in PwT1D.Methods: (…)
• 02:00
  777-P: Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Diabetes
  Introduction: In people with T2D and preexisting ASCVD, either SGLT2i or GLP1RA are indicated by treatment guidelines to reduce MACE. We evaluated predictors of prescription of SGLT2i vs GLP1RA in a population eligible for either.Methods: An electronic health record (EHR) based registry was (…)
• 02:00
  776-P: Potent Weight Loss and Favorable Glycemic Control Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Animal Models Diabetes
  Introduction & Objective: The prevalence of obesity is increasing worldwide, urging development of obesity drugs with better efficacies and weight loss qualities. HM15275 is a GLP-1/GIP/Glucagon triple agonist designed to have well-harmonized activities and long-acting property for maximized (…)
• 02:00
  775-P: Influence of Eating Behavior on Therapeutic Effects of GLP-1 Receptor Agonists over a One-Year Period Diabetes
  To evaluate the relationship of GLP-1RA therapy on HbA1c and body weight with eating behavior, a multicenter, prospective, observational study was conducted in Japanese individuals with T2D who had begun taking GLP-1RAs. The participants received two questionnaires: the Dutch Eating Behavior (…)
• 02:00
  774-P: Impact of Newer GLP-1 RAs on HbA1c in U.S. Adults with Type 2 Diabetes—A Population-Level Time-Series Analysis Diabetes
  Introduction & Objective: It is unclear whether glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatments improve population-level diabetes-related outcomes. This study examined the impact of GLP-1 RA uptake on population-level HbA1c in US adults with type 2 diabetes.Methods: This (…)
• 02:00
  773-P: Trends in Obesity Drug Initiation after the Approval of Tirzepatide in Adults without Type 2 Diabetes Diabetes
  Introduction & Objective: Tirzepatide was approved for the treatment of type 2 diabetes (T2D) (May 2022) and more recently for obesity (November 2023). However, tirzepatide has been used off-label for the treatment of obesity in adults without T2D prior to November 2023. The utilization (…)
• 02:00
  772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk Diabetes
  Introduction & Objective: Glucagon-like peptide-1 receptor agonists (GLP1RA) may increase pancreatitis and biliary disease risk. We investigated the association between GLP1RA initiation and the risk of pancreatitis or biliary disease among patients with type 2 diabetes (T2D) at (…)
• 02:00
  771-P: Efficacy of CT-996, an Oral Small Molecule GLP-1 Receptor Agonist, in Human GLP-1 Receptor Knockin Mice and Obese Cynomolgus Monkeys Diabetes
  Since FDA approval of exenatide in 2005, injectable GLP-1 receptor agonists (RAs) have established their clinical utility in the management of type 2 diabetes and obesity. However, rising treatment utilization urgently necessitates cost-effective, simpler solutions. Here, we describe CT-996, a (…)
• 02:00
  1903-LB: Real-World Bolus Dose Timing and Glycemic Impact Using the Tempo Platform Diabetes
  Background: Optimization of bolus dose timing is associated with better glycemic control and dose timing variability can be associated with negative glycemic impact. Use of the Tempo Platform in multiple daily insulin users allows visualization of bolus behavior. The objective for this analysis (…)
• 02:00
  1913-LB: Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study (BURST)—A 6-Month Analysis Diabetes
  Introduction & Objective: The Bigfoot Unity® System is an FDA-cleared smart pen cap system incorporating CGM data (Abbott FreeStyle Libre 2), real-time alerts, and clinician-directed insulin dose recommendations. The objective was to analyze real world, 6-month data for System users.Methods: (…)
• 02:00
  1912-LB: Quantifying Environmental Waste from Diabetes Devices in the U.S. Diabetes
  Introduction: In the U.S. in 2018, the average person generated 66.68 kg of waste/month. With 3.9 million continuous glucose monitor (CGM) users and 745,000 insulin pump users in the U.S. in 2023, diabetes devices may contribute significantly to that amount. Objective: To quantify the (…)
• 02:00
  1911-LB: Developing CGM Knowledge Survey for Non-endocrinologists Diabetes
  Introduction: Optimal use of continuous glucose monitoring (CGM) is essential for healthcare professionals (HCPs), including primary care practitioners and allied health professionals, to enhance diabetes care. We designed the CGM Knowledge Survey (CGM KS) as an assessment and learning tool to (…)
• 02:00
  190-OR: Development and Validation of a Social Risk Screening Tool for Adults with Type 2 Diabetes Diabetes
  Introduction & Objective: Social risk factors are the adverse social conditions associated with poor health including poor diabetes outcomes. Despite being important for assessing social needs and integrating social care into medical care, most measures that assess social determinants of (…)
• 02:00
  1909-LB: Patient Preferences for Continuous Glucose Monitoring Devices—A Discrete Choice Experiment Study of People Living with Type 2 Diabetes Diabetes
  Introduction & Objective: While continuous glucose monitoring (CGM) devices have received approval for use in eligible patients, there remains limited evidence regarding patient preferences for these devices. This study aims to determine the important attributes of CGM devices for patients (…)
• 02:00
  526-P: Risk Factor for Prolonged Hospital Stay in Patient with Diabetes-Related Foot Infection Admitted to a Specialized Unit—A Retrospective Cohort Study Diabetes
  Introduction: Diabetes-related foot infections (DFI) demand high costs for health systems due prolonged hospital stay (PHS). We evaluated factors associated with PHS in patients hospitalized with DFI.Methods: We conducted a retrospective cohort study of patient>18 years hospitalized in a (…)
• 02:00
  525-P: Use of a Remote Thermovisual Monitoring System in High-Risk Patients—A Pilot Study Diabetes
  Introduction: Diabetic foot ulcer (DFU) recurrence rates are high, at 40% in 12 months. We investigated patient adherence to, and effects of, a remote thermovisual monitoring system (Bluedrop Medical) in high-risk diabetic patients. We hypothesized that at-home thermovisual monitoring is easy, (…)
• 02:00
  524-P: Diabetic Foot Ulcer Wound Dressings May Serve as an Untapped Source of Predictive and Monitoring Biomarkers of Healing Outcome Diabetes
  Introduction and Objective: The purpose of our study was to utilize discarded wound dressings from diabetic foot ulcers (DFUs) in order to identify potential predictive and diagnostic biomarkers by the proteomic analysis of cells and exosomes captured from wound exudate.Methods: DFU patients (…)
• 02:00
  523-P: Proteomic Predictors of Diabetic Foot Ulcer Healing Time Diabetes
  Background and Aims: Longer diabetic foot ulcer (DFU) healing time is associated with a 10 to 20 times higher risk of foot amputations in people with diabetes than in nondiabetic subjects, however no biomarkers for DFU healing exist. We investigated foot ulcer swap proteins associated with DFU (…)
• 02:00
  522-P: Inhibition of Lipoprotein(a) [Lp(a)] Oxidation by Atorvastatin Active Hydroxylated Metabolites during High Glucose Compared with Rosuvastatin In Vitro Diabetes
  Background: Elevated lipoprotein(a) (Lp(a)) levels are causally and independently associated with increased cardiovascular (CV) risk due to increased inflammation and macrophage uptake. Levels of oxidized Lp(a) were more predictive of CV events and endothelial dysfunction in type 2 diabetes than (…)
• 02:00
  521-P: Association between the Hepatic Steatosis and the TyG Index in a Population of Healthy Adults in Korea Diabetes
  It has been established that the triglyceride glucose (TyG) index is a reliable indicator of insulin resistance (IR), which strongly impact to development of hepatic steatosis and non-alcoholic fatty liver disease (NAFLD). However, the relation between NAFLD and the TyG index remains not fully (…)
• 02:00
  520-P: Plasma Sphingolipid Profiles Correlate with Circulating Lipoproteins and Adiposity Diabetes
  Objective: Dysregulation of cholesterol and sphingolipids (SPL) is associated with metabolic diseases. This study tested the correlation between plasma sphingolipids and plasma cholesterols (Chl), triglycerides (TG), and adiposity factors in normoglycemic individuals.Methods: We assayed plasma (…)
• 02:00
  51-PUB: Assessment the Effect of Therapeutic Education on Nutritional Habits among Pregnant Women with Gestational Diabetes Diabetes
  Background: Maternal obesity elevates the risk of gestational diabetes (GD) andimpacts perinatal outcomes, stemming from excessive caloric intake and unhealthynutrient habits.Objective: To evaluate the effect of therapeutic education on food intake, and itsadequacy to nutritional recommendations (…)
• 02:00
  51-OR: Vascular Sorbs2 Deficiency Is an Independent Risk of Vascular Complications in Diabetes Diabetes
  Introduction & Objective: We have recently reported that Sorbs2 (sorbin and SH3 domain-containing 2) proteins are abundantly expressed in vasculature and linked to BK channelopathies in Sorbs2 null mice. However, the role of Sorbs2 on vascular physiology is unknown.Methods: We created the (…)
• 02:00
  519-P: Association of Circulating Sphingolipids with Glycemia in People without Diabetes Diabetes
  Objective: Sphingolipids (SPL) are involved in the pathogenesis of diabetes. We examined plasma SPL levels in relation to glycemic markers in people without diabetes.Methods: Plasma SPL levelsceramides (Cer), monohexosylceramides (MHC), sphingomyelin (SM) and sphingosine (So) were assayed using (…)
• 02:00
  518-P: Advanced Glycation End Products Impair HDL Particles' Function of Cholesterol Efflux Capacity in Newly Diagnosed Type 1 Diabetes (InLipoDiab1 Study) Diabetes
  Introduction: Type 1 diabetes (T1DM) is characterized by high serum HDL, which does not translate into a better cardiovascular (CVD) prognosis. It is probably related to the impaired function of HDL particles. One of the main functions of HDL is the anti-atherosclerotic role related to reverse (…)
• 02:00
  517-P: Postprandial Circulating Endocannabinoidome Mediators—Impact of Host's Metabolic Health and Dietary Fatty Acid Profile Diabetes
  Introduction & Objective: Food digestion and the activity of the gut microbiota enable the production of several nutrient-derived bioactive metabolites. Notably, lipids can be metabolized into endocannabinoidome (eCBome) mediators, a large family of endocannabinoid and their congeners such (…)
• 02:00
  516-P: High-Fat Feeding Alters Circulating Triglyceride Profile by Decreasing SCD Activity and Depleting n-3 Fatty Acids Diabetes
  Introduction and Objective: Hypertriglyceridemia is a risk factor for type 2 diabetes and cardiovascular disease (CVD), and plasma triglyceride (TG) is considered as a major component in the assessment of diabetes or CVD risk. However, previous lipidomics studies demonstrated that not all TG (…)
• 02:00
  515-P: Do Circulating Sphingolipid Species Correlate with Age? A Study in a Normoglycemic Population Diabetes
  Objective: Sphingolipids (SPL) in circulation have been associated with pathological outcomes of metabolic and cardiovascular diseases that are known to be influenced by aging. We sought to determine the age association of plasma SPL species in people with no diabetes.Methods: We determined (…)
• 02:00
  513-P: Sustained Reduction of Atherogenic Lipoproteins Two Years after Modest Weight Loss in the POUNDS Lost Trial Diabetes
  Apolipoprotein C-III (ApoC3) delays clearance of VLDL and LDL. Lipoprotein subspecies that contain ApoC3 are most predictive of CHD in type 2 diabetes. Our study's objective was to determine if diet-induced weight loss would reduce the concentration of atherogenic lipoproteins including (…)
• 02:00
  512-P: The Effect of Remnant Cholesterol on the Onset of Diabetes Mellitus Diabetes
  Remnant cholesterol (Rem-C) is the cholesterol content found in triglyceride-rich lipoproteins, which are produced in the metabolic process of VLDL and chylomicrons. REM-C is associated with an increased risk of cardiovascular disease and is a target of lipid-lowering therapies. Conversely, (…)
• 02:00
  511-P: Serum Tsukushi Is Associated with HDL Dysfunction in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Diabetes
  Introduction & Objective: Tsukushi (TSK) is a recently identified hepatokine and animal studies have suggested that TSK can affect systemic cholesterol homeostasis. Gain- and loss-of-function experiments in mice showed that TSK reduced circulating HDL-cholesterol (HDL-C). We therefore (…)
• 02:00
  510-P: Remnant Cholesterol and Triglyceride-Rich Lipoproteins Are Associated with Insulin Resistance and Subclinical Inflammation in Youth and Young Adults Diabetes
  Introduction: Remnant cholesterol (Rem-C) and triglyceride-rich lipoproteins (Rem-TRLp) increase risk for atherogenesis in adults but the concentrations and relationship with insulin resistance (IR) and subclinical inflammation in youth and young adults (YYA) is unclear.Methods: We measured (…)
• 02:00
  50-PUB: Maternal Apolipoprotein C3 and Diabetes in Pregnancy in a High-Risk Cohort Diabetes
  Introduction & Objective: Apolipoprotein C-III (ApoC3) regulates lipid metabolism by inhibiting lipoprotein lipase and reducing hepatic triglycerides uptake, higher levels associate with insulin resistance (IR). The role of ApoC3 in pregnancy is unclear. We study if apolipoprotein levels (…)
• 02:00
  50-OR: Metabolic Dysfunction Attenuates D-dopachrome Tautomerase (DDT) Expression in the Heart—A Key Mechanism Exacerbates Myocardial Post-ischemic Injury Diabetes
  Metabolic abnormalities affect clinical recovery and long-term survival in patients with acute myocardial infarction, but the underlying mechanisms remain unclear. D-dopachrome tautomerase (DDT) in cardiomyocytes protects the heart from injury during hypoxia-ischemia in mice. Our present study (…)
• 02:00
  509-P: The Nuclear Receptor Nr5a1 Promotes Adipogenesis as a Novel Transcriptional Regulator of PPARgamma Diabetes
  Introduction & Objective: The nuclear receptor subfamily 5 group A member 1 (Nr5a1) recognized as a transcription factor in adrenal and gonadal organs is also found to regulate lipid metabolism in the islets. However, its involvement in the development of white adipose tissue (WAT) in which (…)
• 02:00
  508-P: The Metabolic Phenome of the Hepatoprotective HSD17B13 Splice Variant rs72613567:TA Suggests Higher Lactate Clearance Diabetes
  Introduction & Objective: A common (~25%) splice variant rs72613567:TA in hydroxysteroid dehydrogenase 17-beta 13 (HSD17B13) was shown to reduce the risk of hepatic fibrosis and cirrhosis. The mechanism underlying the protective function remains unclear.Methods: Carriers (n=647 of 1353) of (…)
• 02:00
  507-P: Human Liver-Specific Regulation of Lipogenesis by Long Noncoding RNA hLMR1 Diabetes
  Hepatic de novo lipogenesis (DNL) significantly contributes to circulating triglycerides in the presence of high carbohydrate diets, making liver-specific inhibition of DNL an attractive strategy for relieving hypertriglyceridemia to control coronary artery disease (CAD) risk. We recently (…)
• 02:00
  506-P: Branched-Chain Amino Acids Promote Occurrence and Development of Cardiovascular Disease Dependent on Triglyceride Metabolism via Activation of the mTOR/SREBP-1/Betatrophin Pathway Diabetes
  Background: Branched-chain amino acids (BCAAs) has been associated with the development of cardiovascular disease (CVD). However, the underlying mechanism remains uncertain.Methods: The clinical study included 1302 subjects guided by diet and exercise intervention for 4 years and subsequent (…)
• 02:00
  1917-LB: Association of FreeStyle Libre Utilization and Glycemic Outcomes among People with Type 2 Diabetes Treated with Basal Insulin and GLP-1RAs Diabetes
  Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medication that is highly effective at treating Type 2 diabetes (T2D) due to its glucose-lowering ability. Although people with T2D treated with basal insulin may use both GLP-1 RA and Freestyle Libre (FSL) glucose monitors, (…)
• 02:00
  1916-LB: Prevalence, Characteristic, and Chronic Complications of Patients with the Fast-Glycator Phenotype in Type 1 Diabetes Diabetes
  Objective: To investigate the prevalence, characteristic and chronic complications of patients with the fast-glycator phenotype in type 1 diabetes (T1D), as well as the relationship between the fast-glycator phenotype and hemoglobin glycation index (HGI).Methods: We enrolled individuals with T1D (…)
• 02:00
  1915-LB: Impact of Glycemic Variability on the Relationship between TIR and GMI among Type 2 Diabetes Patients with TIR >70% Diabetes
  Aim: Previous studies proved that glucose variability (GV) affected the relationship between TIR and glucose management indicator (GMI) in T2D patients with poor glycemic control. This study aimed to explore whether GV indexes affect the relationship between TIR and GMI in T2D patients with TIR (…)
• 02:00
  1914-LB: The Combined Effect of CGM with Antidiabetes Medications and the Association with Improved A1C in People with Type 2 Diabetes (PWT2D) Not on Insulin Therapy (NIT) Diabetes
  Background: CGMs are used to guide lifestyle modifications, prevent hypoglycemia, and inform therapies. This study aimed to evaluate whether CGM, alongside various classes of anti-diabetes medications, is associated with lower A1c in PWT2D NIT.Materials and Methods: A retrospective analysis of (…)
• 02:00
  869-P: Gastrin Reduces Incidence of Type 1 Diabetes through Reducing Inflammation and Preserving ß-Cell Mass in Animal Model Diabetes
  Introduction: Progressive destruction of insulin-producing ?-cells by autoimmunity is a primary feature of type 1 diabetes (T1D). Therapies that block immune attacks on islet cells and preserve or restore the functional ?-cell mass are needed to halt or reverse disease progression. Here, we (…)
• 02:00
  868-P: Efficacy and Safety of Crisugabalin with Acetyl-Levo-Carnitine in Chinese Patients with Diabetic Peripheral Neuropathic Pain—A Multicentre, Randomized, Open-Label, Positive-Controlled, Parallel-Group, Phase 2 Trial Diabetes
  Background: Crisugabalin (HSK16149) was found to be a novel, potent treatment option for patients with diabetic peripheral neuropathic pain (DPNP); However, efficacy and safety data specifically for Chinese individuals were limited to several researches, and there was no comparative evidence on (…)
• 02:00
  867-P: Cardiovascular Outcomes in Patients Initiating a Second Diabetes Medication after Metformin—The BESTMED Study Diabetes
  Introduction: In patients with T2D at high cardiovascular (CV) risk, several classes of medications have been found to reduce incidence of CV events. However, long-term CV outcomes of T2D medications in lower risk patients are unknown.Methods: We conducted a causal inference study by emulating a (…)
• 02:00
  866-P: Assessing the Generalizability of the FIDELIO-DKD and FIGARO-DKD Criteria to the Canadian Population with Type 2 Diabetes in a Community Endocrinology Setting Diabetes
  Finerenone improves renal and cardiovascular outcomes in CKD and T2D, as demonstrated in the FIDELIO and FIGARO trials. While the ADA guidelines advise finerenone for residual renal risk, Canadian guidelines lack such recommendations. Previous studies established the applicability of the FIDELIO (…)
• 02:00
  865-P: Metformin Reduces Insulin Dose and Visceral Fat Accumulation, and Increases GDF15 without Reducing Insulin Resistance in Adults with Type 1 Diabetes—A 26-Week, Randomized, Double-Blind Placebo-Controlled Trial (INTIMET) Diabetes
  Insulin resistance is a cardiovascular (CV) risk factor in type 1 diabetes (T1D). The effect of metformin on liver and muscle insulin resistance has not been studied in adults with T1D. We recruited 40 adults with T1D (HbA1c 7.5±0.9% [58±10mmol/mol], diabetes duration 22.9±8.9 years, age (…)
• 02:00
  864-P: GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Decreases Appetite, Increases Satiation, and Reduces Food Intake in Patients with Type 2 Diabetes Diabetes
  Background: GLY-200 is an investigational oral non-absorbed polymeric drug designed to bind to and enhance the barrier function of gastrointestinal mucus as a non-invasive alternative to metabolic surgery and duodenal exclusion devices. In healthy volunteers, GLY-200 lowered glucose and (…)
• 02:00
  863-P: Genetically Proxied GLP-1 Receptor Agonism Improves Kidney Function—A Mendelian Randomization Study Diabetes
  Recently, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has been associated with prevention of kidney function decline and reducing the risk of chronic kidney disease (CKD). However, it is not clear whether GLP-1 receptor agonism has a direct causal effect on renal function. (…)
• 02:00
  862-P: Efficacy and Safety of Orlistat in People with Overweight/Obese and Hyperuricemia—Results of a Randomized, Double-Blind, Placebo-Controlled Trial Diabetes
  Objective: Obesity is associated with elevated serum uric acid (SUA) and frequent gout flares. Losing weight can lower SUA and reduce gout flares. In this study, we investigated the effects of orlistat on SUA and gout flares compared to placebo in people with overweight/obese and hyperuricemia (…)
• 02:00
  861-P: Efficacy of Digital Intervention vs. Metformin for Women with Polycystic Ovary Syndrome—A Randomized Clinical Trial Diabetes
  Objective: To evaluate the efficacy of digital intervention versus metformin treatment for women with polycystic ovary syndrome (PCOS) with insulin resistance (IR).Methods: A total of 80 women with PCOS with IR were randomly assigned to receive either digital intervention (n = 40) or metformin (…)
• 02:00
  860-P: Effects of the Combination Treatment with SGLT2 Inhibitors and GLP1 Receptor Agonists among Japanese Patients with Type 2 Diabetes Mellitus and Obesity Diabetes
  Background: The combination treatment of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1Ras) is increasing in clinical practice. We previously reported that the preceding drug did not influence the renal outcomes in patients with this (…)
• 02:00
  85-OR: The Impact of Type 2 Diabetes (T2D) on the Outcomes of Liver Transplantation in the United States from 2007–2022 Diabetes
  Introduction & Objective: Type 2 diabetes (T2D) and associated non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) can negatively impact outcomes of patients with chronic liver disease (CLD). The aim of this study was to assess the impact of (…)
• 02:00
  859-P: ALN-KHK, an Investigational RNA Interference Therapeutic, Successfully Targets Hepatic Ketohexokinase in a Single Ascending Dose Study of Overweight to Obese Adults Diabetes
  Introduction & Objective: Rising obesity rates are attributed in part to high dietary sugar consumption, including fructose, which is linked to development of hepatosteatosis and type 2 diabetes. ALN-KHK is an investigational RNA interference therapeutic designed to decrease hepatic (…)
• 02:00
  857-P: Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes—An Observational Study (PAUSE) Diabetes
  Introduction & Objective: This study aimed to determine the real-world effectiveness of injectable semaglutide once weekly (sema OW) on weight and HbA1c outcomes among people with type 2 diabetes (T2D) in the US.Methods: This observational cohort study involved adults with uncontrolled T2D (…)
• 02:00
  856-P: Prevention of Type 1 Diabetes with MSC-EV Diabetes
  Objective: Type 1 diabetes (T1D) is an autoimmune disease characterized by immune cell-mediated destruction of beta cells resulting in loss of insulin production and glucose homeostasis. Mesenchymal stem cells (MSCs) are a heterogeneous population of adult stem cells that can be isolated from (…)
• 02:00
  318-OR: Podocyte-Specific Expression of REDD1 Promotes Altered Glomerular Pathology and Renal Function Deficits in a Rodent Model of Diabetic Nephropathy Diabetes
  Introduction & Objective: The pathogenesis of diabetic nephropathy (DN) is complex and multi-factorial; however, it is well accepted that podocyte injury and death are crucial factors in the development of renal complications. We previously observed that the stress response protein REDD1 (…)
• 02:00
  191-OR: Symposium on the International Consensus Statement and Movement to End Diabetes Stigma Diabetes
  Diabetes stigma is recognized as a highly prevalent experience for people living with diabetes across the lifespan. Diabetes stigma has been demonstrated to negatively impact health and quality of life for people living with diabetes. With the appreciation that many health practitioners have (…)
• 02:00
  1919-LB: GlucoseReady—Technical Validation of a Novel GxP Platform for Real-Time CGM Capture Diabetes
  Introduction: FDA guidance recommends continuous glucose monitoring (CGM) for diabetes clinical trials. Real-time monitoring in such trials demands high-speed data frameworks. Here, we sought to develop a fully GxP-compliant platform that integrates with CGM devices and rapidly transmits (…)
• 02:00
  1918-LB: rtCGM Improves Postoperative Glucose Control in Liver Transplant Recipients with Diabetes Mellitus Diabetes
  Introduction: Glycemic management early after liver transplantation (LTx) is challenging due to the patients’ critical state and corticoid therapy and can be complicated by preexisting diabetes mellitus (DM). We analyzed data from continuous glucose monitoring (CGM) in LTx recipients from an (…)
• 02:00
  907-P: The Effect of Imeglimin on Glycemic Management in Japanese Patients with Type 2 Diabetes Diabetes
  Background: Imeglimin exerts hypoglycemic actions by stimulating insulin secretion in a glucose concentration-dependent manner and by improving insulin resistance. We evaluated the effects of imeglimin on glycemic management, insulin secretion, body weight(BW) and composition in Japanese (…)
• 02:00
  906-P: Safety and Efficacy of Polmacoxib for Diabetes-Associated Frozen Shoulder—Prospective Randomized Control Trial Diabetes
  Introduction and Objective: Adhesive Capsulitis (AC) or frozen shoulder is a common complication of uncontrolled T2DM having prevalence of 10-39%. Shoulder pain and disability index(SPADI) is visual analogue scale tool to quantify disease severity in AC. Polmacoxib, a novel COX2 inhibitor is (…)
• 02:00
  905-P: Increased GDF15 Levels Are Unrelated to Anterior Pituitary Hormone Shifts in Metformin Use Diabetes
  Metformin is a widely used medication in the management of type 2 diabetes, and its weight-lowering effects involve the central nervous system. Growth differentiation factor 15 (GDF15) acts on the mid-brain, is increased with metformin, and is positively correlated with weight loss. Pituitary (…)
• 02:00
  904-P: Glycemic Improvement in Patients with Type 2 Diabetes under Treatment with a Fixed-Dose Combination Glimepiride/Vildagliptin/Metformin with Failure to Previous Dual Therapy Diabetes
  Introduction & Objective: Failure to type 2 diabetes (T2D) treatment leads to complications. Combination therapies with different mechanisms of action are often required to achieve glycemic goals. This study aimed to evaluate the efficacy and safety of glimepiride/vildagliptin/metformin in (…)
• 02:00
  903-P: Glycemic Control Enhancement with Imeglimin in Type 2 Diabetes Mellitus Diabetes
  Imeglimin is a first-in-class oral hypoglycemic agent used for the treatment of T2DM and targets mitochondrial bioenergetics to ameliorate insulin resistance and enhance ?-cell function. It has also been shown to improve glycemic control when added to metformin or sitagliptin monotherapy in T2DM (…)
• 02:00
  902-P: GlucoLo Plus, a Complementary and Alternative Medicine (CAM) Used in Type 2 Diabetes Management, Is Associated with Lipid Profile Improvement Diabetes
  Introduction & Objective: Diabetes is a chronic disease associated with many comorbidities and a higher risk of all-cause and cardiovascular mortality. The GLEEN Study is a previously reported double-blind randomised placebo-controlled trial that evaluated the efficacy and safety of daily (…)
• 02:00
  901-P: COVALENT 112—A Clinical Trial Assessing BMF-219, an Oral Covalent Menin Inhibitor in Type 1 Diabetes Diabetes
  Background and Aims: Inhibition of menin, a scaffold protein, results in beta cell proliferation and enhanced insulin secretion in T1D. BMF-219, an oral covalent menin inhibitor, is in clinical development for T1D and T2D. Based on ex-vivo islet microtissue data and preclinical animal models, we (…)